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ABSTRACT OF THE DISSERTATION 
Identification of Functional Variants in Alzheimer’s Disease-Associated Genes 
by 
Sheng Chih Jin 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Human and Statistical Genetics) 
 
Washington University in St. Louis, 2014 
Professor Alison Goate, Chairperson 
 Alzheimer’s disease (AD) is the most common form of dementia affecting the health of more than 5 million 
Americans in 2013. Understanding how genetic variants contribute to AD is important to develop effective 
therapeutics for delaying and eventually curing the disease. Recent sequencing studies have identified rare variants 
p.V232M in PLD3 and p.R47H in TREM2 significantly associated with AD risk. Additionally, genome-wide 
association studies (GWAS) uncovered common variants in ABCA7, BIN1, CD33, CD2AP, CLU, CR1, EPHA1, 
MS4A4A, and PICALM that contribute to AD; however, the most-significant variants in these loci are located within 
non-coding regions and have no direct functional impact on AD pathogenesis. We hypothesized that if PLD3 and 
TREM2 are truly AD risk genes, they will carry additional functional variants that can substantially affect AD risk. 
Moreover, we hypothesized that GWAS genes carry additional risk alleles across the frequency spectrum so that 
common, low frequency or rare variants within these genes may contribute to AD risk. We undertook pooled 
sequencing of exonic and flanking intronic sequence for the aforementioned genes in 3,730 European Americans 
(EA) (2,082 AD cases and1,648 controls) and 336 African Americans (AA) (204 AD cases and 132 controls). We 
found rare variants in PLD3 and TREM2 are more frequently seen in cases than in controls of EA descent. Single-
variant analyses showed that p.M6R and p.A442A in PLD3 and p.R62H in TREM2 are significantly associated with 
AD risk besides p.V232M in PLD3 and p.R47H in TREM2. We found rare variants in PLD3 (PSKAT-O=1.44×10-11) 
and TREM2 (PSKAT-O=5.37×10-7) are genome-wide significantly associated with AD. Additionally, we found a 
significant association for PLD3 coding variants with AD risk in AA (PSKAT-O=1.40×10-3). However, we did not find 
evidence of association for TREM2 variants with AD risk in AA. We validated 90 coding variants in GWAS-
identified genes and bioinformatic analyses implicated that a large proportion of these variants are functional. 
 The International Genomics of Alzheimer’s Project recently performed meta- and gene-wide analyses and 
identified 23 loci associated with AD risk, of which 13 were novel. However, these loci’s role in affecting the 
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molecular pathways of AD remains unknown. To determine whether these loci are also associated with 
cerebrospinal fluid (CSF) amyloid-beta 1-$ȕ42) and phosphorylated tau181 (ptau181) levels, we combined CSF 
biomarker datasets from several studies and performed single-variant, set-based, and conditional analyses for each 
locus. In the APOE locus, rs769449 is genome-ZLGHVLJQLILFDQWO\DVVRFLDWHGZLWK&6)$ȕ42 and ptau181 levels 
independently of APOE-İDQGAPOE-İ613VDQGWKHDVVRFLDWLRQIRU&6)SWDX181 OHYHOVZDVQRWGULYHQE\$ȕ
metabolism. We found rs7937331, within the CELF1 fine-mapping region, tags the same signal as the IGAP top 
SNP (rs62003531) and is significantly DVVRFLDWHGZLWK&6)$ȕ42 levels and AD risk. Additionally, rs62003531, 
located in the intronic region of FERMT2, tags the same association as the IGAP top SNP (rs17125944) and is 
DVVRFLDWHGZLWK&6)$ȕ42 levels. None of the SNPs within the IGAP-identified AD risk loci except the APOE locus 
are significantly associated with CSF ptau181 levels after multiple test correction. In investigating the potential 
regulatory functions associated with IGAP top SNPs and CSF top SNPs, most of GWAS top SNPs have no 
significant regulatory potential and are unlikely to be functional variants for AD risk. However, RegulomeDB 
predicts that several proxy SNPs in linkage disequilibrium (LD) with rs7937331 may be cis-acting expression 
quantitative trait loci (eQTLs) for nearby genes. The IGAP study also identified an intergenic polymorphism near 
TREML2 suggestively associated with AD risk; however, due to the study design, it was not possible to uncover the 
underlying functional variant or to determine whether this observed association was driven by the known AD risk 
allele, TREM2 p.R47H, or represented a novel locus. We performed analyses using whole-exome sequencing data, 
CSF biomarker analyses and meta-analyses to demonstrate that the AD risk association is likely driven by a 
TREML2 variant p.S144G (rs3747742) independently of TREM2 p.R47H risk for AD. 
 Finally, we sought to functionally characterize the effects of novel TREM2 variants on TREM2 cell surface 
transport. We transduced a T cell hybridoma cell line with virus containing TREM2 wild type (WT) and risk variants 
and measured TREM2 cell surface expression with a TREM2-specific monoclonal antibody. We found cells 
expressing p.T66M and p.R136W have a robust effect on TREM2 cell surface expression but cells expressing 
p.R47H and p.R62H are similar to hTREM2 WT. Additionally, since polymorphisms in the CELF1 fine-mapping 
region were implicated to be eQTLs for nearby genes, we performed cis-eQTL analysis for mRNA expression levels 
in several brain regions using four publicly available datasets to identify genetic determinants of gene expression in 
human brains. We found several C1QTNF4-expression-associated SNPs which tag the same signal are in LD with 
UVWKHWRS&6)$ȕ42 SNP in the CELF1 fine-mapping region. Additionally, we found evidence of 
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differential expression in the C1QTNF4 transcript between AD cases and controls in human brains. These findings 
provide additional evidence that genes involved in the inflammatory response play an important role in AD 
pathogenesis. 
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Chapter 1 
Background and significance 
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1.1  OVERVIEW OF THIS DISSERTATION 
 Alzheimer’s disease (AD) is a devastating neurodegenerative disease affecting more than 5 million 
Americans and costing US $200 billion in 2012. The number of AD patients is projected to quadruple in the next 40 
years and is becoming a major public health problem worldwide. Early genetic studies have identified disease-
causing mutations in the amyloid precursor protein (APP)1, presenilin 1 (PSEN1)2,3 and presenilin 2 (PSEN2)2,4, 
while polymorphisms in apolipoprotein E (APOE)5-7 affect risk for developing late onset AD (LOAD), providing a 
better understanding of AD pathogenesis. Genome-wide association studies (GWAS), a method that can rapidly 
investigate millions of “common” polymorphisms across the human genome in thousands of individuals, have 
identified several novel loci influencing LOAD8-11, yet genetic markers within these loci only explain a small 
proportion of the genetic phenotypic heritability (i.e. the proportion of phenotypic differences between individuals 
that is due to genetic differences). The underlying mechanisms involved in LOAD remain largely unknown. Recent 
studies which used emerging next-generation sequencing (NGS) technologies have analyzed the entire human 
genome with large sample sizes to identify “rare” coding variants in the triggering receptor expressed on myeloid 2 
(TREM2)12,13 and phospholipase D3 (PLD3)14 genes as risk factors for AD. Together, these genetic studies support 
the paradigm that, both common, low-penetrant and rare, high-penetrant alleles contribute to AD pathogenesis 
(Figure 1). 
 Our recent work has used next-generation sequencing technology to identify rare variants in APP, PSEN1 
and PSEN2 associated with risk for LOAD15. We also found rare variants in APP along with the microtubule-
associated protein tau (MAPT) and progranulin (GRN), two genes associated with frontotemporal dementia, in 
clinically diagnosed AD patients of hispanic descent16. These findings clearly highlight the importance of 
performing deep re-sequencing studies in AD-associated genes to identify additional novel variants that may be 
pathogenic 15,16. On the other hand, our previous work has shown that cerebrospinal fluid (CSF) biomarkers can be 
effectively used as quantitative traits in genetic analyses to not only identify novel genetic markers but also to 
generate testable hypotheses regarding underlying mechanisms17-24. Additionally, these studies clearly demonstrated 
WKDWXVLQJ&6)DPLQRDFLGIUDJPHQWVRIDP\ORLGEHWD$ȕ42; decreased in AD) and tau phosphorylated at 
threonine 181 (a proxy for hyperphosphorylated tau; ptau181; increased in AD) as quantitative traits has increased 
power relative to qualitative clinical diagnosis to identify common, functional variants in AD-associated genes and  
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to determine whether the identified genetic markers affect AD pathogenesis through an $ȕ-dependent or a tau-
dependent mechanism18,19,22,24. In summary, a combination of next-generation sequencing studies coupled with 
endophenotype-based association studies can lead to identification of potential functional variants. 
 The objective of this dissertation is to identify potential functional variants in AD-associated genes and to 
determine the pathogenic mechanisms associated with these variants. In this chapter, I will give a concise but 
comprehensive introduction to AD and describe why this dissertation is important to the understanding of AD 
biology. I will briefly describe what is known about amyloid beta and tau proteins and how they are linked to AD 
etiology. I will review the known genetic risk factors for AD and their potential roles in AD pathogenesis. I will also 
summarize a variety of biomarkers that are currently used IRUPHDVXULQJ$ȕWDXDQGQHXURGHJHQeration. In Chapter 
2, I will describe how I used deep re-sequencing to identify novel functional rare variants in AD-associated genes. 
Then in Chapter 3, I will describe how I used &6)$ȕ42 and ptau181 levels as quantitative phenotypes to identify 
novel common variants and further determine whether these potential functional variants affect risk for LOAD 
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WKURXJKDQ$ȕ-dependent, a tau-dependent mechanism or another unspecified mechanism (e.g. expression 
quantitative trait loci [eQTL]). In Chapter 4, I will discuss why I selected variants in TREM2 for functional studies 
and how I conducted in vitro cell-based assays. Finally in Chapter 5, I will make a final conclusion and discuss 
future directions and plans. The results of this dissertation could accelerate progress in understanding pathogenic 
mechanisms associated with AD-implicated genes and may provide molecular targets for treatment. 
1.2 ALZHEIMER’S DISEASE 
 AD -is the most common type of dementia, accounting for approximately 60-70% of all dementia cases25. 
Other types of dementia include Lewy body dementia, Parkinson’s disease, frontotemporal dementia, vascular 
dementia, progressive supranuclear palsy, corticobasal degeneration, Huntington’s disease, normal pressure 
hydrocephalus, Wernicke-Korsakoff syndrome, and Creutzfeldt-Jakob disease. It is estimated that AD affected an 
estimated 5.2 million Americans in 2013, is the sixth leading cause of death in the USA, and is the only cause of 
death among the top 10 that cannot be prevented, and is incurable 26. AD is the third most expensive disease, costing 
the U.S. government close to $203 billion in 201326. With a global prevalence of 30 million, which is expected to 
quadruple over the next 40 years, AD is an emergent public health crisis in the 21st century. 
 AD can be clinically classified into 4 stages: pre-clinical, mild, moderate, and severe. The pathologic 
changes associated with AD start many years before producing symptoms. Preclinical AD is not benign and affected 
individuals will develop AD symptoms if they live long enough. An individual with preclinical AD is characterized 
by cognitive decline. A preclinical AD patient may perform completely normal on physical examination and mental 
status testing. Normally, there are no changes in judgments or abilities to perform tasks in social or work settings. 
In the mild AD stage, memory loss continues and other cognitive deficits emerge. The mild AD stage is normally 
characterized by memory loss, attention deficits, spatial disorientation and executive dysfunction. In the moderate 
stage, signs and symptoms of AD become more conspicuous and widespread. A patient with mild AD has more 
obvious difficulty with memory and other cognitive functions and lose the abilities to perform activities of daily 
living25. In the final stage, Alzheimer’s dementia, almost all cognitive and physical functional are severely 
deteriorated. Patients need help with all activities of daily living, and lose the ability to respond to their environment, 
to conduct a conversation, and to control movement. 
 AD is a devastating neurodegenerative disorder, with progressive stages of cognitive and functional 
deterioration. AD is often classified based on the age at onset (AAO) and familial aggregation; familial AD (FAD), 
5 
 
the rare form of the disease, usually has an early AAO (less than 65 years of age), follows an autosomal dominant 
pattern, and accounts for less than 1% of AD patients. LOAD, accounting for > 99% of AD patients, has a late AAO 
(greater than 65 years of age) and is clinically and genetically complex. Although FAD and LOAD can generally be 
distinguished by AAO and familial aggregation, both are pathologically characterized by extensive neuronal loss 
and the presence of extracellular amyloid-EHWD$ȕSODTXHVFRPSRVHGRI$ȕSURWHLQDQGLQWUDFHOOXODUQHXURILEULOODU\
tangles composed of hyperphosphorylated tau (ptau) protein25. $ȕSODTXHVXVXDOO\RFFXUXSWR\UVEHIRUHFOLQLFDO
onset while neurofibrillary tangles occur closer to the time of onset of symptoms. 
1.3 AMYLOID BETA PLAQUES 
 $ȕ plaques are fibrillar aggregates of $ȕ peptides surrounded by damaged axons and neurites in the 
extracellular space of brain. $ȕSHSWLGHVDUH 35-43 amino acids resulting from proteolytic cleavage of APP27 (see 
Figure 2). $ȕSODTXHVFDQEHmicroscopically classified into neuritic plaques and diffuse plaques28 (see Figure 3). 
The neuritic plaques, also called senile plaques, are fibrillar extracellular deposits with Dȕ-sheet conformation, 
which can be visualized through immunofluorescence microscopy using Congo red and Thioflavin S stains28 (see 
Figure 3A). These neuritic plaques are surrounded by degenerating axons and dendrites and contain hypertrophic 
gliosis and activated astrocytes and microglia. It has been suggested that this inflammatory reactivity results in brain 
injury even though other evidence shows that glial cells may also have an opposite effect against brain 
inflammation29,30. Diffuse plaques, which can be detected via immunohistochemical techniques, are aggregated in an 
Į-helical (non-fibrillar) structure and UHSUHVHQWWKHPDMRULW\RI$ȕSODTXHV (see Figure 3B). Diffuse plaques are less 
toxic and can be found in brains of cognitively normal elderly individuals, which may represent the early stage of 
plaque biology in AD brains31,32. 
1.4 NEUROFIBRILLARY TANGLES 
 Neurofibrillary tangles (NFTs) are composed of intracellular hyperphosphorylated tau protein, a protein 
that is expressed in neurons, astrocytes and oligodendrocytes33-36. Normal tau protein binds to tubulin and stabilizes 
microtubules, which is essential to intracellular support. In AD brains, tau becomes hyper-phosphorylated, and 
subsequently results in dissociation from microtubules. The dissociated tau self aggregates into tangles of paired-
helical filaments, which can contribute to neuronal dysfunction and other tauopathies. Tau can spread throughout the 
EUDLQDQGWDXSDWKRORJ\LVPRUHVWURQJO\FRUUHODWHGZLWKFOLQLFDOGHPHQWLDWKDQ$ȕSDWKRORJ\7KHUHIRUHWKH
neurologist can determine the stage of the disease based on the pattern of spread of tau pathology.  
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1.5  ALZHEIMER’S GENETICS 
1.5.1 Early dementia genes – APP, PSEN1, and PSEN2 
 Despite the fact that FAD accounts for less than 1% of AD cases, studies of rare autosomal dominant 
familial early-onset AD (EOAD) have provided valuable insights into the pathogenesis of AD. Mutations in the 
APP, PSEN1, and PSEN2 genes were initially identified in familial EOAD, with AAO usually between the ages of 
30 and 601-4; however, several recent studies have found pathogenic mutations in these genes in late-onset 
families15,160RVWRIWKHVHPXWDWLRQVDUHDVVRFLDWHGZLWKLQFUHDVHG$ȕRU$ȕ42 SURGXFWLRQUHVXOWLQJLQLQFUHDVHG$ȕ
aggregation in the brain25. 7KHVHILQGLQJVVXJJHVWHGWKDWWKH$ȕDJJUHJDWLRQDQGPLVIROGLQJLVFHQWUDOWRWULJJHULQJ
AD pathogenesis and to direct brain damaging25,27. 
 APP is an integral membrane protein that is expressed in many tissues and primarily in the synapses of 
neurons. The primary function of APP is not known even though APP has been implicated to regulate synapse 
formation37, neural plasticity38, and iron export39. Mutations in APP cause FAD, cerebral amyloid angiopathy 
(CAA), or a combination of both40-43. There are several isoforms of APP, including 695, 751, and 770 amino acids in 
length. The 695- amino acid isoform is highly expressed in neurons but the 751- and 770- amino acid isoforms are 
primarily expressed in astrocytes44,45. Proteolysis of APP SULPDULO\RFFXUVDWWKHVLWHVRI$33HQGRSURWHRO\VLVE\Į-
secretase, ȕ-VHFUHWDVHDQGȖ-secretase (see Figure 2). APP is first proteolyzed within the lumenal domain by Į-
secretase or ȕ-secretase, resulting in ectodomain shedding and producing membrane-WHWKHUHGȕ- or Į-C-terminal 
fragments46. Next, the ȕ- and Į-C-terminal fragmented are cleaved by Ȗ-secretase within the transmembrane domain 
to release AȕDQGSSHSWLGHVLQWRH[WUDFHOOXODUVSDFH46. 7KHPDMRULW\RI$33LVFOHDYHGE\Į-secretase and Ȗ-
secUHWDVHZLWKLQWKH$ȕGRPDLQUHVXOWLQJLQQRQSDWKRJHQLFV$33ĮDQGĮ-C-terminal fragment (CTF). Alternatively, 
APP can be proteolyzed by ȕ-VHFUHWDVHDQGȖ-secUHWDVHWRSURGXFH$ȕSHSWLGHVV$33ȕDQGȕ-CTF46. 
 Most missense mutations in APP are positioned in or near the sites of ȕ-secretase DQGȖ-secretase1,47,48 
cleavage. Mutations close to the C terminus of the AȕUHJLRQFRQWULEXWHWRLQFUHDVHGUDWLRs of Aȕ40 or Aȕ42 without 
affecting total AȕOHYHOV49,50. Even though the most abundant AȕVSHFLHVLVAȕ40, Aȕ42 is more fibrillogenic and has 
been shown to be the first AȕVSHFLHVGHSRVLWed in AD51,52. The increased Aȕ42:Aȕ40 ratio caused by elevated Aȕ42 
production suggests that physiological processing of APP is central to AD pathogenesis. On the contrary, the 
Swedish FAD mutation (p.K670N/p.M671L), ORFDWHGFORVHWRWKHȕ-secretase cleavage site, results in an increase in 
DOOVSHFLHVRI$ȕDQGLVDVVRFLDWHGZLWKERWK$'DQG&$$53. The evidence that incrHDVHG$ȕSURGXFWLRQFRQWULEXWHV 
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to AD is also strengthened by the fact that people with Down syndrome (Trisomy 21) and individuals in families 
with an APP duplication all develop AD symptoms and neuropathology54. 
 Some APP PXWDWLRQVWKDWFDXVH)$'DQG&$$GRQRWDIIHFW$ȕSURGXFWLRQDQGDUHSRVLWLRQHGLQWKH$ȕ
peptide. These mutations, C-WHUPLQXVWRWKHĮ-secretase cleavage site in APPPRGLI\WKH$ȕVHTXHQFHE\HQKDQFLQJ
WKHSURSHQVLW\RI$ȕWRROLJRPHUL]HILEULOOL]HRUbe removed less efficiently42,43,55. A recent study described an 
autosomal recessive pattern of AD inheriWDQFHUHVXOWLQJIURPWKHGHOHWLRQRIRQHDPLQRDFLGDWSRVLWLRQLQ$ȕ, 
resulting in a highly fibrillogenic form of Aß56,57. Another study also reported a recessive mutation in APP, 
p.A673V, that VLJQLILFDQWO\LQFUHDVHVDP\ORLGRJHQLFȕ-secretase cleavage58. In contrast, a different codon change in 
the same position (p.A673T) results in a reduction in the formation of amyloidogenic peptides and protects against 
AD59. These studies clearly highlight the importance of beta-amyloid accumulation in AD pathogenesis. 
 Besides APP, mutations in PSEN1 and PSEN2 also have been associated with the rare, autosomal dominant 
form of FAD2,3. PSEN1 and PSEN2 are the catalytic component of gamma-secretase. PSEN1 and PSEN2 encode 
highly homologous polytopic transmembrane proteins. PSEN mutations can contribute to a selective and significant 
LQFUHDVHLQWKHWRWDOOHYHORI$ȕ42 RUWKHUDWLRRI$ȕ42 WR$ȕ4o in the plasma60. Transgenic mice with PSEN mutations 
KDYHLQFUHDVHG$ȕ42 in the brain61. Additionally, when breeding transgenic mice with PSEN mutations with 
transgenic mice with FAD mutant human APPWKHVHPLFHSUHVHQWDFFHOHUDWHG$ȕGHSRVLWLRQ62,63. Primary neurons 
from PSEN1 NQRFNRXWPLFHSURGXFH$ȕOHVVHIILFLHQWO\DVDUHVXOWRIGHFUHDVHGȖ-secretase activity64. 64. Several 
studies have shown that PSEN1 mutations cause partial loss of function, resulting in a slight increase in Aȕ42 
production DQGORZHUSURGXFWLRQRI$ȕ4065,66. The partial loss of function caused by PSEN1 mutations is associated 
with APP FOHDYDJHLQHIILFLHQF\DQGUHODWLYHLQFUHDVHGSURGXFWLRQRI$ȕ427KLVUHODWLYHLQFUHDVHLQ$ȕ42 production 
HOHYDWHVWKHWHQGHQF\RI$ȕWRDJJUHJDWHHDUOLHULQWKHEUDLQ 
 To summarize, the mechanism by which APP, PSEN1 and PSEN2 mutations cause the autosomal dominant 
form of FAD supports the amyloid hypothesis, in which the neurodegenerative process results from an imbalance 
EHWZHHQ$ȕSURGXFWLRQDQG$ȕFOHDUDQFH27. It also implicated that any genes involved in these pathways may also be 
associated with risk for developing AD. 
1.5.2 Strongest risk factor for late-onset AD – APOE  
 LOAD cases account for more than 95% of AD cases and APOE has by far the greatest effects on risk for 
developing LOAD5. APOE is located on chromosome 19q13.2 and there are three major isoforms in humans, 
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ApoE2, ApoE3 and ApoE4, which were resulted from three alleles- APOE İAPOE İDQGAPOE İ7KHVHAPOE 
isoforms differ in sequence by one amino acid at either position 112 or position 158 of the protein. The APOE İ
DOOHOHLQFUHDVHVWKHULVNIRU$'ZKLOHWKHİDOOHOHGHFUHDVHVWKHULVNIRU$'6,7. One APOE İ alleles roughly 
increases AD risk by 3 fold and two alleles by 12 fold67. The risk associated with APOE İDOOHOHVis also associated 
ZLWKDJHDWRQVHWDSSUR[LPDWHO\\UVİDOOHOHLQDGRVH-dependent manner6. However, about 50% of LOAD 
patients do not carry the APOE İDOOHOHVXJJHVWLQJWKDWRWKHUJHQHWLFIDFWRUVDOVRaffect LOAD risk. 
 Several hypotheses have been proposed about how APOE could influence AD pathogenesis. In vitro and in 
vivo experiments show that APO(LVDQ$ȕELQGLQJPROHFXOHZKLFKDIIHFWVQRWRQO\ WKHFOHDUDQFHRIVROXEOH$ȕEXW
DOVRWKHWHQGHQF\RI$ȕWRDJJUHJDWHE\FKDQJLQJ$ȕVHHGLQJDQGSRO\PHUL]DWLRQ68, both suggesting the potential 
LQIOXHQFHRQ$ȕDJJUHJDWLRQin vivo. Neuropathological and neuroimaging studies demonstrated WKDW$ȕGHSRVLWLRQ
EHJLQVHDUOLHULQİFDUULHUVWKDQİQRQ-carriers in both cognitively normal individuals and AD patients69-71. Studies 
have shown that APO(VLJQLILFDQWO\DOWHUVWKHOHYHODPRXQWDQGVWUXFWXUHRI$ȕGHSRVLWLRQLQWKHEUDLQXVLQJ
transgenic mouse models of AD in an isoform-GHSHQGHQWPDQQHUİ!İ!İ72-75. Recent studies have reported 
association between APOE JHQRW\SHDQGFHUHEUDO$ȕGHSRVLWLRQDQG&6)$ȕ42 and tau levels18,22,70. Overall, these 
genetic, cellular, mouse and human studies demonstrate that APOE affects LOAD risk by influencing Aȕ clearance 
and aggregation. 
1.5.3 GWAS versus Sequencing 
 GWAS and sequencing studies are both powerful tools to discover disease-associated variants and genes 
for human diseases while there are some divergent aspects between GWAS and sequencing studies. The primary 
differences between GWAS and sequencing studies lie in the type of variants identified and the genetic-association 
hypotheses tested. Because the commercial genotyping arrays largely ignore low-frequency and rare variants (lack 
of systematic catalog of rare variants for assay design), GWAS are mostly used directly (through genotyping or 
imputation) or indirectly (through linkage disequilibrium) to identify “common” variants associated with disease 
traits; therefore, GWAS has been characterized as a method to test the common disease - common variant (CDCV) 
hypothesis. However, the GWAS-identified disease-related variants usually have small effects (odds ratio [OR] 
usually between 0.8~1.2). Moreover, common variants identified in GWAS usually explain a small fraction of the 
heritability even when the sample size of the study is huge. These findings implicate that additional functional 
genetic variants remain unidentified. Contrary to CDCV hypothesis, the alternative common disease – rare variant 
10 
 
(CDRV) hypothesis has been postulated to be able to explain the missing heritability, and sequence-based studies 
allow scientists to completely investigate “low-frequency” and “rare variants”. Even though it remains debatable 
whether CDCV or CDRV will explain the missing heritability, current genetic studies suggest that CDCV and 
CDRV are not mutually exclusive and that human diseases are attributed to a combination of common and rare 
variants12,76,77. 
1.5.4 GWAS-identified AD loci 
 Recent GWAS have revealed many single nucleotide polymorphisms (SNPs) within several loci (ABCA7, 
APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, EPHA1, FERMT2, HLA-DRB5/DRB1, IGHV1-67, 
INPP5D, MEF2C, MS4A6A, NME8, PICALM, PTK2B, SLC24A4, SORL1, TP53INP1, and ZCWPW1) associated 
with AD risk, providing novel insights into potential biological pathways associated with AD pathogenesis8,10,11,78. 
These findings highlight several previously suspected biological pathways relevant to LOAD, including, amyloid 
precursor protein metabolism (SORL1 and CASS4), tau metabolism (CASS4 and FERMT2), lipid metabolism 
(ABCA7 and CLU), innate and adaptive immunity (CR1, CD33, HLA-DRB5/DRB1, IGHV1-67, INPP5D, MEF2C, 
and MS4A6A); cell adhesion (EPHA1), cell migration (PTK2B), and intracellular trafficking, (BIN1, CD2AP, and 
PICALM)8,79. Additionally, these results implicated several novel pathways underlying AD, including hippocampal 
synaptic function (MEF2C and PTK2B), apoptosis (TP53INP1), and cytoskeleton function and axonal transport 
(CELF1, NME8, and CASS4)8. However, some of these GWAS-identified genes may not be the bona fide disease-
associated genes as many of these loci have multiple genes in the associated region. Therefore, the genuine AD-
associated genes within these loci remain unclear. 
 Even though GWAS have identified several loci associated with AD risk, variants identified in these 
studies are usually common and non-coding variants that have no direct connection to potential biological 
mechanisms8,10,11,78. Additionally, these identified variants only account for a small proportion of heritability and 
have small effect sizes (OR between 0.8 and 1.2). One potential explanation is that these tagging GWAS-implicated 
SNPs are most likely surrogate markers for the underlying causal variants in each locus since tagging SNPs designed 
by the SNP chips cannot comprehensively capture all of the functional variants. Recent studies tend to support the 
hypothesis that rare variants could explain some of the missing heritability and have larger effect sizes for common 
diseases80-82. 
1.5.5 Sequencing-identified genes – PLD3 and TREM2 
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 Due to the significant improvement in NGS technology, whole-genome or whole-exome DNA sequencing 
have become cost-efficient and high-throughput tools for conducting genetic studies. Recently, two independent 
groups utilized whole-exome and whole-genome sequencing to uncover a low-frequency variant p.R47H in TREM2 
associated with increased AD risk12,13. Similarly, our lab carried out whole-exome sequencing in 14 large LOAD 
families and identified a rare variant p.V232M in PLD3 gene segregated within two independent families14. Follow-
up genotyping in seven independent case-control series demonstrated that p.V232M in PLD3 increases AD risk by 
2- fold14. In contrast to GWAS, these studies have used sequencing strategies to identify rare coding variants (ex: 
p.V232M in PLD3 and p.R47H in TREM2) with significant effects and the consequences of these variants on 
disease mechanism can be more easily investigated by conducting in vitro or in vivo studies, which can provide 
more promising targets for therapeutics12-14. 
 PLD3 is a non-classical member of the PLD protein family, which is a group of enzymes that hydrolyze 
phospholipids into fatty acids and lipophilic substances83. Unlike PLD1 and PLD2, which were previously reported 
to be involved in APP trafficking, PLD3 is poorly characterized and has no reported catalytic activity84. A recent 
study using whole-exome sequencing coupled with additional genotyping in large-scale independent case-control 
cohorts identified a rare variant p.V232M in PLD3 which increases AD risk by two-fold. PLD3 is highly expressed 
in brains in the hippocampus, entorhinal cortex, and frontal cortex. Over-expression of PLD3 in vitro results in 
VLJQLILFDQWO\ORZHUHGLQWUDFHOOXODU$33DQGH[WUDFHOOXODU$ȕ42 DQG$ȕ40 levels14; however, the underlying 
mechanism remains unclear. 
 TREM2 is a type one transmembrane receptor protein expressed on myeloid cells including microglia, 
monocyte-derived dendritic cells, osteoclasts and bone-marrow derived macrophages 85,86. Additionally, protein 
expression of TREM2 in neurons has been reported87. TREM2 transduces its intracellular signaling through DAP12 
(TYROBP)85,86. Although the natural ligands of TREM2 remain unknown, upon ligand binding, TREM2 associates 
with DAP12 to mediate downstream signaling. In the brain, TREM2 is primarily expressed on microglia and has 
been shown to control two signaling pathways: regulation of phagocytosis and suppression of inflammatory 
reactivity88-90. A previous study used microarray and laser mLFURGLVVHFWLRQRI$ȕ plaque-associated areas in an 
animal model of AD and found that TREM2 LVGLIIHUHQWLDOO\H[SUHVVHGLQ$ȕSlaque-DVVRFLDWHGYHUVXV$ȕSODTXH-
free tissue 91. Several studies have shown that homozygous loss-of-function mutations in TREM2 or DAP12 are 
associated with Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL)92-95. 
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Recent studies identified a TREM2 variant p.R47H as a risk factor for LOAD with an OR around 212,13, which is 
similar to the increased AD risk associated with carrying one APOE İDOOHOH67. Several additional rare variants 
were enriched in AD cases; however, these variants failed to reach statistical significance12,13,96. Overall, both 
GWAS and sequencing studies suggest that inflammatory genes play a key role in mediating AD risk12,13,97,98. 
1.6 BIOMARKERS FOR AD 
 'XHWRDGYDQFHVLQRXUXQGHUVWDQGLQJRIWKHELRPDUNHUVRI$'WKHDFFXPXODWLRQDQGGHSRVLWLRQRI$ȕFDQ
now be identified by several methods in humans regardless of their clinical status. Amyloid imaging using positron 
emission tomography (PET) scans has bHHQXVHGWRGHWHFWHGSUHVHQFHTXDQWLW\DQGORFDWLRQRI$ȕE\ELQGLQJWR
ILEULOODUIRUPVRI$ȕLQWKHEUDLQ99,100,QDGGLWLRQPHDVXUHPHQWRI$ȕ42 in CSF is a sensitive and specific method to 
DVFHUWDLQWKHSUHVHQFHRUDEVHQFHRI$ȕGHSRVLWLRQLQWKHEUDLQ101-103 while CSF tau and ptau181 levels are well 
correlated with the number of neurofibrillary tangles and tangle load in the human brain. Moreover, the fact that 
CSF tau/ptau181 OHYHOVLQFUHDVHDQG&6)$ȕ42 levels decrease in AD patients indicate their roles as effective 
biomarkers for AD22,104. Functional magnetic resonance imaging (MRI) is able to directly measure task-based 
activation and resting neural connectivity and indirectly measures neuronal activity and network integrity by 
utilizing blood-oxygen level dependent (BOLD) T2 techniques. Other useful biomarkers include resting synaptic 
function via glucose metabolism, visinin-like protein-1 (VILIP-1) in CSF, cortical thinning in parietal and temporal 
cortices, and hippocampal volume105. Novel and highly-effective biomarkers are still urgently needed to help 
identify individuals at high risk for developing AD.  
1.7 ENDOPHENOTYPE GENETICS 
 Instead of associating genetic markers with case-control status, endophenotype studies correlate genetic 
markers with quantitative traits in genetic analyses. The main advantages of using quantitative endophenotypes for 
AD are the increased statistical power and generation of testable hypothesis regarding the biological mechanism 
associated with genetic variants. Our previous work has shown that use of CSF biomarkers as endophenotypes for 
AD can lead to the identification of novel variants associated with disease risk, age at onset, and disease 
progression17,19,22 as well as validation of AD genetic risk factors23. UVHRI&6)$ȕ42 and tau/ptau181 levels as 
endophenotypes, which are mechanistically relevant to AD pathology, has identified additional variants and genes 
WKDWPRGLI\$ȕDQGWDXLQ&6)5HFHQWO\VHYHUDOVWXGLHVXVHGJHQHH[SUHVVLRQDVHQGRSKHQRW\SHVWRidentify novel 
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variants and genes affecting quantitative gene expression levels in human brains106-109. These data can be 
subsequently used to design specific functional assays for identified genetic variants to elucidate disease mechanism.  
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Chapter 2 
Targeted re-sequencing of Alzheimer’s disease associated genes 
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2.1  ABSTRACT 
 Recent studies have used DNA sequencing strategies to identify rare variants p.V232M in the 
phospholipase D3 (PLD3) and p.R47H in the triggering receptor expressed on myeloid 2 (TREM2) significantly 
associated with risk for AD. Additionally, genome-wide association studies (GWAS) uncovered ABCA7, BIN1, 
CD33, CD2AP, CLU, CR1, EPHA1, MS4A4A, and PICALM as AD risk loci; however, the most-significant variants 
in these loci are located within non-coding genomic regions and have no direct functional impact on AD 
pathogenesis. Thus, we hypothesized that if PLD3 and TREM2 are bona fide AD risk genes they will carry 
additional functional variants that can substantially affect risk for AD. Additionally, we hypothesized that GWAS-
identified risk genes carry additional risk alleles across the frequency spectrum so that common, low frequency or 
rare variants within these genes may contribute to AD risk. To test these hypotheses, we performed deep re-
sequencing of exonic and flanking intronic sequence for the aforementioned genes in order to identify novel 
functional variants and test for association with AD risk. Our analyses showed that rare variants in PLD3 and 
TREM2 are more frequently seen in cases than in controls of European American (EA) descent (TREM2: 6.7% in 
cases and 2.7% in controls; PLD3: 8.0% in cases and 3.1% in controls). Single-variant analyses showed that p.M6R 
(p=0.02; odds ratio [OR]=7.73 [1.09~61]) and p.A442A (p=3.78×10-7; OR=2.21 [1.58~2.8]) in PLD3 and p.R62H 
(p =2.36×10-4; OR=2.36 [1.47~3.80]) in TREM2 are significantly associated with AD risk in addition to p.V232M in 
PLD3 and p.R47H in TREM2. Gene-based tests demonstrated that PLD3 (PSKAT-O=1.44×10-11; OR=2.75 
[2.05~3.68]) and TREM2 are genome-wide significantly associated with AD (PSKAT-O=5.37×10-7; OR=2.55 
[1.62~3.87]). The associations of PLD3 and TREM2 rare variants with AD risk are still highly significant after 
excluding p.V232M (PSKAT-O=1.5×10-8; OR=2.58 [1.87~3.57]) and p.R47H (PSKAT-O=7.72×10-5; OR=2.47 
[1.62~3.87]) respectively, which suggests that additional PLD3 and TREM2 variants affect AD risk. Additionally, 
we found a significant association for PLD3 coding variants with AD risk in African Americans (PSKAT-O=1.40×10-3; 
OR=5.48 [1.77~16.92]). However, we did not find evidence of association for TREM2 variants with AD risk in 
African Americans at both gene-level and SNP-level. We also validated 90 coding variants in GWAS-identified 
genes, 66 of which were not annotated in the Exome Variant Server, which consists of whole-exome sequencing 
(WES) data in 2,203 African American and 4,300 European American unrelated individuals. Bioinformatic analyses 
predict that 56 of the confirmed variants (62.2%) are damaging. Nucleotide conservation analyses suggest that 57 of 
the validated variants are under evolutionary constraint (a GERP score>2), which suggests that a large proportion of 
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rare coding variants in GWAS-identified genes are potentially functional. Together, these findings suggest that deep 
re-sequencing is an effective strategy to identify additional functional variants in AD-associated genes. 
2.2  INTRODUCTION 
 In the past decade, enormous progress has been made in mapping genetic variants associated with complex 
human disease, one of which is the development of GWAS. GWAS have been successfully used to identify 
thousands of novel susceptibility loci for hundreds of disease traits. However, most of identified loci are located 
within non-coding genomic regions or are far from discovered genes. The susceptibility loci are found to harbor 
common variants which have very weak effect sizes and only explain a small proportion of phenotypic heritability. 
Moreover, it has been challenging to identify underlying functional variants due to their linkage disequilibrium (LD) 
with other variants. The fact that many of these susceptibility loci lie within gene-dense regions makes it difficult to 
identify the bona fide causal genes. Even though GWAS results can potentially reveal genes not previously 
suspected in disease etiology, the difficulties in replicating previous results and in translating these results into 
targets for downstream functional experiments are vivid 
 Due to the dramatic technological developments in next-generation sequencing (NGS), high-throughput 
sequencing of targeted genomic regions of the human genome in thousands of individuals in a single run is now 
cheap and feasible. Recent findings favor the rare variant-common disease hypothesis by which the combination of 
the effects of rare variants could explain a large proportion of the phenotypic heritability81,82,110. A previous study 
involving our group used whole genome, whole-exome and targeted Sanger sequencing to identify a rare variant 
p.R47H in TREM2, that increases AD risk by 2-fold12. In our recent work, Dr. Carlos Cruchaga performed whole-
exome sequencing (WES) in 14 large Late onset AD (LOAD) families and follow-up genotyping of the candidate 
variants in independent large LOAD case-control series14. A rare variant p.V232M in PLD3 segregated with disease 
status in two independent families and doubled risk for AD in seven independent case-control series with a total of 
more than 11,000 cases and controls of European American descent14. These sequencing-based studies clearly 
demonstrated that rare coding variants contribute significantly to AD and may account for the genetic heritability 
that was not fully explained by common variants. In order to test the hypothesis that additional functional variants in 
TREM2/PLD3 significantly influence AD risk, we performed deep re-sequencing of TREM2/PLD3 coding regions 
in European Americans and African Americans to identify functional rare variants that are associated with AD risk.  
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Recent GWAS identified nine novel genes, including ABCA7, BIN1, CD2AP, CD33, CR1, CLU, EPHA1, 
MS4A4A, and PICALM, as AD susceptibility loci9-11,78. However, the most-significant SNPs in these genes had very 
small effect size and only explained 50% of the phenotypic heritability for AD, which has an estimated overall 
heritability of up to 80%111. Recent studies support the paradigm that both common, low-penetrant and rarer, high 
penetrant alleles exist in the same gene contributing to disease risk77,80,112,113. Hence, we hypothesized that rare 
coding variants within GWAS-identified loci have stronger effects on AD risk compared to most-significantly 
associated common variants found in GWAS10,11,78. Our previous work has shown that the pooled-DNA sequencing 
strategy can effectively identify novel rare variants in genes of interest associated with AD risk15,16,114-116. In these 
studies, we used the same method and demonstrated that NGS-identified and GWAS-identified genes contain 
additional rare coding variants and that rare coding variants in NGS-identified genes (PLD3 and TREM2) 
significantly increase AD risk. Further analysis of the underlying mechanisms by which these variants alter protein 
function could provide important insights into AD pathogenesis.  
2.3 MATERIALS AND METHODS 
2.3.1 Participants and Study Design 
The Institutional Review Board (IRB) at Washington University School of Medicine in Saint Louis 
approved the study. Written informed consent was obtained from participants or their collateral source by the 
Clinical Core of the Charles F. and Joanne Knight Alzheimer’s Disease Research Center (Knight-ADRC). The 
approval number for the Knight-ADRC Genetics Core is 93-0006. 
2.3.2 Knight-ADRC study 
The Knight-ADRC samples included 1,082 LOAD cases and 706 cognitively normal controls of EA 
descent, and 149 African American (AA) AD cases and 87 controls, matched for age, gender and ethnicity. These 
individuals were evaluated by the Clinical Core of the Knight-ADRC and a blood sample was drawn for genetics 
studies. Cases received a clinical diagnosis of AD dementia in accordance with standard criteria, and dementia 
severity was determined with the Clinical Dementia Rating (CDR)117, with higher scores being associated with more 
severe cognitive decline. Controls underwent the same assessment but were cognitively normal (CDR=0). The 
Knight-ADRC samples were recruited without enrichment based on family history. Tables 1 and 2 summarize the 
demographic characteristics of re-sequenced samples of EA descent and of AA descent respectively  
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Table 1. Demographic characteristics of re-sequenced individuals of European American descent 
  Knight-ADRC cases NIA-LOAD cases Controls 
N 1,082 1,000 1,648 
Age ± SD (Range) 72.65±9.17 (44-103) 71.77±6.98 (48-98) 76.88±9.00 (50-105) 
% Female 57.72 64.86 60.12 
% APOE-İ3RVLWLYH 55.86 76.21 29.25 
Sample size (N), mean, standard deviation and range for age in years, percentage of female subjects, and percentage 
of subjects that carry at least one APOE-İDOOHOHIRUWKH.QLJKW-ADRC AD cases, NIA-LOAD AD cases, and 
cognitively-normal elderly controls from both studies. We sequenced ABCA7, BIN1, CD33, CD2AP, CR1, EPHA1, 
MS4A4A, PICALM, PLD3 and TREM2 in these samples. 
Table 2. Demographic characteristics of re-sequenced individuals of African American descent 
  Knight-ADRC cases NIA-LOAD cases Controls 
N 149 55 132 
Age ± SD (Range) 75.31±8.57 (51-94) 70.75±7.00 (51-84) 73.37±7.66 (60-94) 
% Female 77.18 75 68.18 
% APOE-İ3RVLWLYH 58.9 62.5 39.39 
Sample size (N), mean, standard deviation and range for age in years, percentage of female subjects, and percentage 
of subjects that carry at least one APOE-İDOOHOHIRUWKH.QLJKW-ADRC AD cases, NIA-LOAD AD cases, and 
cognitively-normal elderly controls from both studies. We sequenced ABCA7, BIN1, CD33, CD2AP, CR1, EPHA1, 
MS4A4A, PICALM, PLD3 and TREM2 in these samples. 
2.3.3 NIA-LOAD study 
The NIA-LOAD study case control series consists of one affected individual from each of 1,000 families 
multiply affected by AD and 942 healthy unrelated controls of EA descent and 55 AD cases and 45 controls of AA 
descent, with no family history of dementia in first-degree relatives. All AD cases were diagnosed with AD 
dementia using criteria equivalent to the National Institute of Neurological and Communication Disorders and 
Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) for probable AD118. All NIA-
LOAD AD cases had a family history of AD. Probands were required to have a diagnosis of definite or probable AD 
and a sibling with definite, probable or possible AD with a similar age at onset. A third biologically-related family 
member (first, second or third degree) was also recruited, regardless of cognitive status. We screened one individual 
from each family by selecting the youngest affected family member with the most definitive diagnosis (i.e. 
individuals with autopsy confirmation were chosen over those with clinical diagnosis only. Written informed 
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consent was obtained from all participants, and the study was approved by local IRB committees. See Tables 1 and 
2 for the demographic characteristics of re-sequenced samples. 
2.3.4 Deep re-sequencing and sequencing analysis 
We used a pooled-DNA sequencing strategy as previously described15,16,97,119. A schematic representation 
of the technique was shown in Figure 1. Equimolar amounts of individual DNA samples were pooled together 
after being measured using Quant-iTTM PicoGreen (Invitrogen) reagent. Pools with 100 ng of DNA from 94 
individuals were made. Protein coding regions of the ABCA7, BIN1, CD2AP, CD33, CR1, CLU, EPHA1, MS4A4A, 
PICALM, PLD3, and TREM2 genes were amplified by the PCR using specific primers and Pfu Ultra high-fidelity 
polymerase (Agilent). We used the web-based Primer3 tool (http://bioinfo.ut.ee/primer3) for the design of PCR 
primers. To guarantee sufficient coverage of each desired exon, a minimum of 50bp of flanking 
sequences on either side was required for the primer design. An average of 20 diploid genomes (0.14 ng 
DNA) per individual was used as the input. PCR products were cleaned using QIAquick PCR (Qiagen) purification 
kits, quantified using Quant-iT PicoGreen reagent and ligated in equimolar amounts using T4 Ligase and T4 
Polynucleotide Kinase. After ligation, concatenated PCR products were randomly sheared by sonication and 
prepared for sequencing on an Illumina HiSeq 2000 according to the manufacturer’s specifications. The pCMV6-
XL5 amplicon (1,908 bp) was included in the reaction as a negative control. The positive controls contained 10 
different constructs (p53 gene) with synthetically engineered mutations at an assigned frequency of one mutated 
copy per 188 normal copies were amplified and pooled with the PCR products. Paired-end reads (150 bp) were 
aligned to the reference sequence (GRCh37/hg19) using SPLINTER120. SPLINTER uses the positive controls to 
estimate sensitivity and specificity for variant calling120. The wild-type-to-mutant ratio in the positive control was 
similar to the relative frequency expected for a single mutation in one pool (1 chromosome mutated in 94 samples = 
1/188). SPLINTER uses the negative controls (first 900 bp) to model the error rates across the 102 bp Illumina reads 
and to create an error model from each sequencing run of the machine. Based on the error model (see Figure S1 for 
an example), SPLINTER calculates a p-value for the probability that a predicted variant is a true positive. A p-value 
at which all mutants in the positive controls were identified was defined as the cutoff to estimate the sensitivity and 
specificity. All mutants included as part of the amplified positive control vectors were found upon achieving .30-
fold coverage at mutated sites (sensitivity=100%) and only ~80 sites in the 1,908 bp negative control vector were 
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predicted to be polymorphic (specificity=~95%). The variants with a p-value below this cutoff value were 
considered for follow-up genotyping. 
2.3.5 SNP genotyping and segregation with disease 
All rare missense or splice site variants identified by SPLINTER were validated by directly genotyping all 
sequenced individuals using Sequenom iPLEX or KASPar genotyping systems as described previously14-16. To 
avoid potential batch/plate effects, genotyping was repeated with heterozygous cases or controls that were randomly 
assigned in the plates. The genotype call rate of these SNPs was >98%. We genotyped confirmed variants in all 
available family members to determine whether these variants segregate with disease status. 
2.3.6 Population structure 
A principal component analysis (PCA) was conducted to infer genetic structure of individuals who have 
GWAS data available using the EIGENSTRAT software as previously described121. When GWAS data is not 
available, self-reported ethnicity was used for consideration of inclusion in the final analysis. 
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2.3.7 Statistical analyses 
We used the Fisher’s exact test to test for association between AD risk and each genetic variant in TREM2 
and PLD3 using PLINK 122. For the gene-based association, we tested for association between the confirmed set of 
variants in TREM2 and PLD3 and AD risk using SKAT-O conducted using R package SKAT123. The gene-level 
significance threshold is defined by type-I error rate divided by the number of human genes (0.05/20,000=2.4×10-6). 
For the family-based association analysis, we used the Fisher’s exact test to determine whether any TREM2 variants 
are associated with disease status within families. We did not perform single-variant and gene-based analyses for 
GWAS-identified genes because the direct genotyping has not been completed. 
2.3.8 Bioinformatic analysis 
 The EVS (http://evs.gs.washington.edu/EVS), SeattleSeq Annotation 
(http://snp.gs.washington.edu/SeattleSeqAnnotation137/) and the Ensembl Genome Database 
(http://useast.ensembl.org/index.html) were used to annotate the rare variants. SIFT (http://sift.jcvi.org/) and 
Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) algorithms were used to predict the functional effect of the 
identified variants. The Uniprot database (http://www.uniprot.org/) was used to extract and perform alignment of the 
protein sequences across different species. To determine the effect of the p.A442A variant in PLD3 on splicing we 
used the ESEfinder (http://rulai.cshl.edu/tools/ESE). Multiple sequence alignment was performed by ClustalW2, and 
the PLD3 orthologues were downloaded from Ensembl. 
2.3.9 Gene expression and alternative splicing analyses 
Parietal lobes of 82 AD case brains and 39 individuals without dementia were acquired from the Knight-
ADRC for validating PLD3 gene expression and alternative splicing. Parietal lobes from EA autopsy-confirmed AD 
(N = 2) case brains were selected for validating TREM2 alternative splicing. All subjects signed and provided the 
hospital autopsy form. If the participant does not provide future consent before death, the DPOA (durable power of 
attorney) or next of kin provide it after death. The Washington University IRB reviewed the protocol operated by 
Knight-ADRC Neuropathology Core and determined the study was exempt from approval. RNA was extracted from 
brain tissue using an RNeasy kit (Qiagen) following the manufacture’s protocol. cDNA was synthesized from the 
extracted RNAs (10 ug) by the PCR using the High-Capacity cDNA Reverse Transcriptase kit (ABI). 
Total PLD3 gene expression levels were analyzed by real-time PCR, using an ABI-7900 real-time PCR 
system. TaqMan assays were used to quantify PLD3 mRNA levels. Primers and TaqMan probe for the reference 
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gene, GAPDH, were designed over exon-exon boundaries, using Primer Express software v3 (ABI). Cyclophilin A 
(ABI: 4326316E) was also used as a reference gene. Each real-time PCR run included within-plate triplicates and 
each experiment was performed at least twice for each sample. 
To evaluate alternative slicing changes due to PLD3 p.A442A variant, we selected eight p.A442A carriers 
as well as eight CDR-, age-, APOE-, and PMI-matched individuals to analyze the expression level of exon 11 
containing transcripts, the exon in which the p.A442A variant is located. Real-time PCR assays were used to 
quantify PLD3 exon 7 (forward primer, 5’-GCAGCTCCATCCCATCAACT-3’; reverse, 5’-
CTTGGTTGTAGCGGGTGTCA-3’), exon 8 (forward primer, 5’-CTCAACGTGGTGGACAATGC-3’; reverse, 5’-
AGTGGGCAGGTAGTTCATGACA-3’), 9 (forward primer, 5’-ACGAGCGTGGCGTCAAG-3’; reverse, 5’-
CATGGATGGCTCCGAGTGT-3’), 10 (forward primer, 5’-GGTCCCCGCGGATGA-3’; reverse, 5’-
GGTTGACACGGGCATATGG-3’) and 11 (first pair of primers: forward primer, 5’-
CCAGCTGGAGGCCATTTTC-3’; reverse, 5’-TGTCAAGGTCATGGCTGTAAGG-3’; second pair forward 
primer, 5’-GCTGCTGGTGACGCAGAAT-3’; reverse, 5’-AGTCCCAGTCCCTCAGGAAAA-3’). Two pairs of 
primers were designed for exon 11 as an internal control. SYBR-green primers were designed using Primer Express 
software, v3 (ABI). Each real-time PCR run included within-plate duplicates and each experiment was performed at 
least twice for each sample. Real-time data were analysed using the comparative Ct method. Only samples with a 
standard error of, 0.15% were analyzed. The Ct values for exon 11 were normalized with the Ct value for the exons 
7–10. The relative exon 11 levels for the p.A442A carriers versus the non-carriers were compared using a t-test. 
 According to Ensembl, TREM2 encodes three alternative transcripts (ENST00000373113, 
ENST00000373122, and ENST00000338469). To evaluate TREM2 alternative splicing and determine whether these 
transcripts exist in the human brain, cDNA isolated from parietal lobes of two Alzheimer’s disease brains were 
amplified using PCR with Pfu (Agilent) enzyme. The PrimerQuest Design Tool (Integrated DNA Technology) was 
used to design primers spanning exon junctions. PCR primers include a forward primer located at the junction 
between exons 3 and 4 and a reverse primer located in exon 4 of the longest transcript ENST00000373113 (See 
Table S1 and Fig S2 for primers and the expected amplicon lengths). For the transcript ENST00000373122, we 
designed a unique forward primer, which only exists in this transcript, located spanning the exon3-exon4 junction 
and a reverse primer located in exon 4 to amplify the sequence (See Table S1 for designed primers and the expected 
length). For the transcript ENST00000338469, a forward primer located across the exon3-exon5 junction and a 
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reverse primer located in exon 5 were used to amplify this transcript (See Table S1 and Fig S2 for primers and the 
expected amplicon lengths). Each PCR reaction contained 7.5 µl of PerfeCTa SYBR Green FastMix (Quanta 
Biosciences), 720 nM forward and reverse primers, and 15 ng of cDNA in a final volume of 15 µl. The reaction mix 
was incubated using a program as follows: (1) 45°C for 2 min; (2) 95°C for 2 min; (3) 95°C for 15 sec; (4) 60°C for 
1 min; (5) repeat steps 3-4 for 40 cycles. The resulting PCR product was run on a 2% agarose gel and visualized on 
a Syngene Imaging system. 
2.4 RESULTS 
2.4.1 PLD3 sequencing 
 To identify risk variants in PLD3, we performed deep re-sequencing of PLD3 coding regions in 2,363 cases 
and 2,027 controls of EA descent, and 130 cases and 172 controls of AA descent (see Figure 2). Fourteen variants 
(p.M6R, p.P76A, p.T136M, p.K228R, p.V232M, p.N236S, p.N284S, p.C300Y, p.A325T, p.Q406H, p.T426A, 
p.G452E, p.G454C, and p.R488C; Table 3 and Figure 3) were observed more frequently in cases than in controls, 
including nine variants (p.P76A, p.T136M, p.K228R, p.N284S, p.A325T, p.Q406H, p.T426A, p.G454C, and 
p.R488C) that were unique to cases (a total of 16 carriers; Table 3 and Figure 3). The gene-based burden analysis 
resulted in a genome-wide significant association of carriers of PLD3 coding variants among Alzheimer’s disease 
cases (7.99%) compared to controls (3.06%; p=1.44×10-11; OR=2.75, 95% CI=2.05~3.68; Figure 2). When the 
p.V232M variant was excluded, the association remained highly significant, still passing genome-wide multiple test 
correction (p=1.58×10-8; OR=2.58, 95% CI=1.87~3.57; Figure 2 and Table S2), indicating that there are additional 
variants in PLD3 that increase risk for AD independent of p.V232M. There were two additional highly conserved 
variants (see Figure S3), that were nominally associated with LOAD risk: p.M6R (p=0.02; OR=7.73, 95% 
CI=1.09~61; Table 3), and p.A442A (p=3.78×10-27; OR=2.12, 95% CI=1.58~2.83; Table 3).The p.A442A variant 
was included in the gene-based analysis because our bioinformatics and functional analyses indicate that this variant 
affects splicing and gene expression (see Figures S3 and S4). After excluding both p.V232M and p.A442A from the 
model, the gene-based association remained highly significant (p=1.61×10-3; OR=2.86, 95% CI=1.62~5.06; Figure 
2 and Table S2), which indicates other risk variants in PLD3 remained undiscovered. In order to identify which of 
the remaining variants affect risk for AD, functional studies will be required. 
 If the association for PLD3 with AD risk is real, it is possible that rare coding variants in PLD3 in other 
populations will also increase risk for AD. We therefore sequenced PLD3 in 302 AA AD cases and controls (see 
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Figure 2). Both the p.V232M and p.A442A variants were found in AD cases but not controls, and the p.A442A 
variant showed a significant association with AD risk in African Americans (p = 0.03; Table 3). There was also a 
significant association with LOAD risk at the gene level (p=1.4×10-3; OR=5.48, 95% CI=1.77~16.92; Figure 2). 
This consistent evidence of association with AD risk, at the single-nucleotide polymorphism (SNP) and gene level in 
two different populations strongly supports PLD3 as an AD risk gene. 
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Table 3. Sequence variants found in PLD3 in the NIA-LOAD, Knight-ADRC and NIA-UK datasets. 
Chr. 
position AA 
 
NIA 
LOAD 
Knigh
t 
ADRC 
NIA-
UK total 
MAF
% p-value 
OR 
(95% CI) 
EVS 
MAF% SIFT Polyphen 
40872407 M6R CA 0 8 1 9 0.19 0.02 7.73 NP tolerated deleterious 
  
CO 0 1 0 1 0.02 
 
(1.09-61) 
   
       
 
     40872764 S63G CA 3 1 0 4 0.08 0.74 0.68 0.16 tolerated neutral 
  
CO 5 0 0 5 0.12 
 
(0.18-2.55) 
   
       
 
     40872803 P76A CA 3 1 0 4 0.08 0.12 NA 0.03 tolerated benign 
  
CO 0 0 0 0 0.00 
     
       
 
     40873764 T136M CA 0 1 0 1 0.02 0.54 NA NP tolerated deleterious 
  
CO 0 0 0 0 0.00 
     
       
 
     40876055 H197Y CA 0 1 0 1 0.02 0.49 0.85 NP damaging benign 
  
CO 0 1 0 1 0.02 
 
(0.05-13-7) 
   
       
 
     40877584 K228R CA 1 1 1 3 0.06 0.25 NA NP damaging deleterious 
  
CO 0 0 0 0 0.00 
     
       
 
     40877595 V232M CA 29 16 1 46 0.99 1.05x10-5 3.99  0.48 damaging deleterious 
  
CO 8 2 0 10 0.25 
 
(2.01-7.94) 
   
       
 
     40877608 N236S CA 0 2 0 2 0.04 0.40 1.71  0.01 damaging deleterious 
  
CO 0 1 0 1 0.02 
 
(0.15-18.91) 
   
       
 
     40877752 N284S CA 0 1 0 1 0.02 0.54 NA NP tolerated deleterious 
  
CO 0 0 0 0 0.00 
     
       
 
     40880407 C300Y CA 2 3 0 5 0.10 0.46 2.14  0.09 tolerated deleterious 
  
CO 1 0 1 2 0.04 
 
(0.41-11.06) 
   
       
 
     40880481 A325T CA 0 1 0 1 0.02 0.54 NA NP damaging deleterious 
  
CO 0 0 0 0 0.00 
     
       
 
     40883725 Q406H CA 1 0 0 1 0.02 0.54 NA NP tolerated neutral 
  
CO 0 0 0 0 0.00 
     
       
 
     40883783 T426A CA 1 0 0 1 0.02 0.54 NA NP tolerated neutral 
  
CO 0 0 0 0 0.00 
     
       
 
     40883911 G435V CA 0 0 0 0 0.00 0.46 NA 0.02 damaging deleterious 
  
CO 1 0 0 1 0.02 
     
       
 
     40883933 A442A CA 48 35 12 95 2.09 1.08x10-5 2.31  1.59 - - 
  
CO 17 12 7 36 0.90 
 
(1.56-3.41) 
   
       
 
     40883956 Q450L CA 0 0 0 0 0.00 0.46 NA  NP tolerated neutral 
  
CO 0 0 1 1 0.02 
     
       
 
     40883962 G452E CA 4 6 0 10 0.21 0.16 2.86 0.09 tolerated deleterious 
  
CO 0 2 1 3 0.07 
 
(0.78-10.4) 
   
       
 
     40883967 G454C CA 0 1 0 1 0.02 0.54 NA NP damaging deleterious 
  
CO 0 0 0 0 0.00 
     
       
 
     40884037 D477G CA 0 1 0 1 0.02 0.49 0.42 0.02 damaging deleterious 
  
CO 0 1 0 1 0.02 
 
(0.04-4.72) 
   
       
 
     40884069 R488C CA 0 3 0 3 0.06 0.25 NA 0.02 damaging deleterious 
  
CO 0 0 0 0 0.00 
     
       
 
     total 
 
CA 1106 1114 143 2363  
     
total 
 
CO 928 913 183 2024 
 
     The coding region of PLD3 was sequenced in 2,363 AD cases and 2,024 controls (see materials and methods) from the Knight-ADRC, NIA-LOAD and the NIA-UK datasets. The table 
shows the coding variants identified as well as the number of carriers in each dataset. The minor allele frequency (MAF) in cases and in controls, the p-value and the OR for the association 
with case-control status is shown. The MAF of the identified variants in the Exome Variant Server (EVS) is shown. We also used SIFT and Polyphen to predict the impact of the non-
synonymous changes on protein function. NA: not available. NP: not present 
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2.4.2  TREM2 sequencing 
TREM2 was sequenced in 2,082 AD cases and 1,648 cognitively-normal elderly controls of EA descent and 
204 AD cases and 132 controls of AA descent using pooled-DNA sequencing (see Tables 1 and 2). In European 
Americans, pooled sequencing identified sixteen rare variants in TREM2, six of which were not identified in the 
recent studies12,13,96: p.R52H, p.R136W, p.E151K, p.W191X, p.E202D, and p.H215Q (see Table 4 and Figure 4A). 
Nine variants (p.R52H, p.T66M, p.R136W, p.R136Q, p.H157Y, p.W191X, p.E202D, p.H215Q and p.T223I) were 
only found in AD cases (a total of 13 carriers; Table 4), three of which were not reported in the Exome Variant 
Server (EVS) database (p.R136W, p.E220D and p.H215Q). The protein sequence conservation analysis suggests 
that p.R47H, p.R52H, p.R62H, p.T66M, p.D87N, p.T96K, p.E151K, p.H157Y, p.L211P, and p.T223I are 
particularly conserved across species (see Figure 4B). For the single-variant analyses, we replicated the association 
of p.R47H with AD risk (p=9.17×10-4; OR=2.63 [1.44~4.81]; Table 4). The minor allele (T) of a second variant, 
p.R62H was also significantly associated with increased AD risk (p=2.36×10-4; OR=2.36 [1.47~3.80]; Table 4 and 
Figure 4A) after multiple test correction. In African Americans, a total of eleven coding variants were identified in 
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TREM2, four of which were not identified in previous studies (p.A105V, p.E151K, p.W191X, and p.E202D; Table 
5 and Figure 4A). None of these TREM2 variants, including the confirmed risk factor p.R47H, were significant 
associated with AD risk which may due to our small AA sample size (see Table 5). 
To determine whether TREM2 rare variants collectively contribute to AD risk, we performed a gene-based 
association test using the optimal SNP-set sequence kernel association test (SKAT-O). In European Americans, 
gene-based association testing for TREM2 achieved genome-wide significance (PSKAT-O=5.37×10-7; OR=2.55 
[1.80~3.67]; Table 4) and remained highly significant after excluding p.R47H (PSKAT-O=7.72×10-5; OR=2.47 
[1.62~3.87]; Table S3), the only confirmed risk factor for AD, in TREM2. This result demonstrates that additional 
rare variants in TREM2 contribute to AD risk. The cumulative carrier frequency of all TREM2 variants is 6.7% (139 
out of 2,082) in AD cases and 2.7% (45 out of 1,648) in cognitively normal elderly controls of EA descent. 
However, we did not identify significant association for TREM2 coding variants with AD risk (PSKAT-O=1; OR=0.73 
[0.44~1.23]; Table 5). The cumulative carrier frequency of TREM2 variants is 25.4% (52 out of 204) in AD cases 
and 31.8% (42 out of 132) in controls of AA descent.  
Next we used the NIA-LOAD family series to test whether TREM2 variants are associated with disease 
status within families. We found that p.R47H and p.R62H were more frequently found in AD cases than in controls 
(Fisher’s exact p=4.65×10-2 and 6.87×10-3 for p.R47H and p.R62H respectively; Table 6) after directly genotyping 
all samples individually from 13 and 21 independent families respectively. Other variants were either too rare or the 
families were not sufficiently large to provide statistical evidence of association with disease within and across 
families (see Table 6 and Figure S4). These results strongly support p.R62H as a risk factor for AD in addition to 
p.R47H. 
Two of the identified TREM2 (p.W191X and p.E202D, found only in AD cases) variants are only located 
in the coding region of the predicted shortest transcript (ENST00000338469), encoding a soluble form of TREM2 
(sTREM2). However, it remains unclear whether sTREM2 results from alternative splicing or sequential cleavage of 
the transmembrane form of TREM2 molecules. To confirm the existence of this alternative transcript, we performed 
polymerase chain reaction (PCR) on cDNA from 2 human brains using transcript-specific primers to amplify each 
isoform based on the Ensembl database. Gel electrophoresis analysis confirmed that there are at least three distinct 
TREM2 transcripts: ENST00000373113, ENST00000373122, and ENST00000338469 expressed in the parietal
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Table 4. Rare TREM2-variant association in sequenced samples of EA descent* 
   
Guerreiro et al. # Cuyvers et al.@ AD Cases Controls 
   AA 
Change SNP 
CHR:BP 
(hg19) P
# OR (95% CI)# P@ OR (95% CI)@ No. of Cases 
No. of 
Carriers 
No. of 
Controls 
No. of 
Carriers P
! OR (95% CI) PolyPhen 
All 
variants           5.37×10
-7& 2.55 (1.80-3.67)  
p.Q33X rs104894002 6:41129295 0.25 NA NA NA 2050 1 1611 1 1 0.81 (0.05-12.97) NA 
p.R47H rs75932628 6:41129252 <0.001 4.5 (1.7-11.9) 0.08 3.01 (0.83-10.94) 2050 46 1616 14 9.17×10-4 2.63 (1.44-4.81) Damaging 
p.R52H rs374851046 6:41129237 NA NA NA NA 2077 1 1642 0 1 NA Damaging 
p.R62H rs143332484 6:41129207 0.5 0.8 (0.5-1.4) 0.08 1.54 (0.96-2.49) 2050 68 1618 24 2.36×10-4 2.36 (1.47-3.80) Benign 
p.T66M rs201258663 6:41129195 0.5 NA NA NA 2052 1 1622 0 1 NA Damaging 
p.D87N rs142232675 6:41129133 0.02 NA NA NA 2051 9 1619 4 0.41 1.84 (0.56-5.96) Damaging 
p.T96K rs2234253 6:41129105 0.72 1.4 (0.3-6.0) NA NA 2044 2 1609 2 1 0.81 (0.11-5.77) Damaging 
p.R136W NA 6:41127606 NA NA NA NA 2003 2 1562 0 0.51 NA NA 
p.R136Q rs149622783 6:41127605 1 1.8 (0.1-28.6) NA NA 2047 1 1623 0 1 NA Benign 
p.E151K rs79011726 6:41127561 NA NA NA NA 2077 0 1642 1 0.45 0 Damaging 
p.H157Y rs2234255 6:41127543 0.36 NA NA NA 2052 3 1610 0 1 NA Damaging 
p.W191X rs2234258 6:41126429 NA NA NA NA 1816 1 1440 0 1 NA NA 
p.E202D NA 6:41126395 NA NA NA NA 2077 1 1642 0 1 NA NA 
p.L211P rs2234256 6:41126655 0.56 0 NA NA 2043 2 1605 2 1 0.81 (0.11-5.76) Benign 
p.H215Q NA 6:41126642 NA NA NA NA 2001 1 1560 0 1 NA NA 
p.T223I rs138355759 6:41126619 NA NA NA NA 2077 2 1642 0 0.51 NA Benign 
* NA represents not applicable. # These values were derived from Table 2 in Guerreiro et al12. @ These values were derived from Table 1 in Cuyvers et al96.! The Fisher's exact test was used to 
calculate the p values using the default commands in PLINK. & This p value summarizes the gene-based association of the identified SNP set and was estimated using the SKAT-O algorithm. 
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Table 5. Rare TREM2 variants found in African Americans 
   
AD Cases Controls  
   
Variant SNP Position No. of Cases 
No. of 
Carriers 
No. of 
Controls 
No. of 
Carriers P
! OR (95% CI) SIFT PolyPhen 
All variants       1
& 0.73 (0.44-1.23)   
p.R47H rs75932628 6:41129252 203 0 131 1 0.39 0 Tolerated Damaging 
p.R62H rs143332484 6:41129207 203 1 131 0 1 NA Tolerated Benign 
p.T66M rs201258663 6:41129195 203 1 132 0 1 NA Damaging Damaging 
p.D87N rs142232675 6:41129133 203 1 131 1 1 0.64 (0.04-10.35) Tolerated Damaging 
p.T96K rs2234253 6:41129105 200 45 131 38 0.19 0.72 (0.45-1.14) Damaging Damaging 
p.A105V rs145080901 6:41129078 203 1 131 1 1 0.64 (0.04-10.35) Damaging Damaging 
p.E151K rs79011726 6:41127561 204 1 132 0 1 NA NA Damaging 
p.H157Y rs2234255 6:41127543 203 1 132 0 1 NA Damaging Damaging 
p.W191X rs2234258 6:41126429 183 12 122 8 1 1 (0.40-2.48) NA NA 
p.E202D NA 6:41126395 204 0 132 1 0.39 0 Damaging NA 
p.L211P rs2234256 6:41126655 201 46 131 38 0.29 0.78 (0.49-1.22) Tolerated Benign 
* NA represents not applicable. & This p value summarizes the gene-based association of the identified SNP set and was estimated using the SKAT-O algorithm 
! The Fisher's exact test was used to calculate the p values using plink. 
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Figure 4. Schematic representation of protein structure for TREM2 and for the soluble form of TREM2, 
location of variants, protein conservation of the mutated positions, and the results of alternative splicing 
assays. (A) The top panel shows the protein structure of TREM2 (based on ENST00000373113), a type-I 
transmembrane receptor that is encoded by a gene containing 5 exons. The isoform ENST00000373122 encodes a 
different protein coding sequence after exon 3 (gradient fill rectangle) compared to ENST00000373113. The soluble 
form of TREM2 (ENST00000338469) lacks exon 4, which encodes the transmembrane domain, and contains a 
coding region after exon 5 (texture fill rectangle). Figures shown below include the structure of three different 
TREM2 isoforms, the location of confirmed variants in the most common TREM2 transcript (ENST00000373113), 
and the location of confirmed variants only in the sTREM2 transcript (ENST00000338469). Most of the variants in 
the transmembrane form of TREM2 are located in the extracellular domain with three exceptions, located in the 
cytoplasmic tail. We identified two variants that are located near the C-terminus of the soluble form of TREM2. (B) 
The protein conservation analysis of confirmed TREM2 variants. Variants are shown with an arrow identifying the 
corresponding amino acid position. Protein sequences were downloaded from UniProt. The entries used for each 
species are as follows: Q9NZC2 (Human), Q99NH8 (Mouse), D3ZZ89 (Rat), H2QSZ0 (Chimp), F7CW35 (Frog), 
Q2YHU4 (Chicken), and E2RP46 (Dog). (C) Results of alternative splicing validation. PCR was performed to 
amplify the cDNA of two AD cases (Brain ID =1 and 2) extracted from autopsy brain tissue obtained from the 
Knight-ADRC. ENST00000373113, ENST00000338469, and ENST00000373122 were amplified using 7 different 
primer pairs designed to specifically amplify one of the three transcripts (Primer ID=1.1 and 1.2 for 
ENST00000373113; Primer ID=2.1, 2.2 and 2.3 for ENST00000338469; Primer ID=3.1 and 3.2 for 
ENST00000373122). The amplicon length is 100 bp for 1.1, 84 bp for 1.2, 135 bp for 2.1, 81 bp for 2.2, 104 bp for 
2.3, 103 bp for 3.1, and 127 bp for 3.2. The gel electrophoresis analysis clearly shows the presence of three distinct 
isoforms in the cDNA extracted from brains of two AD cases.  
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cortex of human brain (see Figure 4C). The variant p.W191X is predicted to result in a premature stop codon in the 
ENST00000338469 transcript; however, the impact of this variant on AD pathogenesis remains unknown, due to the 
rarity of the allele (1/1,816 cases). 
Table 6. Segregation of rare variants in available family members 
   Affected Unaffected  
Variant # of families Status Carriers Non-carriers Carriers Non-carriers P 
p.Q33X 1 Nasu Hakola variant 0 2 1 1 1 
   NA 75±0 56 58  
p.R47H 13 Confirmed risk factor 15 4 4 7 4.65×10-2* 
   70.8±7.9 72.3±10.7 74±4.5 78.7±7.7  
p.R62H 21 Previously identified 18 11 11 28 6.87×10-3* 
   71.8±5.7 67.9±7.7 71.5±11.4 71.4±8.8  
p.D87N 2 Previously identified 2 0 2 3 4.29×10-1 
   81.8±1.4 NA 71±1.4 74.3±9.0  
p.H157Y 1 Previously identified 2 1 0 0 1 
   67±5.7 85 NA NA  
p.H215Q 1 Novel variant 1 1 0 0 1 
   79 70 NA NA  
p.T223I 1 Novel variant 1 0 1 0 1 
   62 NA 73 NA  
Family-based association analysis was performed for variants when samples from family members of the probands were 
available. The same variant was genotyped to test whether the rare allele is associated with disease status. Variants, number of 
families performed, variant type, the number of affected carriers, non carriers and un-affected carriers, non-carriers, the average 
and standard deviation of age at onset (years) for the affected individuals and the average and standard deviation of age at last 
assessment (years) for the unaffected individuals were shown. All of the confirmed carriers only carried one rare allele. Novel 
variants were not identified in previous studies12,13. A two-tailed Fisher's exact test was used to determine evidence of 
segregation for each variant. * denotes significant association. NA represents not applicable. 
2.4.3 GWAS-identified genes sequencing 
 Deep re-sequencing in the coding regions of GWAS-identified genes was undertaken in the same AD cases 
and cognitively-normal elderly controls as TREM2 sequencing (see Tables 1 and 2). We have performed direct 
genotyping and validated 90 non-synonymous variants in these genes (40 in ABCA7, 4 in BIN1, 7 in CD2AP, 7 in 
CD33, 7 in CLU, 11 in EPHA1, 4 in MS4A4A, and 10 PICALM, Table 7), 66 of which were not annotated in the 
EVS database. I did not validate any variants in CR1 due to the fact that this genomic region is highly repetitive, 
which leads to low specificity and a below-average coverage. SIFT and PolyPhen algorithms both provide 
predictions for the possible impact of an amino acid change on the protein structure, which suggests that 56 out of 
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90 (62.2%) non-synonymous variants are damaging. Additionally, 57 out of 90 (63.3%) variants have a GERP 
conservation score equal or greater than two (the greater the score the greater the level of evolutionary constraint 
inferred to be adding on the site). Therefore, based on protein change and evolutionary constraint predictions, a large 
proportion of these validated variants are likely to be functional. We will finish direct genotyping and segregation 
analyses in the coming months and SNP-level and gene-level association testing will be conducted to determine the 
effects on AD risk. 
Table 7. Confirmed variants in GWAS-identified genes 
Gene AA Change SNP CHR:BP (hg19) Function PolyPhen SIFT GERP Score In EVS? 
ABCA7 p.M8I NA 19:1041384 missense DAMAGING TOLERATED 4.78 No 
ABCA7 p.L9M NA 19:1041385 missense DAMAGING DAMAGING -3.59 No 
ABCA7 p.L101R rs201665195 19:1041971 missense-near-splice DAMAGING DAMAGING 4.07 Yes 
ABCA7 p.A172T NA 19:1042760 missense TOLERATED TOLERATED 0.615 No 
ABCA7 p.D245Y rs377552810 19:1043193 missense DAMAGING DAMAGING -1.93 Yes 
ABCA7 p.G272R NA 19:1043356 missense DAMAGING TOLERATED 2.2 No 
ABCA7 p.R281H rs375028339 19:1043384 missense DAMAGING DAMAGING 0.571 Yes 
ABCA7 p.W284X NA 19:1043393 stop-gained NA NA 4.25 No 
ABCA7 p.A676T rs59851484 19:1047336 missense DAMAGING TOLERATED 4.88 Yes 
ABCA7 p.E708X NA 19:1047506 stop-gained NA NA 3.64 No 
ABCA7 p.R907Q NA 19:1051189 missense TOLERATED TOLERATED 4.37 No 
ABCA7 p.A913V NA 19:1051207 missense TOLERATED TOLERATED -0.686 No 
ABCA7 p.A914S rs111940546 19:1051209 missense TOLERATED TOLERATED 3.4 Yes 
ABCA7 p.V960A rs146811533 19:1051502 missense DAMAGING TOLERATED 4.41 Yes 
ABCA7 p.R1026C rs141322593 19:1052054 missense DAMAGING DAMAGING 2.14 Yes 
ABCA7 p.T1060A NA 19:1052243 missense TOLERATED TOLERATED -6.12 No 
ABCA7 p.K1179N NA 19:1054069 missense TOLERATED TOLERATED -0.7 No 
ABCA7 p.R1210Q NA 19:1054243 missense TOLERATED TOLERATED -2.97 No 
ABCA7 p.R1218H NA 19:1054267 missense TOLERATED TOLERATED -5.43 No 
ABCA7 p.R1236C NA 19:1054320 missense DAMAGING TOLERATED 2.59 No 
ABCA7 p.R1385Q rs144595576 19:1055299 missense DAMAGING TOLERATED 3.68 Yes 
ABCA7 p.G1415R rs374185879 19:1056069 missense DAMAGING DAMAGING 2.75 Yes 
ABCA7 p.R1434C rs137888610 19:1056126 missense DAMAGING DAMAGING 0.991 Yes 
ABCA7 p.V1487G rs200825702 19:1056372 missense TOLERATED DAMAGING 3.29 No 
ABCA7 p.R1489X NA 19:1056377 stop-gained NA NA -0.428 No 
ABCA7 p.R1505H rs113269196 19:1056426 missense TOLERATED TOLERATED -3.6 Yes 
ABCA7 p.V1598M NA 19:1057340 missense DAMAGING DAMAGING 3.65 No 
ABCA7 p.L1625M NA 19:1057421 missense DAMAGING DAMAGING 2.61 No 
ABCA7 p.W1628S NA 19:1057916 missense DAMAGING DAMAGING 4.22 No 
ABCA7 p.M1634V NA 19:1057933 missense DAMAGING DAMAGING 3.2 No 
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ABCA7 p.M1634V NA 19:1057933 missense DAMAGING DAMAGING 3.2 No 
ABCA7 p.E1679X NA 19:1058154 stop-gained NA NA -0.843 No 
ABCA7 p.N1797H NA 19:1058928 missense TOLERATED DAMAGING 3.14 No 
ABCA7 p.M1807I NA 19:1059042 missense TOLERATED TOLERATED -6.97 No 
ABCA7 p.L1813W rs200308069 19:1059059 missense DAMAGING DAMAGING 4.45 No 
ABCA7 p.R1932C rs114787084 19:1063624 missense DAMAGING DAMAGING 0.096 Yes 
ABCA7 p.R1976S NA 19:1063837 missense DAMAGING DAMAGING 2.3 No 
ABCA7 p.C1992F NA 19:1064183 missense DAMAGING DAMAGING 3.25 No 
ABCA7 p.L2022P NA 19:1064950 missense DAMAGING DAMAGING 4.24 No 
ABCA7 p.A2075V NA 19:1065109 missense TOLERATED TOLERATED 3.73 No 
BIN1 p.S392I NA 2:127808487 missense-near-splice DAMAGING DAMAGING 3.92 No 
BIN1 p.T307M NA 2:127816621 missense TOLERATED TOLERATED 4.01 No 
BIN1 p.G244R NA 2:127819725 missense DAMAGING TOLERATED 5.13 No 
BIN1 p.G238S rs372072916 2:127819743 missense TOLERATED TOLERATED 2.75 Yes 
CD2AP p.G47R NA 6:47471150 missense DAMAGING DAMAGING 4.69 No 
CD2AP p.Q207R NA 6:47541878 missense DAMAGING TOLERATED 6.08 No 
CD2AP p.S233G NA 6:47541955 missense TOLERATED TOLERATED 3.57 No 
CD2AP p.G266S NA 6:47544326 missense TOLERATED TOLERATED 2.26 No 
CD2AP p.P341Q NA 6:47548613 missense DAMAGING TOLERATED 5.42 No 
CD2AP p.K436R NA 6:47567069 missense DAMAGING TOLERATED 5.92 No 
CD2AP p.S510C NA 6:47574012 missense-near-splice DAMAGING DAMAGING 4.53 No 
CD33 p.R91C NA 19:51728707 missense TOLERATED DAMAGING -6.9 No 
CD33 G156Tfs*5 NA 19:51729103 frameshift NA NA NA Yes 
CD33 p.G156S rs201342074 19:51729106 missense DAMAGING DAMAGING 3.08 Yes 
CD33 p.A183V NA 19:51729188 missense DAMAGING DAMAGING 0.739 No 
CD33 p.F243L rs11882250 19:51729594 missense TOLERATED TOLERATED 2.88 Yes 
CD33 p.S324G rs200505271 19:51742818 missense TOLERATED TOLERATED -1.3 No 
CD33 p.H339R rs374286140 19:51742864 missense DAMAGING DAMAGING 1.47 Yes 
CLU p.T445A NA 8:27456140 missense TOLERATED TOLERATED -4.69 No 
CLU p.E387A NA 8:27457457 missense DAMAGING DAMAGING 5.62 No 
CLU p.V385I rs368729462 8:27457464 missense TOLERATED TOLERATED -11.2 Yes 
CLU p.T203I rs41276297 8:27462662 missense TOLERATED TOLERATED 1.03 Yes 
CLU p.R234H rs201670453 8:27462725 missense DAMAGING TOLERATED 0.175 Yes 
CLU p.D226N NA 8:27462750 missense DAMAGING TOLERATED 3.76 No 
CLU p.L58V NA 8:27468073 missense DAMAGING TOLERATED 2.37 No 
EPHA1 p.R891Q NA 7:143090788 missense DAMAGING DAMAGING 5.16 No 
EPHA1 p.L820Q NA 7:143091330 missense DAMAGING DAMAGING 4.58 No 
EPHA1 p.R801Q NA 7:143091387 missense DAMAGING DAMAGING 4.5 No 
EPHA1 p.R534Q NA 7:143095027 missense DAMAGING TOLERATED 4.7 No 
EPHA1 p.V514I NA 7:143095088 missense TOLERATED DAMAGING 2.72 No 
EPHA1 p.A477V rs373049955 7:143095448 missense TOLERATED TOLERATED 0.833 Yes 
EPHA1 p.P460L rs202178565 7:143095499 missense DAMAGING TOLERATED 5.08 No 
EPHA1 p.G408S NA 7:143095808 missense DAMAGING TOLERATED 5.09 No 
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EPHA1 p.D363E NA 7:143095941 missense DAMAGING DAMAGING 1.46 No 
EPHA1 p.Q347R NA 7:143095990 missense TOLERATED DAMAGING 5.09 No 
EPHA1 p.R82H NA 7:143098604 missense DAMAGING DAMAGING 4.99 No 
MS4A4A M26K rs368779495 11:60059733 missense TOLERATED TOLERATED -5.16 No 
MS4A4A M76K NA 11:60064695 missense DAMAGING DAMAGING 1.62 No 
MS4A4A A88T rs183720563 11:60064730 missense TOLERATED TOLERATED -8.13 No 
MS4A4A P96L NA 11:60064755 missense TOLERATED TOLERATED 2.99 No 
PICALM p.M26K rs368779495 11:60059733 missense TOLERATED TOLERATED -5.16 Yes 
PICALM p.M76K NA 11:60064695 missense DAMAGING DAMAGING 1.62 No 
PICALM p.A88T rs183720563 11:60064730 missense TOLERATED TOLERATED -8.13 No 
PICALM p.P96L NA 11:60064755 missense TOLERATED TOLERATED 2.99 No 
PICALM p.G518S rs369070232 11:85692249 missense DAMAGING NA 5.27 Yes 
PICALM p.P411A rs34013602 11:85707896 missense DAMAGING NA 1.57 Yes 
PICALM p.L249I NA 11:85722091 missense TOLERATED NA 2.63 No 
PICALM p.P72T NA 11:85742568 missense DAMAGING NA 5.52 No 
PICALM p.L42V NA 11:85779699 missense TOLERATED NA 4.61 No 
PICALM p.P36L NA 11:85779716 missense DAMAGING NA 4.73 No 
* NA represents not applicable. SIFT (http://sift.jcvi.org/) and PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) algorithms were used to 
predicted     the functional impact of these variants on protein structure. The presence of these variants in the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/) was also annotated for reference.  
DISCUSSION 
 This work provides extensive genetic evidence that PLD3 and TREM2 are AD risk genes: genome-wide 
significant evidence that rare variants in PLD3 and TREM2 increase risk for AD in multiple data sets and two 
populations. Moreover, our later functional studies confirm that PLD3 affects APP processing in a manner that is 
consistent with increased risk of AD14. The studies on TREM212,13 and this project indicate that next-generation 
sequencing technology can help uncover additional low-frequency and rare variants associated with AD. 
TREM2 is a type one transmembrane receptor protein expressed on myeloid cells including microglia, 
monocyte-derived dendritic cells, osteoclasts and bone-marrow derived macrophages85,86. Additionally, protein 
expression of TREM2 in neurons has been reported87. TREM2 transduces its intracellular signaling through DAP12 
(TYROBP)85,86. Although the natural ligands of TREM2 remain unknown, upon ligand binding, TREM2 associates 
with DAP12 to mediate downstream signaling. In the brain, TREM2 is primarily expressed on microglia and has 
been shown to control two signaling pathways: regulation of phagocytosis and suppression of inflammatory 
reactivity88-90$SUHYLRXVVWXG\XVHGPLFURDUUD\DQGODVHUPLFURGLVVHFWLRQRIEHWDDP\ORLG$ȕSODTXH-associated 
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areas in an animal model of AD and found that TREM2 LVGLIIHUHQWLDOO\H[SUHVVHGLQ$ȕSODTXH-associated versus 
$ȕSODTXH-free tissue91. 
Homozygous loss-of-function mutations in TREM2 were initially associated with an autosomal recessive 
form of early-onset dementia, Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL), also known as Nasu-Hakola disease, in Swedish and Norwegian families92. Subsequently, mutations in 
TREM2 were found worldwide in PLOSL patients from different countries and ethnic origins92-95. PLOSL patients 
carrying different TREM2 variants exhibit a similar clinical phenotype with respect to the neurologic and skeletal 
abnormalities92-95. The clinical spectrum of disease associated with TREM2 variants was expanded after the 
identification of three patients from a Lebanese family carrying mutations in TREM2 that exhibited early-onset 
dementia without skeletal symptoms (bone cysts)124. Additional TREM2 variants were also found in three Turkish 
probands with frontotemporal-like dementia without any bone-associated symptoms12. 
Recently, two independent studies reported that a heterozygous rare variant in TREM2 p.R47H is 
significantly associated with AD, with an odds ratio similar to that of an individual carrying one APOE İDOOHOH12,13. 
Subsequently, the association of p.R47H with AD risk was replicated in Spanish and French populations125,126. 
Several studies also found that TREM2 variants are associated with Parkinson’s disease, frontotemporal dementia 
(FTD) and amyotrophic lateral sclerosis98,127-136. Thus, TREM2 variants produce a heterogeneous disease state that 
ranges in clinical phenotypes from skeletal abnormalities to neurodegeneration. 
To our knowledge, this study is the largest deep re-sequencing study to date which aims to identify novel 
rare coding variants in TREM2. Recently, a study has sequenced TREM2 coding regions in a Belgian population and 
found additional coding variants in TREM96. Even though an enrichment of TREM2 variants in both AD and FTD 
patients compared to controls was reported, none of the rare variants were individually significant96. In our study, 
sixteen TREM2 rare coding variants were observed in European Americans, including two variants (p.R47H and 
p.R62H) that were significantly associated with AD risk and six novel variants that were not found in previous 
studies12,13,96. The minor alleles of p.R47H (p=9.17×10-4; OR=2.63 [1.44~4.81]) and p.R62H (p=2.36×10-4; 
OR=2.36 [1.47~3.80]) were associated with increased AD risk after multiple test correction. After adjusting for 
APOE İDQGİDOOHOHVLQWKHORJLVWLFUHJUHVVLRQWKHDVVRFLDWLRQIRUS5+DQGS5+RQO\FKDQJHGVOLJKWO\DQG
remained significant (p=5.91×10-3; OR=2.48 [1.30~4.75] for p.R47H; p=8.08×10-4; OR=2.36 [1.43~3.90] for 
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p.R62H; Table S5), which suggests that p.R47H and p.R62H affect AD risk independently of APOE İDQGİ
alleles. The gene-based test for TREM2 remained highly significant even after dropping p.R47H, suggesting that 
additional variants in TREM2 influence AD risk. After excluding both p.R47H and p.R62H, the gene-based p-value 
is 0.09 (see Table S3), suggesting that most of the statistical significance for the gene-based association comes from 
these two variants. However, the OR for the gene-based analyses when these two variants were removed was 2.95 
(see Table S3), suggesting that additional very- low-frequency variants may have a larger effect size for AD risk 
than p.R47H and p.R62H. This observation is also supported by the fact that nine out of sixteen TREM2 variants are 
identified in 13 AD cases and no controls. The lack of association after excluding p.R47H and p.R62H is likely due 
to the rarity of the other variants and a lack of statistical power. Moreover, we did not identify any rare variants 
significantly associated with AD risk in African Americans as the sample size was too small. Additional AA 
samples are required to help determine whether TREM2 variants influence the susceptibility to AD in the AA 
population. Recently, a study has shown that loss of one copy of TREM2 had no effect on Aȕ biology but it altered 
the morphological phenotype of plaque-associated microglia137. In order to better understand the mechanism by 
which these TREM2 variants affect AD pathogenesis, functional studies are urgently needed. 
We also evaluated the impact on the analysis of excluding individuals who could not be included in the 
PCA owing to a lack of GWAS data. After removing individuals without GWAS data, a total of 1,724 AD cases and 
1,437 controls were included in the analyses. The single-variant association changed slightly but still surpassed the 
multiple test threshold: p.R47H (p=2.99×10-3; OR=2.53 [1.35~4.76]; Table S6) and p.R62H (p=3.25×10-4; OR=2.54 
[1.49~4.35]; Table S6). The gene-based association for TREM2 reduced slightly (PSKAT-O=6.81×10-6; OR=2.56 
[1.74~3.83]; Table S6) and was no longer genome-wide significant (2.5×10-6). These results suggest that the SNP-
level and gene-level significant associations using data including individuals with/without GWAS data are not false 
positives due to population substructure. 
We also identified two variants, p.W191X and p.E202D, which are predicted to be located only in the 
coding region of the shortest transcript (ENST00000338469), encoding a soluble form of TREM2 (sTREM2) 
according to Ensembl. A soluble isoform of TREM2 protein has been described as a transcript that encodes a soluble 
form of TREM2 138,139. Extracellular TREM2 could be derived from the sTREM2 alternative transcript, a 
posttranslational cleavage product, or a combination of both. A previous study has described the presence of soluble 
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TREM2 protein in human cerebrospinal fluid (CSF) and serum140. Furthermore, CSF levels of sTREM2 were found 
to be elevated in patients with multiple sclerosis140. Experimental data suggests that soluble TREM1 results from 
sequential cleavage of the transmembrane form of this related protein140,141 and so TREM2 may be cleaved in a 
similar fashion. In this study, we showed the presence of cDNA corresponding to the predicted sTREM2 transcript 
in brain tissue from AD cases (see Figure 4C). Together, this study provides evidence of the presence of sTREM2 
mRNA in the human brain. The p.W191X variant introduces a nonsense mutation into this sTREM2 transcript at 
codon 191. It is unclear whether this would result in a truncated protein or removal of the mutant mRNA by 
nonsense mediated decay. 
 Despite that fact that GWAS have been very successful in pinpointing the regions of the human genome 
that associate with AD, the underlying causal variants and genes remain unclear as the LD with other SNPs prevents 
the identification of the functional variants and most of these susceptibility loci are located in gene-dense regions. 
For instance, a recent meta-GWAS analysis discovered an intergenic signal for rs981040, located approximately 5.5 
kb downstream from TREML2 and 24 kb upstream from TREM28 but it was impossible to determine whether this 
GWAS signal is driven by TREM2 or TREML2 due to its study design (a meta analysis), leaving the underlying 
causal variants and genes unknown. A recent study performed bioinformatic analyses and predicted that several top 
GWAS SNPs may affect protein binding or mRNA expression of a gene target using data from the ENCODE 
Project Consortium, but evidence of regulatory function are primarily in blood or cancer cells142. Recently, two 
independent studies reported that gene expression of some GWAS-identified genes were altered in AD brains and 
some of these GWAS-identified genes harbor cis-variants affecting gene expression in human brains143,144. 
Nonetheless, another independent study assessed the regional expression in the human brain but did not find any of 
these GWAS loci had eQTLs explaining the association109. Even though most of these findings did not yield a very 
strong association and not yet replicated in other studies, these results suggested that some of these GWAS-
identified variants and genes can affect AD pathogenesis through regulating gene expression in the human 
brains109,143,144. 
 Alternatively, Holton et al. also found that coding variability may explain the ABCA7 association but 
common coding variability does not explain any of the other loci, which indicates rare coding variants within these 
GWAS loci can also contribute to AD risk109. Our recent work has performed deep re-sequencing of APP, PSEN1, 
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and PSEN2, three genes cause early-onset familial AD, in LOAD families in order to identify rare coding 
variants15,16. We found that the impact of rare coding variants in APP, PSEN1, and PSEN2 on LOAD risk is more 
than previously estimated15,16. These findings suggest that rare variants in these genes (APP, PSEN1, and PSEN2) 
can account for a portion of the LOAD cases that cannot be detected by GWAS. In this study, we have confirmed 90 
rare coding variants, 66 of which were not present in the EVS database. 56 out of 90 (62.2%) confirmed variants are 
predicted to be damaging in terms of changes to protein structures and evolutionary constraint, which recapitulates 
that rare coding variants within these GWAS loci can play a key role in AD risk association.  
 In conclusion, to our knowledge, this study is the largest deep re-sequencing study to date which aims to 
uncover novel rare coding variants in PLD3, TREM2, and GWAS-identified genes. This study demonstrated that 
there multiple rare coding variants exist in PLD3 and TREM2 and that cumulatively these variants are associated 
with AD risk. The analysis of GWAS genes also identified many rare and novel coding variants, which need to be 
tested for association with disease risk. Together, these data support the paradigm that both common, low penetrant 
and rarer, higher penetrant alleles exist in the same gene in common diseases (ex: coronary heart disease and type 1 
diabetes)80,145. These findings can provide better targets for downstream functional studies and may eventually lead 
to effective therapies. 
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SUPPLEMENTAL TABLES 
Table S1. Information for primers designed for TREM2 alternative splicing assays 
Primer 
ID 
Amplicon 
Length 
Amplified 
Transcript ID Forward Primer Reverse Primer 
1.1 100 ENST00000373113 5'-GCATCTCCAGGAGCCTCT-3' 3'-CTGGCTGCTAGAATCTTGATGAG-5' 
1.2 84 ENST00000373113 5'-GATGCTGGAGATCTCTGGTT-3' 3'-CAAGAGGCTCCTGGAGATG-5' 
2.1 135 ENST00000338469 5'-AGCATCTCCAGGGCTGA-3' 3'-CTCTTGCCAGAGCAGAACAA-5' 
2.2 81 ENST00000338469 5'-GATGCTGGAGATCTCTGGTT-3' 3'-CTCAGCCCTGGAGATGC-5' 
2.3 104 ENST00000338469 5'-ATCTCCAGGGCTGAGAGACAC-3' 3'-GGTGGCCAAGTGGCAAGTAT-5' 
3.1 103 ENST00000373122 5'-CATCTCCAGGCCATCTCAAG-3' 3'-AGGAGGAGAAGGATGGAAGT-5' 
3.2 127 ENST00000373122 5'-AAGGTCCTGGTGGAGGT-3' 3'-CTTGAGATGGCCTGGAGATG-5' 
Primer IDs, amplicon lengths, corresponding transcript IDs, forward- and reverse-primer sequences were listed. Each primer set was uniquely 
designed to amplify the corresponding transcript. The PrimeQuest Design Tool (Integrated DNA Technology) was used to design the primers. 
 
 
 
Table S3. Gene-based analyses for TREM2 
 
AD Cases  Controls   
All variants including p.R47H P OR 
Non- Carriers 1,943   1,603 
5.37×10-7 2.55 (1.80-3.67) 
Carriers 139   45 
Excluding p.R47H     
Non- Carriers 1,943   1,603 
7.72×10-5 2.47 (1.62-3.87) 
Carriers 93   31 
Excluding p.R47H and p.R62H 
  Non- Carriers 1,943  1,603 0.09 2.95 (1.23-8.09) 
Carriers 25  7 
Results of SKAT-O analyses including all the coding variants with/without p.R47H and without p.R47H and p.R62H were 
presented.  
 
 
Table S2. Comparison of the gene-based analysis including all PLD3 coding variants or only variants predicted to be deleterious 
 Benign + deleterious Only deleterious 
P OR (CI) P OR (CI) 
All variants 1.44×10-11 2.75 (2.05-3.68) 2.52×10-12 2.86 (2.10-3.88) 
Excluding p.V232M 1.58×10-8 2.58 (1.87-3.57) 2.95×10-8 2.54 (1.81-3.57) 
Excluding p.A442 and p.V232M 1.61×10-3 2.86 (1.62-5.06) 5.88×10-5 3.20 (1.59-6.45) 
Gene-based analyses were performed by SKAT-O. Variants that were predicted to be benign by both SIFT and Polyphen were removed for the 
second analysis 
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Table S4. TREM2 segregation data for each independent family with available DNA samples 
   Affected Unaffected 
Variant Anonymous family ID Status Carriers Non-carriers Carriers Non-carriers 
p.Q33X 1 Nasu Hakola variant 0 2 1 1 
      NA 75±0 56 58 
p.R47H 2 Confirmed risk factor 1 1 0 0 
      80 60 NA NA 
p.R47H 3 Confirmed risk factor 1 0 0 1 
      81 NA NA 84 
p.R47H 4 Confirmed risk factor 0 1 1 0 
      NA 85 79 NA 
p.R47H 5 Confirmed risk factor 1 0 1 0 
      68 NA 68 NA 
p.R47H 6 Confirmed risk factor 1 0 0 1 
      67 NA NA 68 
p.R47H 7 Confirmed risk factor 1 0 1 0 
      66 NA 74 NA 
p.R47H 8 Confirmed risk factor 2 0 0 1 
      61±1.4 NA NA 74 
p.R47H 9 Confirmed risk factor 1 1 0 1 
      80 68 NA 77 
p.R47H 10 Confirmed risk factor 2 0 0 1 
      71.5±16.3 NA NA 73 
p.R47H 11 Confirmed risk factor 1 1 0 1 
      78 76 NA 89 
p.R47H 12 Confirmed risk factor 2 0 0 0 
      67.5±3.5 NA NA NA 
p.R47H 13 Confirmed risk factor 0 0 1 1 
      NA NA 75 86 
p.R47H 14 Confirmed risk factor 2 0 0 0 
     71±1.4 NA NA 64 
p.R62H 15 Previously identified 1 0 0 3 
      83 NA NA 78.3±3.5 
p.R62H 16 Previously identified 1 1 0 1 
      69 63 NA 55 
p.R62H 17 Previously identified 2 0 0 1 
      70±0 NA NA 72 
p.R62H 18 Previously identified 0 0 1 2 
      NA NA 83 76±4.2 
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p.R62H 19 Previously identified 1 0 0 4 
      70 NA NA 74.8±15.5 
p.R62H 20 Previously identified 0 3 1 8 
      NA 76.7±5.9 91 65.5±4.2 
p.R62H 21 Previously identified 0 2 1 0 
      NA 61±11.3 77 NA 
p.R62H 22 Previously identified 1 0 1 1 
      65 NA 53 73 
p.R62H 23 Previously identified 2 0 0 1 
      72.5±3.5 NA NA 80 
p.R62H 24 Previously identified 0 1 1 1 
      NA 70 79 86 
p.R62H 25 Previously identified 2 0 0 1 
      71±8.5 NA NA 68 
p.R62H 26 Previously identified 1 1 0 0 
      72 65 NA NA 
p.R62H 27 Previously identified 1 0 1 0 
      79 NA 70 NA 
p.R62H 28 Previously identified 1 0 1 0 
      65 NA 58 NA 
p.R62H 29 Previously identified 1 0 0 1 
      76 NA NA 64 
p.R62H 30 Previously identified 1 0 0 1 
      62 NA NA 71 
p.R62H 31 Previously identified 1 0 1 0 
      79 NA 68 NA 
p.R62H 32 Previously identified 1 0 1 0 
      71 NA 67 NA 
p.R62H 33 Previously identified 1 0 0 1 
      75 NA NA 78 
p.R62H 34 Previously identified 0 1 1 0 
      NA 66 79 NA 
p.R62H 35 Previously identified 0 2 1 2 
      NA 65.5±4.9 62 70.5±3.5 
p.D87N 36 Previously identified 2 0 0 1 
      81±1.4 NA NA 64 
p.D87N 37 Previously identified 0 0 2 2 
      NA NA 71±1.4 79.5±0.7 
p.H157Y 38 Previously identified 2 1 0 0 
      67±5.7 85 NA NA 
p.H215Q 39 Novel variant 1 1 0 0 
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      79 70 NA NA 
p.T223I 40 Novel variant 1 0 1 0 
      62 NA 74 0 
Variants, anonymous family ID, variant status, the number of affected carriers, non-carriers and un-affected 
carriers, non-carriers, the average and standard deviation of age at onset (years) for the affected individuals and 
the average and standard deviation of age at last assessment for the unaffected individuals were listed. 
 
 
Table S5. Unadjusted and adjusted analyses for TREM2 p.R47H and p.R62H variants 
 
Unadjusted* Adjusted& 
Variant P OR (95% CI) P OR(95% CI) 
p.R47H 9.17×10-4 2.63 (1.44-4.81) 5.91×10-3 2.48 (1.30-4.75) 
p.R62H 2.36×10-4 2.36 (1.47-3.80) 8.08×10-4 2.36 (1.43-3.90) 
*A Fisher's exact test was used to evaluate the case-control association with p.R47H and p.R62H. & Logistic regression was used to evaluate 
case-control association adjusting for APOE İDQGİVWDWXV$QDO\VHVZHUHSHUIRUPHGXVLQJGHIDXOWFRPPDQGVLQ3/,1.122. 
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Table S6. Rare TREN2 variant association in sequenced samples with GWAS data* 
   
AD Cases Controls 
 
 
AA Change SNP CHR:BP (hg19) No. of Cases 
No. of 
Carriers 
No. of 
Controls 
No. of 
Carriers P! OR (95% CI) 
All variants       6.81×10
-6& 2.56 (1.74-3.83) 
p.Q33X rs104894002 6:41129295 1700 1 1406 1 1 0.83 (0.05-13.33) 
p.R47H rs75932628 6:41129252 1701 39 1414 13 2.99×10-3 2.53 (1.35-4.76) 
p.R52H rs374851046 6:41129237 1724 1 1433 0 1 NA 
p.R62H rs143332484 6:41129207 1700 55 1415 19 3.25×10-4 2.54 (1.49-.4.35) 
p.T66M rs201258663 6:41129195 1701 1 1419 0 1 NA 
p.D87N rs142232675 6:41129133 1701 7 1417 3 0.36 1.96 (0.51-7.59) 
p.T96K rs2234253 6:41129105 1696 0 1406 2 0.21 0 
p.R136W NA 6:41127606 1671 1 1364 0 1 NA 
p.R136Q rs149622783 6:41127605 1697 1 1419 0 1 NA 
p.E151K rs79011726 6:41127561 1724 0 1433 1 0.46 0 
p.H157Y rs2234255 6:41127543 1701 1 1406 0 1 NA 
p.W191X rs2234258 6:41126429 1513 1 1281 0 1 NA 
p.E202D NA 6:41126395 1724 1 1433 0 1 NA 
p.L211P rs2234256 6:41126655 1693 0 1402 2 0.21 0 
p.H215Q NA 6:41126642 1669 1 1363 0 1 NA 
p.T223I rs138355759 6:41126619 1724 2 1433 0 0.5 NA 
A total of 1,724 AD cases and 1,437 controls were used for analysis.*NA represents not applicable. !The Fisher's exact test was used 
to calculate the p values using the default commands in PLINK. &This p value summarizes the gene-based association of the 
identified SNP set and was estimated using the SKAT-O algorithm.  
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SUPPLEMENTAL FIGURES 
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Figure S2. DNA and mRNA transcripts of TREM2. The top panel of (A)-(C) represents the genomic structure of 
each transcript and the bottom panel of (A)-(C) represents the corresponding mRNA transcript. Red arrows indicate 
the location where the isoform-specific primers are located. The length of each exon is indicated above each exon 
box. ENST00000373113 is the longest transcript of TREM2, which contains 5 exons. The designed forward and 
reverse primers for ENST00000373113 are located in exon3-exon4 junction and exon 4. ENST00000373122 has an 
additional proportion of exon4 relative to ENST00000373113. The designed forward and reverse primers for 
ENST00000373122 are located in exon3-exon4 junction and exon 4. ENST00000338469 lacks the exon4 which 
encodes the transmembrane domain. The forward and reverse primers for amplifying ENST00000338469 are 
located in exon3-exon5 junction and exon 5. 
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Figure S3. Multiple Sequence alignment of PLD3 amino acid sequences among homologous genes. The p.M6R 
(A), p.V232M (B) and p.A442A (C) variants are highlighted in yellow. The HKD signature motif (expanded to H-x-
K-x(4)-D-x(6)-G-T-x-N in this subfamily, where x represents any amino acid residue) is also noted in the figures 
A. p.M6R 
ENSP00000387050/Human MKPKLMYQELKVPAEEPANELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSGGOP00000010739/Gorilla MKPKLMYQELKVPAEEPANELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSPPYP00000011181/Pongo MKPKLMYQELKVPAEEPANELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSMMUP00000031602/macaca  MKPKLMYQELKVPAEEPANELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSBTAP00000041666/BosT MKPKLMYQELKVPAEEPASELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSCAFP00000007996/canis MKPKLMYQELKVPAEEPASELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSMUSP00000112942/MusMus MKPKLMYQELKVPVEEPAGELPLNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSRNOP00000054004/rattus MKPKLMYQELKVPVEEPAGELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMT 
ENSEEUP00000013322/C.Ele MKTKSLLLSHSIVAIVAVIITTAIWLT TYFVAV----NPNINNNGGQVINNYSNN 
FBpp0297826/D.melano MPEYKKLEDQESDVENANRTTVQN-TATVQDAGEGQRQAAGQQAGQ-MVT VSLFM 
ENSDARP00000083110/DanioR MKSDIPYEKMVDV-ELSR--------GEGHHGSQKYYRCLIVLTCITTVLLILLSL 
 
 
B. p.V232M 
ENSP00000387050/Human LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCL 
ENSGGOP00000010739/Gorilla LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCL 
ENSPPYP00000011181/Pongo LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCL 
ENSMMUP00000031602/macaca  LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCL 
ENSBTAP00000041666/BosT LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCL 
ENSCAFP00000007996/canis LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYIGSANMDWRSLTQVKELGVVMYNCSCL 
ENSMUSP00000112942/MusMus LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCL 
ENSRNOP00000054004/rattus LQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCL 
ENSEEUP00000013322/C.Ele LQSXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXVKELGVVMYNCSCL 
FBpp0297826/Drosophila GAAEVVSISFPKYFGSGVLHTKLWVVDNKHFYLGSANMDWRALTQ-VKEMGVLVQNCPEL 
ENSDARP00000083110/DanioR ATGAEVRGVDLQSITGGILHTKLWVVDKKHVYLGSANMDWRSLTQ-VKEVGVALEDCGCL 
 
C.  p.A442A 
ENSP00000387050/Human  VTERATYIGTSNWSGNYFTETAGTSLLVTQNGRGGLRSQLEAIFLRDWDSPYSHDLDTSA 
ENSGGOP00000010739/Gorilla VTERATYIGTSNWSGNYFTETAGTSLLVTQNGRGGLRSQLEAIFLRDWDSPYSHDLDTSA 
ENSPPYP00000011181/Pongo VTERATYIGTSNWSGNYFTETAGTSLLVTQNGRGGLRSQLEAIFLRDWDSPYSHDLDTSA 
ENSMMUP00000031602/macaca VTERATYIGTSNWSGNYFTETAGTSLLVMQNGRGSLRSQLEAIFLRDWDSPYSHDLDASA 
ENSBTAP00000041666/BosT  VTERATYIGTSNWSGSYFTETAGTSLLVTQNGRGGLRSQLEAVFLRDWDSPYSHDLDAAA 
ENSCAFP00000007996/canis VTERATYIGTSNWSGSYFTETAGTSLLVTQNGRGGLRSQLEAVFLRDWDSPYSHDLDTSA 
ENSMUSP00000112942/MusMus VTERASYIGTSNWSGSYFTETAGTSLLVTQNGHGGLRSQLEAVFLRDWESPYSHDLDTSA 
ENSRNOP00000054004/rattus VTERTTYIGTSNWSGSYFTETAGTSLLVTQNGHGGLRSQLEAVFLRDWESPYSHNLDTSA 
ENSEEUP00000013322/C.Ele VTESAAYIGTSNWSSDYWQYTAGIGIVIRADDFTSKSKLVQQFTSVFERDWSSTYTIPLL 
FBpp0297826/Drosophila VTDRVAYIGTSNWSGDYFTDTAGIGLVLSETFETETTNTLRSDLRNVFERDWNSKYATPL 
ENSDARP00000083110/DanioR VTDQVAYIGTSNWSGDYFVNTAGSALVVNQTSASASSTVQEQLQAVFERDWESAYSTDIN 
 
HKD signature motif 
HKD signature motif 
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(A)        (B) 
 
Figure S4: The PLD3- p.A442A variant modifies a splicing enhance binding site. A) ESEfinder predicts that the 
chr19:40883933 G>A change (p.A442A) disrupts a splicing enhancer binding site by making the sequence less 
similar to the consensus for the human SR protein SF2/ASF. The WT (chr19:40883933>G) allele has a prediction 
score of 3.57 for the SRSF1 protein. The A- allele has a prediction score of 1.X, below the threshold for SRSF1 
binding. B) Conservation of the chr19:40883933>G allele. The chr19:40883933>G is the most conserved nucleotide 
of the neighboring nucleotides.  
chr19:40883933>G 
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Chapter 3 
Use of cerebrospinal fluid as endophenotypes to fine-map 
Alzheimer’s disease associated genes 
 
 
 
 
 
 
 
 
 
The research work in this chapter resulted in the following publications. 
1. Cruchaga C, Kauwe JS, Harari O, Jin SC, et al. GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants 
for Alzheimer’s Disease. Neuron. 2013 Apr 24; 78(2): 256-58. 
2. Benitez BA*, Jin SC*, et al. Missense Variant in TREML2 Protects Against Alzheimer’s Disease. Neurobiology 
of Aging. 2013 Dec 21. doi: 10.1016/j.neurobiolaging.2013.12.010. (*Equal contribution)  
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3.1 ABSTRACT 
  The International Genomics of Alzheimer’s Project (IGAP) performed meta- and gene-wide analyses and 
identified 23 loci associated with Alzheimer’s disease (AD) risk, of which 13 were novel. However, the mechanisms 
by which most of these loci affect the molecular pathways leading to AD remain unknown. To determine whether 
these loci are also associated with cerebrospinal fluid (CSF) biomarker levels, we combined CSF biomarker datasets 
from several studies and performed single-variant, set-based, and conditional analyses for each locus. In the APOE 
locus, rs769449 is genome-wide significantly associated with CSF amyloid-beta 1-$ȕ42) and phosphorylated 
tau181 (ptau181) levels. Furthermore, as reported before in a smaller dataset the association between rs769449 and 
CSF ptau181 levels is only partLDOO\H[SODLQHGE\GLIIHUHQFHVLQ&6)$ȕ42 levels. We also revealed that the 
DVVRFLDWLRQRIUVZLWK&6)$ȕ42 and ptau181 levels is independent of APOE-İDQGAPOE-İJHQRW\SHV
which suggests that another APOE risk variant is present in addition to known APOE-İDQGAPOE-İDOOHOHV We 
found evidence of association (p<0.05) for the top IGAP single nucleotide polymorphisms (SNPs), rs4147929 
(ABCA7), rs17125944 (FERMT2), and rs35349669 (INPP5DZLWK&6)$ȕ42 levels, and for rs6656401 (CR1), 
rs17125944 (FERMT2), rs190982 (MEF2C), rs10792832 (PICALM), rs28834970 (PTK2B), and rs11218343 
(SORL1) with CSF ptau181 levels. Our locus-specific analyses suggested that after multiple test correction, 
rs7937331, within the CELF1 fine-mapping region, is significantly DVVRFLDWHGZLWK&6)$ȕ42 levels and AD risk, 
and tags the same signal as the IGAP top SNP, rs10838725. Additionally, rs62003531, located in the intronic region 
of FERMT2, WDJVWKHVDPHDVVRFLDWLRQDVWKH,*$3WRS613UVDQGLVDVVRFLDWHGZLWK&6)$ȕ42 levels. 
The association for the CELF1 and FERMT2 fine-PDSSLQJUHJLRQVZLWK&6)$ȕ42 levels was confirmed in set-based 
analyses. None of the SNPs within the IGAP-identified AD risk loci except the APOE locus are significantly 
associated with CSF ptau181 levels after multiple test correction. When investigating the potential regulatory 
functions associated with IGAP top SNPs and CSF top SNPs, most of GWAS top SNPs have no significant 
regulatory potential and are unlikely to be the functional variants for AD risk. However, RegulomeDB predicts that 
several proxy SNPs in linkage disequilibrium (LD) with rs7937331 in SLC39A13 may be cis-acting expression 
quantitative trait loci (eQTLs) for nearby genes and are located in transcription factor binding sites. In summary, our 
results suggest that AD risk variants may not necessarily be associated with CSF biomarker levels, and that GWAS-
identified non-coding variants may affect AD risk through regulatory mechanisms. The IGAP study also identified 
an intergenic polymorphism near TREML2 suggestively (p<10-6) associated with AD risk; however, due to the study 
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design, it was not possible to uncover the underlying functional variant or to determine whether this observed 
association was driven by the known AD risk allele, TREM2 p.R47H, or represented a novel locus. Here, we 
conducted comprehensive analyses using whole-exome sequencing (WES) data, CSF biomarker analyses and meta-
analyses (16,254 cases and 20,052 controls) from several independent cohorts to demonstrate that the AD risk 
association is likely driven by a TREML2 missense variant p.S144G (rs3747742) and that this association is 
independent of TREM2 p.R47H risk for AD. 
3.2 INTRODUCTION 
 Recently, IGAP performed meta-analysis of genome-wide association studies (GWAS) and gene-wide 
analysis in more than 74,000 individuals and identified 23 loci (ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, 
CELF1, CLU, CR1, EPHA1, FERMT2, HLA-DRB5/DRB1, IGHV1-67, INPP5D, MEF2C, MS4A6A, NME8, 
PICALM, PTK2B, SLC24A4, SORL1, TP53INP1, and ZCWPW1) significantly associated with risk for LOAD8, 13 
of which were novel. However, these loci contain multiple genes within the associated region and therefore, the 
suggested genes may not contain the underlying functional variants. Additionally, the most-significant 
polymorphisms within these loci were located in non-coding regions and thus there is no clear functional impact of 
these variants linked to AD pathogenesis8. It is also possible that multiple functional variants reside within the same 
locus affecting AD risk independently. Endophenotype-based analyses along with conditional analyses can help to 
identify the potential drivers of the associations, infer the underlying mechanisms associated with AD, and 
determine whether there are multiple independent genetic variants affecting AD pathogenesis. 
 AD is characterized pathologically by intracellular neurofibrillary tangles and extracellular amyloid 
plaques. Previous studies have shown that CSF $ȕ42 is a useful biomarker for plaques104 and CSF ptau181 levels are 
well correlated with the number of neurofibrillary tangles and tangle load in the human brain146. Moreover, the fact 
that CSF ptau181 levels increase and CSF $ȕ42 levels decrease in AD patients indicate their roles as effective 
biomarkers for AD22,104. Changes in CSF biomarkers in cognitively normal people are also strong indicators of 
future cognitive decline147. 2XUSUHYLRXVZRUNKDVXVHG&6)$ȕ42 and ptau181 levels as endophenotypes to validate 
AD genetic risk factors23, to generate hypotheses regarding the mechanism by which AD risk variants contribute to 
AD development18, and to find novel variants associated with age at onset and disease progression17,19. Similarly, in 
WKLVVWXG\ZHXVHG&6)$ȕ42 and ptau181 levels as endophenotypes to determine whether the top polymorphisms 
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identified in the IGAP GWAS meta-analysis are also associated with CSF biomarker levels and to test whether there 
are multiple independent signals within the same locus affecting AD. This information can also provide clues to the 
mechanism of the disease-associated variants. Furthermore, since the most significant genetic markers within these 
loci are located outside of protein coding regions, we utilized RegulomeDB (http://regulomedb.org), a database 
including experimental datasets and computational algorithms, to predict regulatory potential for these variants.  
 The IGAP study also identified an intergenic polymorphism (rs9381040; p<6.3×10-7) located 5.5 Kb 
downstream from TREML2 and 2.2 Kb upstream from TREM28 suggestively associated with AD risk8. The TREM 
and TREM-like receptor genes clustered on chromosome 6p.21 have different patterns of LD among them22,148. This 
genomic region has previously been implicated in genetic risk for AD12,13,98,130-135. A low frequency missense variant 
in TREM2 (p.R47H, minor allele frequency [MAF]=0.003), identified through sequencing studies was reported to 
substantially increase risk for AD12,13,125. Single nucleotide polymorphisms (SNPs) in this region were also found to 
be associated with CSF ptau181 levels22. Because of the design of the IGAP study (a meta-analysis) and the low 
frequency of the p.R47H variant in TREM2, it was not possible to determine whether the GWAS signal (rs9381040) 
was independent of the TREM2-p.R47H variant (rs75932628). Here, we analyzed WES data to identify the most 
likely functional variant in TREML2 responsible for the GWAS signal and tested whether this signal is independent 
of the TREM2-p.R47H variant. 
3.3 MATERIALS AND METHODS 
3.3.1 CSF samples and data cleaning 
 CSF samples were obtained from the Charles & Joanne Knight Alzheimer’s Disease Research Center 
(Knight-ADRC) (N=748), the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study (ADNI-1) (N=382), 
ADNI-2 Study (N=377), the Mayo Clinic (N=441), Lund University (Swedish) (N=294), University of Pennsylvania 
(Penn) (N=181), University of Washington (UW) (N=323), and Saarland University (German) (N=102). Individuals 
were diagnosed with dementia of the Alzheimer’s type (DAT) according to the National Institute of Neurological 
and Communication Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA)118. Control individuals were evaluated using the same criteria and showed no symptoms of cognitive 
impairment. All participants provided written informed consent and the ethics committee approved the study (IRB 
ID #: 201105364).  
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 CSF was collected in a standardized manner101. Biomarker measurements within each study were 
conducted using internal standards and controls to achieve consistency and reliability. However, differences in the 
measured values between studies were observed which are likely due to differences in the antibodies and 
technologies used for quantification (standard ELISA with Innotest for Knight-ADRC, UW, Swedish, German, and 
Mayo versus Luminex with AlzBia3 for ADNI-1, ADNI-2, and Penn), ascertainment, and/or in handling of the CSF 
after collection. The differences in the number of freeze thaw cycles prior to analysis may also introduce some 
variation. To normalize CSF biomarker distributions, we log-transformed the values and then subtracted the mean of 
the transformed values for each dataset. The standardized CSF measurements were normally distributed after 
transformation and thus the standardized CSF biomarker measurements were used for the following analyses (see 
Figure S1). 
 We identified unanticipated duplicates and cryptic relatedness using pair-wise genome-wide estimates of 
proportion identity by descent (IBD) using the PLINK program122. When duplicate samples or a pair of samples with 
cryptic relatedness was identified, priority was given to samples with higher call rates. In order to control for 
population substructure, a principal component analysis (PCA) was conducted using the EIGENSTRAT software121. 
HapMap samples (CEU: CEPH Europeans from Utah; JPT: Japanese in Tokyo; YRI: Yoruba in Ibadan, Nigeria) 
were included in the analyses in order to remove outliers and confirm self-reported ethnicity. Samples were 
excluded if not within the CEU cluster (see Figure S2 A-B). We also checked whether the gender was discordant by 
analyzing the X-chromosome SNPs using PLINK. Individuals were removed if the recorded gender did not match 
the gender reported by our analyses. Individuals with an age under 45 were also removed. After these initial quality 
control (QC) steps, we applied several inclusion criteria for selection of cohorts into the final analyses in order to 
attain stable analytical results. Cohorts were excluded if they met any of the following conditions: (1) sample size 
less than 200 after QC, (2) an r-squared (R2) value for APOE-İDVVRFLDWLRQOHVVWKDQVDPSOHWUXQFDWLRQ
based on specific biomarker cutoffs. A total of 2,036 individuals from Knight-ADRC, ADNI-1, ADNI-2, Mayo, and 
UW passed QC filters and were finally analyzed. Table 1 summarizes the sample characteristics used in the final 
analyses. 
 Samples were genotyped on either the Illumina 660 Chip (N = 614) or the Omniexpress Chip (N = 1,422). 
Samples genotyped on the Illumina 660 Chip included 183 from Knight-ADRC, 74 from UW and 351 from ADNI-
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1. Samples genotyped on the Illumina Omniexpress included 431 from the Knight-ADRC, 216 from UW, 349 from 
ADNI-2 and 426 from the Mayo Clinic. Standard procedures were used to determine APOE genotypes (rs7412 and 
rs429358) as previously described149. Stringent quality thresholds were applied to the genotype data. SNPs were 
dropped if they fulfilled any one of the following criteria: i) genotyping success rate<98% per SNP or per 
individual; ii) Hardy-Weinberg equilibrium (HWE) (p<1×10í); iii) MAF < 0.01. QCs were carried out separately 
based on genotyping chips (Illumina 660 versus Omniexpress). 
 After removing low quality SNPs and individuals, genotype imputation was performed using the Impute2 
program150 with haplotypes derived from 1,000 Genomes Project (released June 2012). Genotype imputation was 
performed separately based on the genotype platform used (Illumina Omniexpress versus 660K chip). SNPs with an 
info-score quality of less than 0.3 reported by Impute2, with a MAF < 0.05 or out of HWE were removed. A total of 
4,185,256 imputed and directly-genotyped SNPs and 2,036 individuals were used for final analyses. After quality 
control filtering, a total of 2,036 individuals (614 from Knight-ADRC, 357 from ADNI-1, 349 from ADNI-2, 426 
from Mayo, and 290 from UW) were used for final analyses (see Table 1). 
 In order to determine whether IGAP intergenic signal rs9381040 is independent of the TREM2 p.R47H 
variant, rs9381040 and TREML2 p.S144G (rs3747742), a coding variant in TREML2 in tight LD with rs9381040, 
were extracted from the GWAS data22, and confirmed by direct genotyping. The TREM2 p.R47H was genotyped 
using KASPaR genotyping assay (LGC Genomics), as previously described15,16. 
3.3.2 Exome-sequencing data from Knight-ADRC 
 Enrichment of coding exons and flanking intronic regions was performed using a solution hybrid selection 
method with the SureSelect human all exon 50Mb kit (Agilent Technologies, Santa Clara, CA, USA) following the 
manufacturer’s standard protocol on 46 unrelated AD cases and 39 unrelated controls from the Knight-ADRC. This 
was performed by the Genome Technology Access Center at Washington University in St. Louis 
(https://gtac.wustl.edu/). The captured DNA was sequenced by paired-end reads on the HiSeq 2000 sequencer 
(Illumina, San Diego, CA, USA). Raw sequence reads were aligned to the reference genome National Center for 
Biotechnology Information (NCBI) 36/hg18 by using Novoalign (Novocraft Technologies, Selangor, Malaysia). 
Base and/or SNP calling was performed using SNP SAMtools151. SNP annotation was carried out using version 5.07  
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Table 1. Summary characteristics of the CSF study participants       
 
Knight-ADRC ADNI-1 ADNI-2 Mayo UW 
N 614 357 349 426 290 
Age Mean ± SD 
(range) 
70.49 ± 8.85 (46-91) 77.88 ± 6.97 (58-93) 72.84 ± 7.40 (55-91) 78.72 ± 6.38 (50-95) 66.91 ± 10.45 (45-88) 
$32(İ 39.51 51.54 38.4 25.12 47.59 
CDR 0 (%) 71.99 26.89 31.81 78.17 58.97 
Male (%) 45.11 61.06 55.87 60.33 47.93 
Ptau181 Mean ± SD 66.79 ± 36.11 33.78 ± 17.64 23.67 ± 10.13 23.07 ± 10.48 60.57 ± 30.50 
Aß42 Mean ± SD 613.69 ± 272.27 168.84 ± 55.55 215.93 ± 74.03 331.29 ± 122.11 135.62 ± 40.80 
Sample size, age in years at lumbar puncture (LP), the percentage of the subjects that carry at least one $32(İ allele, the percentage of subjects with 
Clinical Dementia Rating (CDR) = 0, the percentage of male participants, and the mean in pg/ml, standard deviation, and range for CSF ptau181 and 
Aß42 for samples from Washington University Charles F. & Joanne Knight Alzheimer’s Disease Research Center (Knight-ADRC), Alzheimer's Disease 
Neuroimaging Initiative Study (ADNI-1), ADNI2 Study (ADNI-2), Mayo Clinic (Mayo) and the University of Washington (UW) are shown. 
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of SeattleSeq Annotation server (http://snp.gs.washington.edu/SeattleSeqAnnotation138/)152. On average, 95% of 
the exome had > 8 fold coverage. 
3.3.3 UK- National Institute on Aging (UK-NIA) dataset 
 A description of the UK-NIA dataset can be found in Guerreiro et al12. This dataset includes whole-exome 
sequencing data from 143 AD cases and 186 elderly controls individuals without dementia. All individuals were of 
European descent. 
3.3.4 Alzheimer’s Disease Genetic Consortium methods 
 Data used in the preparation of this article were obtained from the Alzheimer’s Disease Genetic 
Consortium (ADGC), which includes 2,247 individuals from Adult Changes in Thought study, 4,325 individuals 
from Alzheimer’s Disease Center, 413 individuals from ADNI, 1,256 individuals from Multi-Site Collaborative 
Study for Genotype-Phenotype Associations in Alzheimer’s Disease, 2,087 individuals from University of 
Pittsburgh, 279 individuals from Oregon Health &Science University, 1,614 individuals from National Institute on 
Aging Late-onset AD, 2,263 individuals from University of Miami, 588 individuals from Multi-Institutional 
Research on Alzheimer’s Genetic Epidemiology, 1,049 individuals from the Ruth University Religious Orders 
Study/Memory and Aging Project, 1,210 individuals from Translational Genomics Research Institute series, 481 
individuals from Washington University in St. Louis, and 1,880 individuals from Mayo Clinic. To control for 
population substructure, we performed PCA using the EIGENSTRAT software121 and a total of 19,673 (10,067 AD 
cases and 9,606 controls) individuals of European ancestry were used for final analysis (see Figure S2 C-D). A 
description of the sample included in the study as well as the methods used can be found in Naj et al11. Genome-
wide imputation was performed per cohort using MACH software with HAPMAP phase 2 (release 22) CEPH Utah 
pedigrees reference. Imputation quality was set at r20.50. A multivariate logistic regression was performed to 
evaluate the association between genetic markers and risk for AD adjusting for age, gender, population substructure, 
and study-specific effects. 
3.3.5 Genetic and Environmental Risk for Alzheimer’s Disease Consortium 
 Data were obtained from the Genetic and Environmental Risk for Alzheimer’s Disease (GERAD) 
Consortium. The imputed GERAD sample comprised of 3,177 AD cases and 974 healthy elderly (age<70 yrs) 
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control subjects with available age and gender data. Cases and screened control subjects were recruited by the 
Medical Research Council (MRC) Genetic Resource for AD (Cardiff University; Institute of Psychiatry, London; 
Cambridge University; Trinity College Dublin), the Alzheimer’s Research UK Collaboration (University of 
Nottingham; University of Manchester; University of Southampton; University of Bristol; Queen’s University 
Belfast; the Oxford Project to Investigate Memory and Aging, Oxford University); Washington University in St. 
Louis; Medical Research Council PRION Unit, University College London; London and the South East Region AD 
Project, University College London; Competence Network of Dementia, and Department of Psychiatry, University 
of Bonn, Germany; the National Institute of Mental Health AD Genetics Initiative. A number of 6,129 control 
subjects were drawn from large existing cohorts with available GWAS data, including the 1,958 British Birth Cohort 
(http://www.b58cgene.sgul.ac.uk), the KORA F4 Study, and the Heinz Nixdorf Recall Study. All AD cases met 
criteria for either probable (National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s disease and Related Disorders Association [NINCDSADRDA], Diagnostic and Statistical Manual of 
Mental Disorders [DSM-IV]) or definite (Consortium to Establish a Registry for Alzheimer’s Disease [CERAD]) 
AD. All elderly controls were screened for dementia using the MMSE or ADAS-cog. Additionally, individuals with 
a Braak score of 2.5 or lower were also included as controls. Genotypes from all cases and controls were previously 
included in the AD GWAS by Harold et al78. Imputation of the dataset was performed using IMPUTE2 and the 
1,000 Genomes (http://www.1000genomes.org/) Dec 2010 reference panel (NCBI build 37.1). The imputed data 
was then analyzed using logistic regression including covariates for country of origin, gender, age, and first three 
principal components were obtained with EIGENSTRAT (EIGENSOFT 4.2)153 software based on individual 
genotypes (best guess) for the GERAD study participants. 
3.3.6 European Alzheimer’s Disease Initiative Consortium 
 All AD cases were ascertained by neurologists from Bordeaux, Dijon, Lille, Montpellier, Paris, Rouen, and 
were identified as French Caucasian154,155. Clinical diagnosis of probable AD was established according to the DSM-
III-R and NINCDS-ADRDA criteria. Control subjects were selected from the 3C Study155. This cohort is a 
population-based, prospective (7-year follow-up) study of the relationship between vascular factors and dementia. It 
has been carried out in 3 French cities: Bordeaux (southwest France), Montpellier (southeast France), and 
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Dijon (central eastern France). A sample of non-institutionalized subjects over 65yrs was randomly selected from 
the electoral rolls of each city. Between January 1999 and March 2001, 9,686 subjects meeting the inclusion criteria 
agreed to participate. After recruitment, 392 subjects withdrew from the study. Thus, 9,294 subjects were finally 
included in the study (2,104 in Bordeaux, 4,931 in Dijon, and 2,259 in Montpellier). Genomic DNA samples of 
7,200 individuals were transferred to the French Centre National de Génotypage. At the end, we removed 308 
samples because they were found to be first- or second- degree relatives of other study participants, or were assessed 
non-European descent based on genetic analysis using methods described in Heath et al156. In this final sample, at 7 
years of follow-up, 459 individuals suffered from AD with 97 prevalent and 362 incident cases. These AD cases 
were included as cases in the European Alzheimer’s disease initiative (EADI) discovery dataset. We retained the 
other individuals as control subjects (N=6,017). After individual sample collection (2,243 AD cases and 6,017 
controls), the imputation was performed using 1,000 Genomes multi-ethnic data (1,000 Genomes phase 1 integrated 
variant set release v3) as a reference panel. Imputation was performed in 2 steps: pre-phasing with SHAPEIT (v2), 
followed by imputation with IMPUTE2. 
3.3.7 Gene and SNP selection 
 For the locus-wide analysis, we selected 23 genes for the final analyses, including ABCA7, APOE, BIN1, 
CD2AP, CD33, CASS4, CELF2, CLU, CR1, EPHA1, FERMT2, HLA-DRB5/DRB1, IGHV1-67, INPP5D, MEF2C, 
MS4A6A, NME8, PICALM, PTK2B, SLC24A4, SORL1, TP53INP1, and ZCWPW1, which were recently identified 
by the IGAP study8. We extracted, imputed, and directly-genotyped genetic markers within the fine mapping regions 
of each locus (see Table S1) DQGWHVWHGIRUDVVRFLDWLRQZLWK&6)$ȕ42 and ptau181 levels. The fine mapping region 
for each locus was defined by the closest recombination hot spots in either direction from the coding region based on 
the estimated recombination rate from the HapMap samples (released March 2008) (see Table S1). Since the 
coordinates of the HapMap data were based on NCBI build 36 (UCSC hg18), we lifted them over to NCBI build 37 
(UCSC hg19) using the UCSC Genome Browser (http://genome.ucsc.edu/). We then calculated the multiple test 
threshold for the fine-mapping regions of each locus by implementing the simpleM157 approach in R (version 3.0.1). 
3.3.9 Statistical analysis 
 For the analyses of CSF biomarker data, we first performed multivariate linear regression for association 
between standardized CSF ptau181 DQG$ȕ42 levels and genetic variants in IGAP-identified loci adjusting for age, 
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gender, the first three principal components (PCs) and sites (coded as dummy variables) using PLINK122. Analyses 
were performed conditioning on the most significant SNP within the locus to determine whether other SNPs within 
the region represent independent associations after adjusting for covariates. Set-based analyses were then used for 
each IGAP-LGHQWLILHGORFXVWRHYDOXDWHWKHHIIHFWVRIDOORIWKH613VZLWKLQHDFKORFXVRQ&6)$ȕ42 or ptau181 levels 
in PLINK122 with default parameters by performing 10,000 permutation tests. 
 For the analyses of case-control data in TREM2/TREML regions, we performed multivariate logistic 
regression to evaluate the association between genetic markers and risk for LOAD adjusting for age, gender, 
population substructure, and study effects using PLINK122. Conditional analysis was performed to identify 
additional independent signals by conditioning on the top case-control GWAS hits. We first estimated the odds 
ratios (OR) for SNPs across cohorts. These models calculate crude OR and confidence intervals from counts of 
heterozygotes in case and control subjects in each study. Then we performed a fixed-effect model to combine the 
odds ratios from study-specific estimates into a summary measure. No multiple-testing correction was used in our 
analyses. The heterogeneity of effects was evaluated using the Woolf test for heterogeneity158. Meta-analysis was 
conducted using the META package (http://www.stats.ox.ac.uk/wjsliu/meta.html) in R (version 3.0.1). 
3.3.10 Power calculation 
 We estimated the power by conducting an overall F test in a one-way, three-group analysis of variance to 
calculate using proc power in SAS. We calculated the effect size, which was measured in fold-difference between 
the means by assigning statistical power equal to 80% for minor allele frequencies from 0.1 to 0.5 and Type I error 
equal to 0.05 and 0.00001(most stringent single SNP multiple testing correction) assuming HWE (see Table S2). 
3.3.11 Genome partitioning 
 The program GCTA (Genome-wide Complex Trait Analysis) was used to estimate the proportion of 
phenotypic variance explained by all imputed/genotyped SNPs, SNPs in the APOE gene, and SNPs that pass 
multiple test correction159. 
3.3.12 Bioinformatic analysis 
 The SeattleSeq Annotation server was used to annotate the variants. The RegulomeDB database 
(http://www.regulomedb.org) was used to investigate potential effects of associated variants on regulatory functions 
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based on data from the ENCODE Project160. Different types of information are integrated in RegulomeDB, which 
includes: (a) ENCODE transcription factor ChIP-seq, histone ChIP-seq, Formaldehyde-Assisted Isolation of 
Regulatory Elements, and DNase 1 hypersensitive site data (The ENCODE Project Consortium 2012),(b) 
transcription factor ChIP-seq data from NCBI Sequence Read Archive, and (c) a large collection of eQTL, DNase I 
sensitivity quantitative trait loci (dsQTL), and ChIP-exo (an advanced ChIP method to specifically identify binding 
sites of DNA-bound proteins at almost single-nucleotide resolution) data totaling 962 data sources covering over 
100 tissues and cell lines. With around 60 million annotations, RegulomeDB provides users with a straightforward 
way to classify variants of interest and thus allow generation of hypotheses regarding the underlying mechanism of 
selected variants, esp. non-coding variants. A score ranging from 1 to 6 is assigned to a variant with a lower score 
representing a higher likelihood of affecting binding and expression of a gene target160. 
3.4 RESULTS 
3.4.1 Sample characteristics 
 For the CSF datasets, sample collection, genotype imputation, and quality controls (QC) for the genotype 
and phenotype data were conducted as described in MATERIALS AND METHODS. A total of 4,185,256 imputed 
and directly-genotyped SNPs and 2,036 individuals passed QC filters (see Table 1). In order to define the fine-
mapping regions, we considered the recombination rate from HapMap samples and finally selected a total of 12,109 
SNPs within the GWAS-identified loci for further analysis8. The multiple test correction threshold for each locus 
was calculated using the simpleM algorithm157 (see Table S1). The final analyses included 2,036 individuals of 
European American (EA) descent from Knight-ADRC, ADNI-1, ADNI-2, Mayo, and UW. The ethnicity of each 
individual was confirmed by PCA before inclusion in the final analyses (see Figure S2 A-B). CSF collection and 
biomarker measurements within each study were conducted using standardized protocols, internal standards and 
controls to achieve consistency and reliability. However, differences in the measured values between studies were 
observed which are likely due to differences in the antibodies and technologies used for quantification, 
ascertainment, and in handling of the CSF samples after collection (see Table 1), e.g. differences in the number of 
freeze thaw cycles prior to analysis may introduce some variation. To normalize CSF biomarker distributions, we 
log-transformed the values and then subtracted the mean of the transformed values for each dataset. The 
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standardized CSF values were normally distributed after transformation; these CSF values were used for the final 
analyses (see Figure S1). 
3.4.2 Effect of the APOE ORFXVRQ&6)$ȕ42 and ptau181 levels 
 Since APOE has by far the greatest effect on LOAD risk anGKDVEHHQUHSRUWHGWRDIIHFW&6)$ȕ42 and 
ptau181 levels in previous studies22,161,162, we examined the association between APOE YDULDQWVDQG&6)$ȕ42 and 
ptau181 levels for reference purposes. The association for the APOE locus with both biomarker levels was significant 
when analyzing each study separately (see Table S3). When conducting a joint-analysis for the combined dataset, 
UVZDVVLJQLILFDQWO\DVVRFLDWHGZLWKERWK&6)$ȕ42 and ptau181 levels (MAF=17.88%; p=7.60×10-79 and 
3.31×10-32 respectively; Table S4). To evaluate whether the association for rs769449 with CSF ptau181 was driven 
by differences LQ$ȕ42 OHYHOV&6)$ȕ42 levels were included in the regression modeling. The association for 
rs769449 with CSF ptau181 levels became less significant but still exceeded the genome-wide significance cutoff 
(p=9.91×10-11), which suggests that rs769449 mediDWHVGLIIHUHQFHVLQWDXELRORJ\LQGHSHQGHQWO\RI$ȕSDWKRORJ\
supporting our previous findings22. To examine whether the association for rs769449 is independent of APOE-İ
and APOE-İ613VZHSHUIRUPHGDQDO\VLVE\LQFOXGLQJAPOE-İDQGAPOE-İDVFRYDULDWHV7KHDVVRFLDWLRQIRU
UVZLWK&6)$ȕ42 and ptau181 levels remained highly significant (p=9.21×10-11and 4.42×10-5 respectively), 
which indicates that another independent signal in the APOE locus contributes to the CSF biomarker association in 
addition to the known APOE İDQGİDOOHOHVGenome partition analyses suggest the overall phenotypic variance 
IRU&6)$ȕ42 and ptau181 levels explained by all genotyped and imputed variants is approximately 31.64% and 
10.40% respectively. The variability for CSF ptau181 levels is slightly higher (10.40% versus 6.79%22) than that in 
our previous study which may due to the use of different imputation software (Impute2 versus Beagle)22. About 
2.70% (CSF Aȕ42) and 0.79% (CSF ptau181) of the phenotypic variance is explained by variants in the APOE fine-
mapping region, suggesting that genetic variants outside the APOE locus account for most of the phenotypic 
variance for both CSF Aß42 and ptau181 levels. 
3.4.3 CELF1, EPHA1, and FERMT2 ORFLDVVRFLDWHGZLWK&6)$ȕ42 levels 
 We examined the association between IGAP-LGHQWLILHGWRS613VDQG&6)$ȕ42 levels8. Our CSF biomarker 
analyses show that the minor alleles of rs4147929 (ABCA7: p=1.00×10-2; Table 2), rs17125944 (FERMT2: 
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p=7.42×10-3; Table 2) and rs35349669 (INPP5D: p=3.40×10-2; Table 2) are associated with lower CSF Aß42 levels, 
which is consistent with the reported direction of effect for each SNP in the IGAP paper (see Table 2)8. Regional 
plots for each locus can be found in Figures S3-S25. 
We WKHQWHVWHGIRUDVVRFLDWLRQEHWZHHQ613VZLWKLQHDFK,*$3ORFXVDQG&6)$ȕ42 levels to determine 
whether other SNPs within each ORFXVVKRZHGVWURQJHUDVVRFLDWLRQZLWK&6)$ȕ42 levels than those associated with 
AD risk. Several SNPs surpassed multiple test thresholds. Rs7937331, the strongest association within the CELF1 
fine-mapping region is approximately 57 kb away from the 5’end of CELF1, but located in an intron of another 
gene, solute carrier family 39 (zinc transporter), member 13 (SLC39A13) (see Figure 1A). The minor allele of 
rs7937331 is significantly DVVRFLDWHGZLWKLQFUHDVHG&6)$ȕ42 values (MAF=33.05%; p=2.30×10-4; ȕ 
[0.01~0.032]; Table 3). Set-based analysis of 211 SNPs in the CELF1 fine-mapping region supports the association 
ZLWK&6)$ȕ42 levels (p=6.30×10-3; Table 5). Rs7937331 is significantly associated with AD risk in the IGAP study 
and the direction of effects is in line with that in our CSF analysis (OR=0.93, p=5.11×10-7, Table 3)8. Rs7937331 
has a high D’ but a low R2 with the IGAP top SNP, rs10838725 (MAF=31.26%) in the CELF1 region (D’=0.97; 
R2=0.21; Table S5)8. When adjusting for rs10838725, the association of rs7937331 with CSF Aȕ42 levels only 
changes slightly (p=1.25×10-3ȕ >a@Table S6 and Figure S4) but that of rs10838725 becomes 
insignificant (p=8.67×10-1ȕ -0.001 [-0.014~0.011]; Table S6 and Figure S4). We also analyzed the ADGC case-
control series in order to confirm rs10838725 and rs7937331 are independent signals. Before adjusting for 
rs10838725, rs7937331 shows evidence of association with AD risk (OR=0.93, p=4.14×10-4; Table S7). The 
association of rs7937331 does not change significantly (OR=0.93, p=3.98×10-3; Table S7) after adjusting for 
rs10838725. However, there were significant differences for association of rs10838725 with AD risk before 
(OR=0.96, p=0.05; Table S7) and after adjusting for rs7937331 (OR=0.99, p=0.61; Table S7). Together, our 
analyses suggest that rs7937331 in SLC39A13 is VLJQLILFDQWO\DVVRFLDWHGZLWKERWK$'ULVNDQG&6)$ȕ42 levels and 
that rs7937331 and rs10838725 in CELF1 tag the same signal. Importantly, rs7937331 is more likely to be the 
causal variant than rs10838725. 
$QRWKHUVLJQLILFDQWDVVRFLDWLRQDIIHFWLQJ&6)$ȕ42 levels was found for rs7802536 within the EPHA1 region 
(MAF=22.36%; p=6.01×10-5; ȕ -0.025 [-0.037~-0.013]; Table 3). Rs7802536, a directly-genotyped SNP, is located 
about 38 kb away from the 5’ end of EPHA1 and is in the intergenic region between the Chloride Channel, Voltage-
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Sensitive 1 (CLCN1) and Family with Sequence Similarity 131, member B (FAM131B) genes (see Figure 1B), 
ZKLFKVXJJHVWVWKDWWKHDVVRFLDWLRQZLWK&6)$ȕ42 levels within the EPHA1 region may not be driven by EPHA1. 
Moreover, rs7802536 and rs11771145 (MAF=34.36%; Table 2), the IGAP-top SNP in EPHA1, are not in LD 
(D’=0.01; R2=0; Table S5)87KHDVVRFLDWLRQRIUVZLWK&6)$ȕ42 levels did not change after adjusting for 
rs11771145 (p=5.97×10-5ȕ -0.025 [-0.037~-0.013]; Table S6 and Figure S5) and vice versa (p=6.53×10-1; 
ȕ >-0.008~0.013]; Table S6 and Figure S5). Set-based analysis of 127 SNPs in this locus suggests evidence 
of association with CSF Aȕ42 levels (P = 1.63×10-2; Table 5). However, we did not find rs7802536 in the IGAP 
dataset and therefore unable to determine whether rs7802536 is significantly associated with AD risk. 
Rs62003531, located in an intron of FERMT2 (see Figure 1C), also survived multiple test correction and was 
VLJQLILFDQWO\DVVRFLDWHGZLWK&6)$ȕ42 levels (MAF=11.54%; p=8.50×10-5ȕ -0.033 [-0.049~-0.016]; Table 3). In 
the stage 1 analysis of the IGAP study, rs62003531 is suggestively associated with AD risk (p=2.75×10-4; Table 3). 
Rs62003531 is in significant LD (D’=0.95; R2=0.70; Table S5) with rs17125944 (MAF=8.95%; Table 2), the IGAP 
top SNP in FERMT2. The DVVRFLDWLRQIRUUVZLWK&6)$ȕ42 levels reduced and became non significant 
when conditioning on rs17125944 (p=5.85×10-3ȕ -0.041 [-0.070~-0.012]; Table S6 and Figure S6) and vice 
versa, which suggests that rs62003531 and rs17125944 tag the same signal. Set-based analyses of 463 SNPs in 
FERMT2 indicated that FERMT2 LVVLJQLILFDQWO\DVVRFLDWHGZLWK&6)$ȕ42 levels (p=7.80×10-3; Table 5). 
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Table 2. Summary statistics for most significant SNP in IGAP top loci 
      
CSF Aȕ42 CSF ptau181 
SNP Chr:bp Nearest Gene P! OR! MAF (%)& Beta (95% CI) P Beta (95% CI) P 
rs4147929 19:1063443 ABCA7 1.06×10í 1.15 18.56 -0.017 (-0.03,-0.004) 1.00×10-2 0.015 (0,0.03) 5.68×10-2 
rs6733839 2:127892810 BIN1 6.94×10í 1.22 33.07 -0.006 (-0.016,0.005) 2.97×10-1 0.006 (-0.006,0.019) 3.40×10-1 
rs7274581 20:55018260 CASS4 2.46×10í 0.88 8.57 -0.007 (-0.025,0.011) 4.29×10-1 -0.011 (-0.033,0.01) 3.03×10-1 
rs10948363 6:47487762 CD2AP 5.20×10í 1.1 28.31 0.007 (-0.005,0.018) 2.49×10-1 0.004 (-0.01,0.017) 6.12×10-1 
rs3865444 19:51727962 CD33 2.97×10í 0.94 31.73 0.007 (-0.004,0.018) 2.37×10-1 -0.007 (-0.02,0.006) 2.83×10-1 
rs10838725 11:47557871 CELF1 1.12×10í 1.08 31.26 -0.009 (-0.02,0.002) 1.09×10-1 0.006 (-0.007,0.019) 3.55×10-1 
rs9331896 8:27467686 CLU 2.77×10í 0.86 39.51 0.01 (-0.001,0.021) 6.47×10-2 -0.008 (-0.021,0.004) 1.86×10-1 
rs6656401 1:207692049 CR1 5.69×10í 1.18 19.50 -0.006 (-0.019,0.007) 3.47×10-1 0.024 (0.009,0.039) 1.88×10-3 
rs11771145 7:143110762 EPHA1 1.12×10í 0.9 34.36 0.002 (-0.008,0.013) 6.70×10-1 0.001 (-0.011,0.014) 8.49×10-1 
rs17125944 14:53400629 FERMT2 7.94×10í 1.14 8.95 -0.024 (-0.041,-0.006) 7.42×10-3* 0.026 (0.005,0.046) 1.57×10-2 
rs9271192 6:32578530 HLA-DRB5/DRB1 2.94×10í 1.11 27.08 -0.005 (-0.018,0.007) 3.79×10-1 -0.001 (-0.016,0.013) 8.73×10-1 
rs35349669 2:234068476 INPP5D 3.17×10í 1.08 47.54 -0.011 (-0.022,-0.001) 3.40×10-2* 0.009 (-0.003,0.022) 1.44×10-1 
rs190982 5:88223420 MEF2C 3.23×10í 0.93 42.20 -0.002 (-0.013,0.008) 6.54×10-1 -0.015 (-0.028,-0.003) 1.20×10-2 
rs983392 11:59923508 MS4A6A 6.14×10í 0.9 40.71 0.002 (-0.008,0.013) 6.63×10-1 -0.011 (-0.023,0.001) 8.29×10-2 
rs10792832 11:85867875 PICALM 9.32×10í 0.87 35.00 0.01 (-0.001,0.021) 7.04×10-2 -0.016 (-0.029,-0.003) 1.27×10-2 
rs28834970 8:27195121 PTK2B 7.37×10í 1.1 36.01 -0.01 (-0.021,0.001) 6.46×10-2 0.016 (0.002,0.029) 1.97×10-2 
rs10498633 14:92926952 SLC24A4 5.54×10í 0.91 22.65 0.001 (-0.011,0.013) 8.78×10-1 -0.003 (-0.017,0.012) 7.28×10-1 
rs11218343 11:121435587 SORL1 9.73×10í 0.7 11.56 0.013 (-0.004,0.029) 1.26×10-1 -0.02 (-0.039,-0.001) 4.25×10-2 
rs2718058 7:37841534 NME8 4.8×10í 0.93 36.02 0.004 (-0.007,0.014) 5.20×10-1 -0.009 (-0.022,0.003) 1.54×10-1 
rs12539172 7:100091795 ZCWPW1 6.02×10í 0.91 28.97 -0.004 (-0.016,0.007) 4.65×10-1 -0.006 (-0.019,0.008) 4.13×10-1 
* These SNPs were not found in our combined dataset and the association with CSF Aȕ42 and ptau181 levels was estimated by proxy SNPs: rs7561528 for rs6733839, 
rs11787077 for rs933189, rs3818361 for rs6656401, rs9271100 for rs9271192, rs28655385 for rs35349669, rs304132 for rs190982, rs10897009 for rs983392, and 
rs3781832 for rs11218343. Chr, chromosome; MAF, minor allele frequency. ! Statistics reported in overall-all analyses of the recent IGAP study8. & MAF in the 
combined CSF dataset. 
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Table 3. 0RVWVLJQLILFDQWDVVRFLDWLRQZLWK&6)$ȕ42 level in each IGAP locus 
Gene SNP Chr:bp Function MAF (%) SNP Type 
Case/control 
association& Beta (95% CI) P 
GERP 
Score 
ABCA7 rs76348507 19:1048116 intron 10.02 Imputed 1.80×10-8 -0.026 (-0.042,-0.009) 2.74×10-3 0.16 
BIN1 rs1469979 2:127896232 intergenic 26.01 Genotyped 0.52 0.011 (-0.001,0.023) 7.89×10-2 1.92 
CD2AP rs13190867 6:47314068 intergenic 8.59 Imputed 0.73 0.031 (0.013,0.05) 9.09×10-4 -0.77 
CASS4 rs17365060 20:55000949 intron 16.29 Imputed 0.96 0.017 (0.003,0.031) 1.76×10-2 -3.79 
CD33 rs10404590 19:51701749 intergenic 29.61 Imputed 3.41×10-3 -0.012 (-0.023,-0.001) 3.81×10-2 NA 
CELF1 rs7937331 11:47430458 intron 33.05 Imputed 5.11×10-7 0.021 (0.01,0.032) 2.30×10-4 2.5 
CLU rs17383366 8:27504228 intron 7.83 Imputed 0.01 0.025 (0.006,0.044) 9.88×10-3 2.81 
CR1 rs79795098 1:207737870 intron 16.24 Imputed 0.1 0.017 (0.002,0.031) 2.61×10-2 0.75 
EPHA1 rs7802536 7:143049973 downstream 22.36 Genotyped NA -0.025 (-0.037,-0.013) 6.01×10-5 -4.05 
FERMT2 rs62003531 14:53357018 intron 11.54 Imputed 2.75×10-4 -0.033 (-0.049,-0.016) 8.50×10-5 0.59 
HLA-DRB5/DRB1 rs115485493 6:32654807 intergenic 27.58 Imputed 0.66 0.013 (0.001,0.024) 2.90×10-2 -2.61 
IGHV1-67 rs75196489 14:107155455 intergenic 11.42 Imputed 7.49×10-7 0.017 (0,0.034) 4.41×10-2 NA 
INPP5D rs13385922 2:234081324 intron 39.86 Genotyped 0.02 0.014 (0.004,0.024) 7.98×10-3 0.16 
MEF2C rs141729694 5:87999371 intergenic 7.75 Imputed 0.04 -0.023 (-0.042,-0.003) 2.07×10-2 -0.47 
MS4A6A rs640219 11:59761679 intergenic 22.19 Imputed 0.13 -0.015 (-0.027,-0.003) 1.33×10-2 1.37 
NME8 rs9655029 18:37974718 intergenic 38.48 Imputed 0.64 -0.016 (-0.027,-0.006) 2.49×10-3 1.62 
PICALM rs573167 11:85831246 intergenic 32.41 Imputed 8.30×10-23 0.017 (0.006,0.028) 2.92×10-3 2.43 
PTK2B rs71519637 8:27334098 intron 9.32 Imputed 7.58×10-8 0.025 (0.007,0.044) 7.43×10-3 2.11 
SLC24A4 rs12887171 14:92824871 intron 31.63 Genotyped 0.31 -0.014 (-0.025,-0.003) 1.54×10-2 1.64 
SORL1 rs7103597 11:121418806 intron 39.19 Imputed 0.22 -0.013 (-0.024,-0.003) 1.46×10-2 1.05 
TP53INP1 rs12548367 8:95929202 intergenic 34.76 Imputed 0.16 0.018 (0.008,0.029) 8.64×10-4 0.36 
ZCWPW1 rs858503 7:99845866 intron 16.87 Imputed 0.11 0.021 (0.007,0.034) 3.11×10-3 0.35 
$VVRFLDWLRQZLWK&6)$ȕ42 levels was analyzed using multivariate linear regression adjusting for age, gender, first three principle components, and dummies for sites.* 
Association that passes the multiple-testing threshold calculated using simpleM algorithm34. Chr, chromosome; MAF, minor allele frequency; CI, confidence interval. & p-
values in the IGAP study{Lambert, 2013 #643}. 
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3.4.4 Several GWAS top hits show evidence of association with CSF ptau181 levels 
For the most significant associations identified in the IGAP paper 8, minor alleles of rs6656401 (CR1: 
p=1.88×10-3; Table 2), rs17125944 (FERMT2: p=1.57×10-2; Table 2), rs190982 (MEF2C: p=1.20×10-2; Table 2), 
rs10792832 (PICALM: p=1.27×10-2; Table 2), rs28834970 (PTK2B: p=1.97×10-2; Table 2), and rs11218343 
(SORL1: p=4.25×10-2; Table 2) showed evidence of association (p<0.05) with CSF ptau181 levels. Importantly, the 
directions of effects on CSF ptau181 levels for these SNPs are in agreement with the results reported in the recent 
IGAP paper, i.e. AD risk alleles are associated with higher CSF ptau181 levels (see Table 2). However, in the locus-
wide analyses, we did not identify any SNPs that exceed multiple testing thresholds for association with CSF ptau181 
levels. Regional plots for each locus can be found in Figures S26-S46. 
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Table 4. Most significant association with CSF ptau181 level in each IGAP locus 
Gene SNP Chr:bp Function MAF (%) SNP Type 
Case/control 
association& Beta (95% CI) P 
GERP 
Score 
ABCA7 rs757232 19:1075979 intron 25.97 Genotyped 4.69×10-9 0.015 (0.002,0.029) 2.40×10-2 -3.43 
BIN1 rs10166461 2:127859413 intron 19.36 Imputed 5.20×10-10 -0.018 (-0.033,-0.003) 2.21×10-2 -7.38 
CD2AP rs12201065 6:47626833 intron 41.06 Imputed 0.01 -0.016 (-0.029,-0.004) 9.02×10-3 -2.1 
CASS4 rs6127744 20:54986274 upstream 11.64 Imputed 8.79×10-7 -0.019 (-0.039,0) 5.53×10-2 0.97 
CD33 rs11668174 19:51763498 intron 6.22 Imputed 1.58×10-3 -0.024 (-0.049,0.001) 6.00×10-2 -0.47 
CELF1 rs7937331 11:47430458 intron 33.05 Imputed 5.11×10-7 -0.015 (-0.028,-0.002) 2.38×10-2 2.5 
CLU rs570164 8:27503653 intron 23.32 Imputed 0.28 0.013 (-0.002,0.027) 8.26×10-2 -1.65 
CR1 rs4844610 1:207802552 intron 18.46 Imputed 6.90×10-23 0.026 (0.01,0.042) 1.14×10-3 0.21 
EPHA1 rs2272251 7:143042837 synonymous 45.72 Genotyped 0.52 -0.014 (-0.026,-0.002) 2.47×10-2 -1.84 
FERMT2 rs78459273 14:53274260 intergenic 8.37 Imputed 7.65×10-3 0.035 (0.013,0.056) 1.54×10-3 -4.07 
HLA-DRB5/DRB1 rs114975350 6:32428062 intergenic 29.73 Imputed 1.98×10-4 0.023 (0.009,0.036) 8.53×10-4 1.45 
IGHV1-67 rs11850600 14:107126781 intergenic 11.15 Imputed 1.85×10-3 -0.028 (-0.048,-0.009) 4.53×10-3 -0.60 
INPP5D rs10170794 2:233894598 upstream 17.71 Imputed NA 0.023 (0.007,0.039) 5.69×10-3 -0.48 
MEF2C rs304132 5:88215594 intergenic 42.2 Genotyped 1.21×10-7 -0.015 (-0.028,-0.003) 1.20×10-2 1.58 
MS4A6A rs663925 11:59815517 3’ UTR 37.7 Genotyped 0.08 -0.021 (-0.033,-0.008) 9.79×10-4 2.66 
NME8 rs2598023 18:37915580 intergenic 37.76 Imputed 0.65 -0.019 (-0.031,-0.006) 3.98×10-3 0.23 
PICALM rs10792828 11:85826797 intergenic 9.89 Imputed 0.20 0.033 (0.013,0.053) 1.51×10-3 1.52 
PTK2B rs41276295 8:27289126 intron 45.03 Imputed 6.90×10-4 0.017 (0.005,0.029) 6.14×10-3 2.05 
SLC24A4 rs12590749 14:92868468 intron 35.61 Genotyped 0.85 0.02 (0.007,0.032) 2.53×10-3 0.63 
SORL1 rs643010 11:121336471 intron 48.23 Imputed 0.15 -0.02 (-0.032,-0.007) 1.57×10-3 -1.21 
TP53INP1 rs61596977 8:95997165 intergenic 12.38 Imputed 5.17×10-3 0.031 (0.012,0.049) 1.38×10-3 -3.21 
ZCWPW1 rs76281814 7:99846414 intron 22.04 Imputed 0.72 -0.016 (-0.031,-0.001) 3.57×10-2 -0.22 
Association with CSF ptau181 levels was analyzed using multivariate linear regression adjusting for age, gender, first three principle components, and dummies for sites. Chr, 
chromosome; MAF, minor allele frequency; CI, confidence interval. & p-values in the IGAP study8. 
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Table 5. Results of set-based analyses for each GWAS-identified locus 
Gene # of SNPs in the set Empirical P$ȕ Empirical Pptau 
ABCA7 73 1.23×10-1 3.41×10-1 
BIN1 391 1 5.98×10-1 
CD2AP 804 1.41×10-1 3.87×10-1 
CASS4 244 2.48×10-1 1 
CD33 118 4.49×10-1 1 
CELF1 211 6.30×10-3* 2.72×10-1 
CLU 149 2.55×10-1 1 
CR1 445 6.23×10-1 2.25×10-1 
EPHA1 127 1.63×10-2* 3.52×10-1 
FERMT2 463 7.80×10-3* 9.62×10-2 
HLA-DRB5/DRB1 3350 6.01×10-1 5.29×10-2 
IGHV1-67 126 1.96×10-1 2.26×10-2* 
INPP5D 517 6.06×10-1 3.56×10-1 
MEF2C 195 4.24×10-1 1.28×10-1 
MS4A6A 618 4.43×10-1 1.95×10-1 
NME8 1071 1.64×10-2* 6.31×10-1 
PICALM 476 2.72×10-1 5.56×10-2 
PTK2B 599 5.19×10-1 1.90×10-1 
SLC24A4 588 7.96×10-1 2.17×10-1 
SORL1 522 5.11×10-1 2.95×10-1 
TP53INP1 677 6.80×10-2 1.61×10-1 
ZCWPW1 244 1.25×10-1 5.02×10-1 
Set-based analyses were implemented to evaluate association between all of the SNPs within the IGAP genes 
ZLWK&6)$ȕ42 and ptau181 levels. Age, gender, population substructure, and dummies for sites were adjusted and 
10,000 permutations were used to estimate the association using default parameters in PLINK. * denotes 
significant association. 
 
3.4.5 CSF analyses for additional recently identified genetic markers 
Recent studies have reported an association for ABCA7 (rs3764650), CR1 (rs6701713), and CD2AP 
(rs9349407) with neuritic plaque burden163 and for CLU (rs11136000) and MS4A6A UVZLWK&6)$ȕ42 
levels164.Therefore, we analyzed the CSF dataset to determine whether these findings could be replicated. 
Rs3764650 in ABCA7 is in borderline GWS association with AD risk (p=3.22×10-7, Table S8) in stage one analysis 
of the IGAP study8. In our combined analyses RIWKHMRLQWGDWDVHWUVLVDVVRFLDWHGZLWK&6)$ȕ42 levels 
(p=4.24×10-3ȕ -0.024 [-0.041~-0.008]; Table S8) but not with CSF ptau181 OHYHOVS ȕ >-
0.014~0.025]; Table S8). Rs3764650 is in modest LD with rs4147929, the IGAP top hit in ABCA7 (D’=0.66; 
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R2=0.22; Table S5) but in almost complete LD with rs76348507, the most significant SNP for the ABCA7 locus in 
our CSF analyses (D’=1; R2=0.99; Table S5). Conditional analyses suggest that rs3764650, rs76348507 and 
rs4147929 tag the same signal but rs3764650 and rs76348507 are in higher LD with the underlying functional 
variant. (Table S6). Our data supports the association of UVZLWK$ȕPHWDEROLVPDQGVXJJHVWVWKDWWKHUHLV
one signal within ABCA7 associated with AD risk. 
In stage 1 of the IGAP study, rs6701713 in CR1 (p=3.47×10-14; Table S8) and rs11136000 in CLU 
(p=1.72×10-16; Table S8) are genome-wide significantly associated with AD risk but rs9349407 in CD2AP 
(p=3.92×10-7; Table S8) and rs2304933 in MS4A6A (p=5.35×10-5; Table S8) are only suggestively associated with 
AD risk. However, we did not observe evidence of association for rs6701713 in CR1 (p=3.47×10-1; Table S8), 
rs9349407 in CD2AP (p=2.66×10-1; Table S8), rs11136000 in CLU (p=5.75×10-2; Table S8), and rs2304933 in 
MS4A6A (p=1.64×10-1; Table S8ZLWK&6)$ȕ42 levels (Table S8). Surprisingly, rs6701713 in CR1 is associated 
with CSF ptau181 levels (p=1.88×10-3ȕ >a@Table S8). Rs6701713 is in significant LD with 
rs6656401 (D'=0.99; R2=0.95; Table S5), the IGAP top SNP in CR1. Additionally, conditional analyses suggest that 
rs6701713, recently reported to be associated with neuritic plaque burden163, tags the same signal as rs6656401 for 
association with CSF ptau181 levels (Table S6). We did not find significant association for rs9349407 in CD2AP, 
rs11136000 in CLU, and rs2304933 with CSF ptau181 levels (Table S8).  
3.4.6 RegulomeDB prediction 
 To better understand potential function roles of the top SNPs within GWAS-identified loci, we utilized the 
RegulomeDB database160 to predict their regulatory potential across several cell lines. With the exception of 
rs9271192 in HLA-DRB5/DRB1(score=1f) and rs1476679 in ZCWPW1 (score=1f), IGAP top SNPs had a 
RegulomeDB score greater than 3, which indicates that the majority of GWAS top SNPs are unlikely to be the 
functional variants for AD risk. Since we did not observe significant regulatory function for variants which were 
significantly associated with CSF $ȕ42 levels (score=4 for rs7937331 in SLC39A13, score=4 for rs7802536 in 
EPHA1 and score=7 for rs62003531 in FERMT2), we searched the SNAP server (based on the CEU populations in 
1,000 Genomes Pilot 1) and our CSF dataset for proxy SNPs in LD (R2>0.8) with these three top SNPs. In total, we 
found 77 proxy SNPs (38 for SLC39A13-rs7937331, 0 for EPHA1-rs7802536, and 39 for FERMT2-rs62003531 (see 
Table S9). Of these 77 proxy SNPs, 24 (24 for CELF1-rs7937331) had a RegulomeDB score <3 (see Table 7), 
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where scores 1 and 2 suggest a potential impact on binding change and targeted-gene expression differentiation (see 
Table S10). Proxy SNPs for rs7802536 in SLC39A13 were predicted to be eQTLs for AMBRA1, C1QTNF4, 
MYBPC3, NR1H3, SNRPG, or SPI1 and are located in the binding motifs for RREB1, Foxl1, E47, EWSR1-FLI1, 
SREBP1, SREBP2, CACCC-binding facot, ZIC1, PLAG1, RFX1, Zfx, or HOXA5. Additionally, these proxy SNPs 
may affect binding of FOXA1, POLR2A, TCF4, BLIMP1, HOXB3, SP1, NFYA, NFYB, FOS, STAT, CTCF, 
POU2F2, CEBPB, MAFK, CREBBP, HMGN3, Gfi1, or Lhx8 (see Table 6). Together, these predictions strongly 
suggest that some of the proxy variants in LD with rs7937331 in the SLC39A13 locus may be functional variants 
affecting AD by regulating RNA transcripts levels and affecting transcription factor binding. 
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Table 6. Detailed descriptions for SNPs with putative regulatory function (RegulomeDB score<3) 
rsid (coordinate) RegulomeDB Score* Function Left Gene - Right Gene eQTL Motifs Protein Binding 
rs1057233 (11:47376448) 1f 3' UTR MYBPC3-SLC39A13 SNRPG - FOXA1 
rs10742803 (11:47439938) 1f downstream SLC39A13-PSMC3 SNRPG - POLR2A 
rs10769258 (11:47391039) 1f intron (SPI1) MYBPC3-SLC39A13 SNRPG, C1QTNF4, SPI1 - - 
rs11604680 (11:47457539) 1b downstream PSMC3-RAPSN SNRPG, C1QTNF4, SPI1 RREB1, Foxl1 TCF4 
rs11605672 (11:47413733) 1f intergenic SPI1-SLC39A13 SNRPG, C1QTNF4, SPI1, MYBPC3 - - 
rs12364432 (11:47902883) 1f intergenic NUP160-PTPRJ SNRPG, C1QTNF4 - - 
rs12418852 (11:47868853) 1f intron (NUP160) LOC100132562-PTPRJ SNRPG, C1QTNF4, SPI1 - BLIMP1, HOXB3,  SP1 
rs12419692 (11:47624714) 1f intergenic C1QTNF4-MTCH2 SNRPG, C1QTNF4, SPI1, MYBPC3, NR1H3 - - 
rs1317149 (11:47486885) 1f downstream RAPSN-CUGBP1 SNRPG, C1QTNF4, SPI1 - - 
rs2053979 (11:47439444) 1b downstream SLC39A13-PSMC3 SNRPG, C1QTNF4, SPI1 E47 POLR2A 
rs2293578 (11:47437403) 2b 3' UTR (SLC39A13) SPI1-PSMC3 - EWSR1-FLI1 POLR2A 
rs2856650 (11:47365199) 1f intron (MYBPC3) MADD-SPI1 AMBRA1, SNRPG, C1QTNF4 SREBP, SREBP1, SREBP2 - 
rs35184771 (11:47475189) 2b upstream RAPSN-CUGBP1 - CACCC-bindingfactor, ZIC1 SP1,NFYA, NFYB 
rs3781625 (11:47443080) 1f intron (PSMC3) SLC39A13-RAPSN SNRPG, C1QTNF4, SPI1 - POLR2A 
rs3781626 (11:47442893) 1f intron (PSMC3) SLC39A13-RAPSN SNRPG, C1QTNF4, SPI1 - POLR2A 
rs4752797 (11:47874364) 1f upstream NUP160-PTPRJ MYBPC3, NR1H3, SPI1 - - 
rs4752801 (11:47907641) 1f intergenic NUP160-PTPRJ SNRPG, C1QTNF4 - TCF4, FOS 
rs4752990 (11:47410393) 1b intergenic SPI1-SLC39A13 SNRPG, C1QTNF4, SPI1 PLAG1 STAT3 
rs4752993 (11:47410951) 1f intergenic SPI1-SLC39A13 SNRPG, C1QTNF4, SPI1 - - 
rs4752999 (11:47428565) 1b upstream SPI1-SLC39A13 SNRPG, C1QTNF4, SPI1, MYBPC3 RFX1 CTCF, POLR2A, POU2F2, CEBPB, MAFK 
rs55876153 (11:47416636) 2b intergenic SPI1-SLC39A13 - Zfx POLR2A, CREBBP, HMGN3 
rs755553 (11:47432303) 1f intron (SLC39A13) SPI1-PSMC3 SNRPG, C1QTNF4, SPI1 - - 
rs7940536 (11:47395240) 1f intron (SPI1) MYBPC3-SLC39A13 SNRPG, C1QTNF4, SPI1 - Gfi1 , Lhx8 
rs896816 (11:47394338) 1f intron (SPI1) MYBPC3-SLC39A13 SNRPG, C1QTNF4, SPI1 HOXA5 - 
DegulomeDB scores and detailed annotations for putative regulatory SNPs in high LD (R2ZLWKUVZHUHVKRZQ)RUFDWHJRULHVRI5HJXORPH'%VFRUHVSOHDVHFKHFN7DEOH6 
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3.4.7 TREM2 and TREML2 distinct effects on AD risk 
 The IGAP study also identified a suggestive association (rs9381040, p=6.3×10-7) located in the intergenic 
region between TREM2 and TREML2; however, it was not possible to determine whether this intergenic signal was 
independent of p.R47H in TREM2 due to the study design (a meta-analysis). Moreover, LD prevents the 
identification of functional variants and genes within this region. To identify potential functional coding variants 
within this region, we first analyzed the whole exome sequencing data from the Knight-ADRC study (46 AD cases 
and 39 controls) and UK-NIA study (143 AD cases and 186 controls). Eight coding variants were validated in the 
TREML2 gene (see Table 7), which constitute 53% (8/15) of the missense variants reported for TREML2 gene in the 
Exome Variant Server (release ESP6500SI-V2) for European Americans. Only 3 variants exhibit a MAF higher than 
1%: p.V25A (MAF=5%), p.T129S (MAF=4.5%), and p.S144G (MAF=30%). Interestingly, according to our exome 
sequencing results, all of these variants are more common in controls than in cases; however they did not reach 
statistical significance because of the small sample size (see Table 7). Interestingly, the missense variant p.S144G 
(rs3747742) exhibited the highest LD (D’=0.86; R2=0.73) with the GWAS SNP, rs9381040 (see Table 7), and 
exhibited the highest MAF among the validated missense variants in TREML2, which made it suitable for further 
analysis. Next, we performed a meta-analysis of the data from the ADGC, GERAD, EADI, and the Alzheimer’s 
Research UK studies (16,254 cases and 20,052 control subjects); we found that the minor alleles of both rs9381040 
(p=1.21×10-5; OR=0.92 [0.88~0.95], and rs3747742 (p=8.66×10-5; OR=0.93[0.89~0.96]) reduce risk for AD (see 
Figures 2A and 2B). When rs3747742 is included in a logistic regression model as a covariate, rs9381040 is no 
longer significant (p=0.43), and vice-versa, indicating that these SNPs tag the same signal. In addition, TREM2-
p.R47H (rs75932628) was successfully imputed (imputation quality score information=0.84 and 0.79) in the 
GERAD and EADI studies, and displays a strong association with AD risk (p=1.3×10-3; OR=1.92 [1.29~2.85]) (see 
Figure 2C). When rs3747742 or rs9381040 are included as covariates in a conditional analysis, rs75932628 remains 
highly significant (p=1.27×10-4 and p=1.19×10-4 respectively) (see Figure 2D), which suggests that the TREML2 
and TREM2 signals are independent from each other. 
 We then performed a linear regression analysis for rs9381040 and rs3747742 with CSF tau and ptau181 
levels (N = 1,269: 501 from Knight-ADRC, 394 from ADNI, 323 from UW, and 51 from Penn)22. Rs9381040 
(p=4.11×10-4, ȕ -0.02) and rs3747742 (p=1.4×10-4, ȕ -0.02) both exhibit a strong association with CSF ptau181 
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levels. The respective associations with CSF ptau181 levels are no longer significant when either SNP is included as a 
covariate in the conditional analysis. These results confirm via 2 independent datasets that the associations of 
rs9381040 and rs3747742 with CSF biomarker levels and with AD risk represent the same signal. The TREM2-
p.R47H variant was also genotyped in a subset of the CSF samples (N=835). In these samples, 3 variants, rs9381040 
(p=0.04, ȕ=-0.02) (see Figure 3A), rs3747742 (p=0.02, ȕ=-0.02) (see Figure 3B), and rs75932628 (p=0.0016, 
ȕ=0.2) (see Figure 3C) demonstrate a nominally significant association with CSF ptau181 levels. To determine 
whether the TREML2 signal (rs3747742) is independent of TREM2-p.R47H, we removed all of the p.R47H carriers 
from the analysis. Rs3747742 remained significantly associated with CSF ptau181 levels (p=0.03) (see Figure 3D). 
Furthermore, when TREM2-p.R47H was included in the model as a covariate for rs3747742 analysis, the association 
remained significant (p=0.02), which suggests that the TREM2 and TREML2 signals are independent. Importantly, 
these associations confirmed the direction of the effect on CSF ptau181 levels: the minor allele of rs3747742 is 
associated with lower ptau181 levels (ȕ=-0.02) and is predicted to be protective for AD risk (OR=0.91 [0.86~0.97]), 
while the minor allele of TREM2-p.R47H is associated with an increased risk for AD (OR=1.91 [1.85~1.97]) and 
higher levels of CSF ptau181 levels (ȕ=0.2). Together, these results demonstrate that the associations of missense 
variants in TREM2 and TREML2 with AD risk are independent. Our analyses also suggest that the AD-associated 
GWAS signal is more likely driven by the TREML2 coding missense variant p.S144G (rs3747742) than by 
rs9381040, the most significant GWAS variant in the TREM2-TREML2 region. 
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Table 7. TREML2 variants identified by exome-sequencing 
Location 
in chr6 
rs# 
AA 
change 
EVS, 
MAF 
AD (n=189) Controls (n=225) 
OR (95% CI) p 
LD with 
rs9381040 Condel Sift Polyphen 
Hets MAF Hets MAF R2 D' 
41166154 rs77704965 D23G 0.22 0 0% 4 2% NA 0.17 0.018 1 Neutral Tolerated Benign 
41166149 rs62396355 V25A 5.05 6 3% 15 7% 0.45 (0.17-1.2) 0.11 0.018 1 Neutral Tolerated Benign 
41166075 rs35512890 M50V NA 16 8% 27 12% 0.67 (0.35-1.3) 0.24 NA NA Neutral Tolerated Benign 
41162562 rs61734887 S129T 4.52 12 6% 22 10% 0.62 (0.30--1.3) 0.2 0.051 1 Neutral Tolerated Benign 
41162538 NA L137H NA 0 0% 1 0% NA 0.35 NA NA Neutral Tolerated Benign 
41162518 rs3747742 S144G 30.44 82 43% 104 47% 0.89 (0.6-1.31) 0.56 0.67 0.86 Neutral Tolerated Benign 
41162371 rs145455750 T193A 0.27 0 0% 1 0% NA 0.35 NA NA Neutral Tolerated Benign 
41162204 rs115991880 S248A 0.34 2 1% 5 2% 0.47 (0.09-2.45) 0.36 0 0 Deleterious Deleterious Benign 
Coding variants in TREML2 were extracted from 46 unrelated AD cases and 39 unrelated controls from the Knight-ADRC study and from 143 unrelated AD cases and 183 
unrelated controls from the NIA-UK exome-sequencing study. R2 and D’ values reported here are coming from the Pilot 1 of the 1000K genome project. Key: AD, Alzheimer’s 
disease; CI, confidence interval; LD, linkage disequilibrium; OR, odds ratio. 
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3.5 DISCUSSION 
Using CSF biomarkers as endophenotypes in genetic studies has been shown to be a useful method to generate 
testable hypotheses regarding biological mechanisms attributable to identified genetic variants and to identify novel 
variants associated with different aspects of disease17-23. To test the hypothesis that GWAS-identified AD risk 
YDULDQWVDUHDOVRDVVRFLDWHGZLWK&6)ELRPDUNHUVZHHYDOXDWHGWKHDVVRFLDWLRQZLWK&6)$ȕ42 and ptau181 
biomarkers at SNP- and SNP set- levels. Power analyses (see Table S2) suggest that we have >80% power to find a 
statistically significant, additive effect of a 0.21 fold-difference between the means when the alpha level is 0.05 for 
all SNPs in this study. Assuming an extremely conservative alpha level of 10-5, all SNPs in this study still achieve 
power of at least 80% for a 0.365 delta (differences in standard deviation). In order to distinguish the effects of 
GWAS-identified genes from flanking genomic regions, we carefully selected fine mapping regions taking into 
account the recombination rates. To avoid using the conservative and stringent Bonferroni correction which can lead 
to false negative association, we utilized the simpleM algorithm 157 to calculate the number of independent 
association tests within the fine mapping regions. 
For the top SNPs identified in the IGAP study, we found evidence of association for ABCA7 (rs4147929), 
FERMT2 (rs17125944), and INPP5D UVZLWK&6)$ȕ42 levels and evidence of association for CR1 
(rs6656401), FERMT2 (rs17125944), MEF2C (rs190982), PICALM (rs10792832), PTK2B (rs28834970), and 
SORL1 (rs11218343) with CSF ptau181 levels. However, the top SNPs within each locus in the IGAP study are not 
the most significant SNPs within each locus in our CSF biomarker analyses (see Tables 2 and 3)8. After correcting 
for multiple testing, the most significant SNPs within the CELF1, EPHA1, and FERMT2 fine-mapping regions are 
significantl\DVVRFLDWHGZLWK&6)$ȕ42 levels. The first association appears to be through rs7937331, located in an 
intron of SLC39A13. We showed that SLC39A13-rs7937331, a SNP significantly associated with CSF $ȕ42 levels, 
and CELF1-rs10838725, the IGAP top SNP significantly associated with AD risk, tag the same association. 
Additionally, although the association between SNPs in SLC39A13 and AD risk was not genome-wide significant 
(p= 5.11×10-7) it was still strong in the IGAP analysis8. Set-based analysis for the CELF1 fine-mapping supports the 
association ZLWK&6)$ȕ42 levels. Together, our result suggests that SLC39A13 may be a novel candidate gene 
DIIHFWLQJ$'WKURXJKDQ$ȕ dependent mechanism. The second association is through rs7802536, located in the 
intergenic region between CLCN1 and FAM131B. The association for this intergenic signal is independent of 
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EPHA1. Set-based analysis for the EPHA1 fine-mapping region provides extra evidence of association with CSF 
$ȕ42 levels. However, this intergenic SNP is not associated with AD risk in the IGAP study, which suggests that the 
signal within this intergenic region may be a false positive finding. The last significant association is through 
rs62003531, located in the intronic region of FERMT2. Our analyses further confirm that rs62003531 tags the same 
signal as the IGAP top SNP in FERMT2. Set-based analysis for the FERMT2 fine-mapping region supports the 
DVVRFLDWLRQZLWK&6)$ȕ42 levels. Our data clearly suggest that there is only one signal within the FERMT2 region 
and that the functional allele affects AD rLVNWKURXJKDQ$ȕ-dependent mechanism. 
We also confirmed that the effect size and direction of effect for SNPs that surpassed multiple test correction 
thresholds are similar and consistent in each locus by conducting stratified, case-only, and control-only analyses (see 
Tables S11 and S12). Genome partition analyses suggest that CELF1-rs7937331, EPHA1-rs7802536, and FERMT2-
UVRQO\H[SODLQRIWKHSKHQRW\SLFYDULDELOLW\IRU&6)$ȕ42 levels (31.64% explained by the GWAS 
chip as a whole), suggesting that additional genetic variants, which may include a combination of common, low 
frequency, rare, or structural variants remain unidentified.  
BIN1 was previously reported to be associated with AD risk via a tau dependent mechanism 165. Moreover, a 
recent study performed functional screening in drosophila and found that the fly orthologs of CD2AP, CELF1, and 
FERMT2 modulate tau metabolism 166. In our analyses, neither the most significant variants in our analyses nor the 
IGAP top SNPs in these genes surpassed multiple test correction thresholds for association with CSF ptau181 and tau 
levels (see Tables 2 and 4) which may be due to lack of statistical power. 
Several recent studies have shown that the RegulomeDB database160 is a comprehensive and fast tool to 
annotate noncoding variants and predict the potential regulatory function associated with SNPs of interest142,160. In 
this study, we used RegulomeDB to examine whether IGAP-identified top SNPs and our CSF-identified top SNPs 
may have any potential regulatory functional impact. We found that several proxy SNPs in LD with rs7937331 in 
the SLC39A13 region are implicated as cis-eQTLs for nearby genes and may affect transcription factor binding. 
However, these regulatory function predictions are primarily based on data in blood and cancer cells. Further 
functional studies using brain tissues are essential to elucidate whether these non-coding variants have any effects in 
human brain and thus contribute to AD. 
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Our power calculation predicts a high likelihood of detecting a significant association in the single-variant 
analyses given our sample size. Plausible explanations for the lack of significant association with CSF ptau181 levels 
include: (1) Current samples size is still not large enough to identify a signal with CSF ptau181 levels given the 
differences in measurement of ptau181 across studies; (2) variants that affect AD risk by modulating tau pathology 
may be involved in other processes rather than affecting CSF ptau181 levels; (3) underlying functional variants 
affecting CSF ptau181 levels are low frequency, rare, or common variants with very small effects; (4) assuming an 
additive genetic effects model did not detect the association with CSF ptau181 levels well; (5) the association for CSF 
ptau181 levels involves gene-gene or gene-environment interaction that cannot be captured using our study design.  
 For the TREM2 and TREML2 regions, our results demonstrate that the associations of missense variants in 
TREM2 and TREML2 with AD risk are independent. Moreover, our analyses suggest that the AD-associated GWAS 
signal is likely driven by the TREML2 missense variant p.S144G (rs3747742); it results in a similar OR to 
rs9381040. We also validated 2 other coding variants p.V25A and p.S129T in TREML2 gene in moderate LD 
(R2=0.05 and D’=1) with the GWAS SNP, which both exhibited a higher frequency among control subjects than in 
AD cases (see Table 7). However, for both variants we only obtained data by whole-exome sequencing which 
limited our analysis about the role that these variants may play in the association of TREML2 with AD risk. To 
prove that these additional variants are associated with AD risk we will need a larger sample size. Additionally, the 
purpose of this study was to find a functional coding variant in the TREML2 gene that could explain the association 
for TREML2 which was found in the recent IGAP meta-analysis. Our data suggest that there is a coding variant in 
TREML2 that could explain the GWAS signal, but our data cannot rule out the presence of functional variants 
outside of the coding region. 
 In summary, our fine-mapping analyses in the APOE locus identified a genome-wide significant 
association for rs769449 in APOE ORFXVZLWKERWK&6)$ȕ42 and ptau181 independently of APOE-İDQGAPOE-İ
SNPs. We also showed that at least part of the association for rs769449 with CSF ptau181 OHYHOVLV$ȕ-independent. 
Our locus-specific analyses identified signals within the CELF1, EPHA1, and FERMT2 fine-mapping regions 
VLJQLILFDQWO\DVVRFLDWHGZLWK&6)$ȕ42 levels after correction for multiple testing. Set-based analyses within the 
CELF1, EPHA1, and FERMT2 fine-mapping regions also supported the significant associations. Additionally, the 
RegulomeDB database showed that several proxy SNPs for rs7937331 in SLC39A13 may have potential regulatory 
effects. However, our data lack statistical power to detect any significant association with CSF ptau181 levels. We 
78 
 
also showed that TREM2- p.R47H is associated with increased risk for AD (OR=1.91 [1.85~1.97]) and TREML2-
p.S144G is associated with reduced risk for AD (OR=0.91 [0.86~0.97]). The mechanisms by which these variants 
influence AD risk are not currently understood, but it has been suggested that modulation of microglial activation 
might influence clearance of Aȕ. These results underline the importance of the inflammatory response in modulating 
risk for AD and suggest that other genes in this gene family may also harbor risk alleles for AD. 
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SUPPLEMENTAL TABLES 
Table S1. Fine-mapping region and multiple test threshold for each gene 
 
Gene Chr Left Boundary 
Right 
Boundary 
Fine-mapping 
region (kb) # SNPs 
# independent 
SNPs 
Multiple testing 
threshold 
ABCA7 19 1038925 1093453 54.528 73 48 1.04×10-3 
APOE 19 45357291 45447145 89.854 118 57 8.77×10-4 
BIN1 2 127750462 127896232 145.77 391 125 4.00×10-4 
CD2AP 6 47310938 47709696 398.758 803 178 2.81×10-4 
CD33 19 51676649 51780994 104.345 113 44 1.14×10-3 
CLU 8 27404137 27504956 100.819 149 64 7.81×10-4 
CR1 1 207568023 207878272 310.249 444 95 5.26×10-4 
CELF1 11 47412614 47639525 226.911 210 47 1.06×10-3 
CASS4 20 54977598 55148084 170.486 243 91 5.49×10-4 
EPHA1 7 143025985 143132563 106.578 127 65 7.69×10-4 
FERMT2 14 53071715 53474112 402.397 461 157 3.18×10-4 
HLA_DRB5/DRB1 6 32427789 32682019 254.23 3350 1053 4.75×10-5 
IGHV1-67 14 107122925 107169570 46.645 126 25 2.00×10-3 
INPP5D 2 233805812 234121692 315.88 515 213 2.35×10-4 
MS4A6A 11 59744901 60107747 362.846 618 138 3.62×10-4 
MEF2C 5 87978904 88223420 244.516 195 57 8.77×10-4 
NME8 7 37405370 37983235 577.865 1070 261 1.92×10-4 
PICALM 11 85601792 85908139 306.347 476 170 2.94×10-4 
PTK2B 8 27067745 27404137 336.392 599 152 3.29×10-4 
SORL1 11 121204601 121661507 456.906 521 165 3.03×10-4 
SLC24A4 14 92758445 93010112 251.667 588 196 2.55×10-4 
TP53INP1 8 95793022 96204513 411.491 677 184 2.72×10-4 
ZCWPW1 7 99816488 100159567 343.079 242 73 6.85×10-4 
The fine-mapping region was defined as the region between the closest recombination hot spots in either direction based on the 
estimated recombination rate from HapMap samples (May 2008). Left and right boundaries were annotated based on hg 19 
build. The simpleM method was used to calculate the number of independent signals within the fine-mapping region157. The 
multiple testing threshold was defined as 0.05 divided by the number of independent SNPs. CHR, chromosome. 
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Table S2. Power calculation 
Minor allele frequency 
Effect size when power = 0.8 
Alpha = 0.05 Alpha = 10-5 
0.10 0.21 0.365 
0.15 0.175 0.308 
0.20 0.157 0.275 
0.25 0.146 0.255 
0.30 0.137 0.24 
0.35 0.132 0.23 
0.40 0.129 0.224 
0.45 0.126 0.222 
0.50 0.125 0.22 
Power estimation for genetic association detection. Power was 
calculated using an overall F test in a one-way, three-group analysis 
of variance. The effect size which was measured in fold-difference 
between the means by assigning statistical power to 80% for minor 
allele frequencies from 0.1 to 0.5 and Type I error equal to 0.05 and 
0.00001. 
 
 
 
Table S3. Top SNP in the APOE locus in each study 
Study 7RS613IRU&6)$ȕ42 P$ȕ Top SNP for CSF ptau181 Pptau 
ADNI-1 rs769449 1.42×10-15 rs2075650 2.90×10-6 
ADNI-2 rs429358 4.81×10-28 rs429358 1.67×10-12 
Mayo rs429358 2.73×10-16 rs429358 1.30×10-5 
UW rs769449 6.92×10-17 rs769449 6.48×10-9 
Knight-ADRC rs769449 2.96×10-23 rs769449 1.10×10-8 
Association for APOE with CSF $ȕ42 and ptau181 levels was examined using a multivariate linear regression adjusting 
for age, gender, and PCs in each study. 
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Table S4. Top SNP in the APOE locus in the combined analysis 
SNP MAF (%) P$ȕ Pptau 
rs769449 17.88 7.60×10-79 3.31×10-32 
Top SNP in APOE locus, minor allele frequency (MAF), and association with CSF $ȕ42 and ptau181 levels were 
shown. Multivariate linear regression adjusting for age, gender, PCs and dummies for sites were performed to 
evaluate the association. 
 
 
 
Table S5. Linkage disequilibrium between selected SNPs 
Gene SNP1 SNP2 D' R2 
ABCA7 rs4147929 rs3764650 0.66 0.22 
ABCA7 rs4147929 rs76348507 0.69 0.23 
ABCA7 rs3764650 rs76348507 1 0.99 
CR1 rs6656401 rs6701713 1 1 
CR1 rs6656401 rs4844610 1 0.95 
CELF1 rs10838725 rs7937331 0.97 0.21 
EPHA1 rs11771145 rs7802536 0.01 0 
FERMT2 rs17125944 rs62003531 0.95 0.7 
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Table S6. Conditional analyses for selected SNPs 
ABCA7 Separate Analysis Conditioning on rs76348507 Conditioning on rs4147929 
rsid Beta$ȕ P$ȕ Beta$ȕ P$ȕ Beta$ȕ P$ȕ 
rs76348507 -0.026 (-0.042,-0.009) 2.74×10-3 NA NA -0.019 (-0.037,0) 5.52×10-2 
rs4147929 -0.017 (-0.030,-0.004) 1.00×10-2 -0.010 (-0.025,0.004) 1.66×10-1 NA NA 
       
ABCA7 Separate Analysis Conditioning on rs4147929 Conditioning on rs3764650 
rsid Beta$ȕ P$ȕ Beta$ȕ P$ȕ Beta$ȕ P$ȕ 
rs4147929 -0.017 (-0.03,-0.004) 1.00×10-2 NA NA -0.011 (-0.026,0.004) 1.41×10-1 
rs3764650 -0.024 (-0.041,-0.008) 4.24×10-3 -0.017 (-0.036,0) 7.36×10-2 NA NA 
       
ABCA7 Separate Analysis Conditioning on rs3764650 Conditioning on rs76348507 
rsid Beta$ȕ P$ȕ Beta$ȕ P$ȕ Beta$ȕ P$ȕ 
rs3764650 -0.024 (-0.041,-0.008) 1.00×10-2 NA NA NA NA 
rs76348507 -0.026 (-0.042,-0.009) 4.24×10-3 NA NA NA NA 
       
CR1 Separate Analysis Conditioning on rs6701713 Conditioning on rs6656401 
rsid Betaptau Pptau Betaptau Pptau Betaptau Pptau 
rs6701713 0.024 (0.009,0.039) 1.88×10-3 NA NA NA NA 
rs6656401 -0.006 (-0.019,0.006) 3.47×10-1 NA NA NA NA 
       
CELF1 Separate Analysis Conditioning on rs7937331 Conditioning on rs10838725 
rsid Beta$ȕ P$ȕ Beta$ȕ P$ȕ Beta$ȕ P$ȕ 
rs7937331 0.021 (0.01,0.032) 2.30×10-4 NA NA 0.02 (0.008,0.032) 1.25×10-3 
rs10838725 -0.009 (-0.02,0.002) 1.09×10-1 -0.001 (-0.014,0.011) 8.67×10-1 NA NA 
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EPHA1 Separate Analysis Conditioning on rs7802536 Conditioning on rs11771145 
rsid Beta$ȕ P$ȕ Beta$ȕ P$ȕ Beta$ȕ P$ȕ 
rs7802536 -0.025 (-0.037,-0.013) 6.01×10-5 NA NA -0.025 (-0.037,-0.013) 5.97×10-5 
rs11771145 0.002 (-0.008,0.013) 6.70×10-1 0.002 (-0.008,0.013) 6.53×10-1 NA NA 
       
FERMT2 Separate Analysis Conditioning on rs62003531 Conditioning on rs17125944 
rsid Beta$ȕ P Beta$ȕ P Beta$ȕ P 
rs62003531 -0.033 (-0.049,-0.016) 8.50×10-5 NA NA -0.041 (-0.070,-0.012) 5.85×10-3 
rs17125944 0.026 (0.005,0.046) 7.42×10-3 0.011 (-0.021,0.043) 5.00×10-1 NA NA 
 
 
 
 
 
 
Table S7. Conditional analyses for rs7937331 and rs10838725 in the CELF1 fine-mapping region in the ADGC datasets 
 Separate Analysis Conditioning on rs7937331 Conditioning on rs10838725 
rsid OR P OR P OR P 
rs7937331 0.93 4.14×10-4 NA NA 0.93 3.98×10-3 
rs10838725 0.96 4.63×10-2 0.99 6.61×10-1 NA NA 
Newly imputed ADGC datasets (1,000 Genomes Phase I March 2012 v3) were used for the conditional analyses. Effect sizes and p 
values were reported. 
 
  
84 
 
Table S8. Summary statistics for recently identified candidate variants   
SNP Chr:bp Nearest gene MAF (%) Case-control association& BetaAß (95% CI) PAß BetaPtau (95% CI) PPtau 
rs3764650 19:1046520 ABCA7 10.28 3.22×10-7 -0.024 (-0.041,-0.008) 4.24×10-3 0.006 (-0.014,0.025) 5.71×10-1 
rs6701713 1:207786289 CR1 19.50 3.48×10-14 -0.006 (-0.019,0.007) 3.47×10-1 0.024 (0.009,0.039) 1.88×10-3 
rs9349407 6:47453378 CD2AP 28.31 3.92×10-7 0.007 (-0.005,0.018) 2.66×10-1 0.003 (-0.01,0.017) 6.16×10-1 
rs11136000 8:27464519 CLU 39.57 1.72×10-16 0.01 (0,0.021) 5.75×10-2 -0.008 (-0.02,0.005) 2.21×10-1 
rs2304933 11:60102507 MS4A6A 33.30 5.35×10-5 -0.008 (-0.018,0.003) 1.64×10-1 0.012 (-0.001,0.025) 6.30×10-2 
These candidate variants were recently found in Shulman et al 163 and Lyzel et al 164$VVRFLDWLRQZLWK&6)$ȕ42 and ptau181 levels was analyzed using multivariate linear 
regression adjusting for age, gender, first three principle components, and dummies for sites. Chr, chromosome; MAF, minor allele frequency; CI, confidence interval.*Proxy 
SNPs: rs9296559 for rs9349407 and rs7935829 for rs7232. &These p values were from stage 1 analyses of the recent IGAP study. 
 
 
85 
 
Table S9. Number of proxy SNPs in linkage disequilibrium with significant SNPs 
Top SNP Find-mapping region Number of proxy SNPs (from SNAP) 
Number of proxy SNPs 
(from CSF) 
rs7937331 CELF1 38 29 
rs7802536 EPHA1 0 0 
rs62003531 FERMT2 0 39 
Proxy SNPs were first searched using the SNAP database (https://www.broadinstitute.org/mpg/snap/ldsearch.php) 
or our CSF GWAS dataset based on linkage disequilibrium with significant or suggestive SNPs using the CEU 
populations from the 1000 Genome Pilot 1. Proxy SNPs were defined as SNPs with a R2 greater or equal to 0.8 
relative to  selected SNPs. 
 
 
Table S10. RegulomeDB Score Category 
Score Supporting data 
1a eQTL + TF binding + matched TF motif + matched DNase Footprint + DNase peak 
1b eQTL + TF binding + any motif + DNase Footprint + DNase peak 
1c eQTL + TF binding + matched TF motif + DNase peak 
1d eQTL + TF binding + any motif + DNase peak 
1e eQTL + TF binding + matched TF motif 
1f eQTL + TF binding / DNase peak 
2a TF binding + matched TF motif + matched DNase Footprint + DNase peak 
2b TF binding + any motif + DNase Footprint + DNase peak 
2c TF binding + matched TF motif + DNase peak 
3a TF binding + any motif + DNase peak 
3b TF binding + matched TF motif 
4 TF binding + DNase peak 
5 TF binding or DNase peak 
6 other 
Score categories were obtained from http://regulome.stanford.edu/help. 
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Table S11. 6WUDWLILHGDQDO\VHVIRUVWDWLVWLFDOO\VLJQLILFDQW613VZLWK&6)$ȕ42 levels 
 
ADNI1  
(N=357) 
ADNI2  
(N=349) 
Mayo  
(N=426) 
UW 
(N=290) 
Knight-ADRC  
(N=614) 
Gene: SNP Beta PAß Beta PAß Beta PAß Beta PAß Beta PAß 
CELF1: rs7937331 0.029 6.90×10-3 0.017 1.87×10-1 0.027 3.05×10-2 0.017 1.47×10-1 0.011 3.89×10-1 
EPHA1:rs7802536 -0.028 2.14×10-2 -0.024 1.04×10-1 -0.003 8.46×10-1 -0.008 5.51×10-1 -0.042 8.99×10-4 
FERMT2:rs62003531 -0.041 1.75×10-2 -0.008 6.84×10-1 -0.042 1.17×10-2 -0.007 7.00×10-1 -0.045 2.10×10-2 
$VVRFLDWLRQZLWK&6)$ȕOHYHOVZDVDQDO\]HGXVLQJPXOWLYDULDWHOLQHDUUHJUHVVLRQDGMXVLQJIRUDJHJHQGHUDQGILUVt 3 PCs in each site. The effect size and 
p-values were given in the table. 
 
 
 
 
 
Table S12. Case-only and control-RQO\DQDO\VHVIRUVWDWLVWLFDOO\VLJQLILFDQW613VZLWK&6)$ȕ42 levels 
 Default model Case-only analysis Control-only analysis 
Gene: SNP Beta (95% CI) PAß Beta (95% CI) PAß Beta (95% CI) PAß 
CELF1: rs7937331 0.021 (0.01,0.032) 2.30×10-4 0.019 (0.003,0.034) 1.78×10-2 0.022 (0.008,0.036) 1.77×10-3 
EPHA1: rs7802536 -0.025 (-0.037,-0.013) 6.01×10-5 -0.012 (-0.029,0.005) 1.82×10-1 -0.032 (-0.047,-0.016) 5.30×10-5 
FERMT2: rs62003531 -0.033 (-0.049,-0.016) 8.50×10-5 -0.028 (-0.05,-0.005) 1.57×10-2 -0.028 (-0.049,-0.006) 1.12×10-2 
Cases and controls were classified based on the Clinical Dementia Rating (CDR). Cases were defined as CDR>0 and controls were defined as CDR=0. Association with 
&6)$ȕOHYHOVZDVDQDO\VHGXVLQJPXOWLYDULDWHOLQHDUUHJUHVVLRQDGMXVWLQJIRUDJHJHQGHUDQGILUVW3&V7KHHIIHFWVL]H and p-values were given in the table. 
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SUPPLEMENTAL FIGURES 
Figure S1. 'LVWULEXWLRQVRIWUDQVIRUPHG&6)$ȕ42 and ptau181 measurements. 
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Figure S2. . Principal component analyses of the studied individuals in the CSF biomarker dataset (A-B) and 
ADGC case-control dataset (C-D) 
(A) All individuals 
 
(B) Individuals of European American descent who were finally analyzed (N=2,036) 
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(C) All ADGC individuals 
 
 
(D) ADGC Individuals of European American descent who were finally analyzed (N=19,673) 
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Figure S3. Regional plots for the APOE locus with CSF Aȕ42 and ptau181 levels. (A) and (B) CSF Aȕ42 and 
ptau181 associations for rs769449; (C) and (D) CSF Aȕ42 and ptau181 association after conditioning on APOE- 
İDQGAPOE- İ613V 
(A) 
 
(B) 
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(C) 
 
(D) 
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Figure S4. Regional plots for the CELF1 locus with CSF Aȕ42 levels before (A) and after conditioning on (B) 
rs10838725 and (C) rs7937331. (D) IGAP regional plot for the EPHA1 (rs10838725). 
(A) 
 
(B) 
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(C) 
 
(D) 
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Figure S5. Regional plots for the EPHA1 locus with CSF Aȕ42 levels before (A) and after conditioning on (B) 
rs11771145 and (C) rs7802536. (D) IGAP regional plot for the EPHA1 (rs11771145). 
(A) 
 
(B) 
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(C) 
 
(D) 
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Figure S6. Regional plots for the FERMT2 locus with CSF Aȕ42 levels before (A) and after conditioning on (B) 
rs17125944 and (C) rs62003531. (D) IGAP regional plot for the FERMT2 (rs17125944). 
(A) 
 
(B) 
 
 
(C) 
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(D) 
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Figure S7. Regional plots for the ABCA7 locus with CSF Aȕ42 levels before (A) and after conditioning on (B) 
rs4147929 and (C) rs76348507. (D) IGAP regional plot for the ABCA7 (rs4147929). 
(A) 
 
(B) 
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Figure S8. Regional plots for the CD2AP locus with CSF Aȕ42 levels before (A) and after conditioning on (B) 
rs10948363 and (C) rs13190867. (D) IGAP regional plot for the CD2AP (rs10948363). 
(A) 
 
(B) 
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Figure S9. Regional plot for the BIN1 locus with CSF Aȕ42 levels. 
 
 
Figure S10. Regional plot for the CASS4 locus with CSF Aȕ42 levels. 
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Figure S11. Regional plot for the CD33 locus with CSF Aȕ42 levels. 
 
Figure S12. Regional plot for the CLU locus with CSF Aȕ42 levels. 
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Figure S13. Regional plot for the CR1 locus with CSF Aȕ42 levels. 
 
Figure S14. Regional plot for the INPP5D locus with CSF Aȕ42 levels. 
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Figure S15. Regional plot for the HLA-DRB5/DRB1 locus with CSF Aȕ42 levels. 
 
Figure S16. Regional plot for the INPP5D locus with CSF Aȕ42 levels. 
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Figure S17. Regional plot for the MEF2C locus with CSF Aȕ42 levels. 
 
Figure S18. Regional plot for the MS4A6A locus with CSF Aȕ42 levels. 
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Figure S19. Regional plot for the NME8 locus with CSF Aȕ42 levels. 
 
Figure S20. Regional plot for the PICALM locus with CSF Aȕ42 levels. 
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Figure S21. Regional plot for the PTK2B locus with CSF Aȕ42 levels. 
 
Figure S22. Regional plot for the SLC24A4 locus with CSF Aȕ42 levels. 
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Figure S23. Regional plot for the SORL1 locus with CSF Aȕ42 levels. 
 
Figure S24. Regional plot for the TP53INP1locus with CSF Aȕ42 levels. 
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Figure S25. Regional plot for the ZCWPW1 locus with CSF Aȕ42 levels. 
 
Figure S26. Regional plots for the HLA-DRB5/DRB1 locus with CSF ptau181 levels before (A) and after 
conditioning on (B) rs9271192 and (C) rs114975350. (D) IGAP regional plot for the HLA-DRB5/DRB1 
(rs9271192). 
(A) 
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(B) 
 
(C) 
 
 
 
112 
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Figure S27. Regional plots for the MS4A6A locus with CSF ptau181 levels before (A) and after conditioning on 
(B) rs983392 and (C) rs663925. (D) IGAP regional plot for the MS4A6A (rs983392). 
(A) 
 
(B) 
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Figure S28. Regional plot for the ABCA7 locus with CSF ptau181 levels  
 
Figure S29. Regional plot for the BIN1 locus with CSF ptau181 levels  
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Figure S30. Regional plot for the CASS4 locus with CSF ptau181 levels  
 
Figure S31. Regional plot for the CD2AP locus with CSF ptau181 levels  
  
117 
 
Figure S32. Regional plot for the CD33 locus with CSF ptau181 levels  
 
Figure S33. Regional plot for the CELF1 locus with CSF ptau181 levels  
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Figure S34. Regional plot for the CLU locus with CSF ptau181 levels  
 
Figure S35. Regional plot for the CR1 locus with CSF ptau181 levels  
 
 
  
119 
 
Figure S36. Regional plot for the EPHA1 locus with CSF ptau181 levels  
 
Figure S37. Regional plot for the FERMT2 locus with CSF ptau181 levels  
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Figure S38. Regional plot for the INPP5D locus with CSF ptau181 levels  
 
Figure S39. Regional plot for the MEF2C locus with CSF ptau181 levels  
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Figure S40. Regional plot for the MS4A6A locus with CSF ptau181 levels  
 
Figure S41. Regional plot for the NME8 locus with CSF ptau181 levels  
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Figure S42. Regional plot for the PICALM locus with CSF ptau181 levels  
 
Figure S43. Regional plot for the PTK2B locus with CSF ptau181 levels  
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Figure S44. Regional plot for the SLC24A4 locus with CSF ptau181 levels  
 
Figure S45. Regional plot for the SORL1 locus with CSF ptau181 levels  
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Figure S46. Regional plot for the ZCWPW1 locus with CSF ptau181 levels  
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Chapter 4 
Functional Studies: 
Cis- acting expression quantitative trait loci analyses 
 TREM2 cell surface expression studies 
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4.1 ABSTRACT 
 While our deep re-sequencing studies have identified numerous variants that can be underlying functional 
variants, the mechanisms by which these associated variants influence AD pathogenesis remain largely unclear. 
Follow-up functional studies are critical to understand the mechanisms behind genetic association and thus link 
disease-associated variants to disease pathogenesis. Our recent work has confirmed that the triggering receptor 
expressed on myeloid 2 (TREM2) is a bona fide AD risk gene. We found that p.R47H and p.R62H are significantly 
associated with AD risk and that several TREM2 variants are only present in AD patients. Bioinformatic and protein 
conservation analyses also predicted that some of these variants are potentially functional. However, the 
mechanisms by which these variants affect molecular pathways involved in AD are unclear. We hypothesized that 
some of these TREM2 variants may affect TREM2 trafficking to the cell surface. To test this hypothesis, we 
introduced TREM2 variants into a TREM2-DAP12 cDNA construct using site-directed mutagenesis, expressed the 
construct in a T cell hybridoma cell line and measured cell surface expression using an antibody against the 
extracellular domain of TREM2. Our flow cytometry analyses suggest that p.T66M and p.R136W variants in 
TREM2 robustly impact cell surface expression of TREM2 but we did not find any differences in cell surface 
expression comparing p.R47H and p.R62H to the wild type (WT), which suggests that p.R47H and p.R62H may 
affect AD through other mechanisms.  
 Although most of the genome-wide associations study (GWAS)-identified variants are located within non-
coding regions, several recent studies have suggested that these non-coding variants may affect disease phenotypes 
by regulating expression levels in cis. Our RegulomeDB analyses have suggested that polymorphisms within the 
CELF1 fine-mapping region may be expression quantitative trait loci (eQTLs) for nearby genes. Therefore, we 
performed cis-eQTL analysis for mRNA expression levels in several brain regions using four publicly available 
datasets to identify genetic determinants of gene expression in human brains. We found that all of the expression-
associated SNPs, including rs7124681, rs10838738, rs2290850, and rs755553, are in tight linkage disequilibrium 
(LD) with rs7937331, the top cerebrospinal fluid (CSF) amyloid-beta 1-42 $ȕ42) SNP in the CEFL1 fine-mapping 
region. Conditional analyses suggested that there is only one independent signal within the CELF fine-mapping 
region. Moreover, the minor allele of the underlying causal variant is associated with reduced C1QTNF4 expression 
levels. Additionally, we found evidence of differential expression in the C1QTNF4 transcript between AD cases and 
controls in human brains. Overall, these results illustrated that the underlying causal variants and genes may not be 
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the gene originally identified in GWAS studies. Our data suggest the causal variants within the CELF1 fine-mapping 
region mediate C1QTNF4 expression levels and may affect AD risk by affecting beta amyloid (AȕELRORJ\7KHVH
findings support the hypothesis that genes involved in the inflammatory response play an important role in AD 
pathogenesis. 
4.2 INTRODUCTION 
 Recent GWAS have uncovered several novel loci significantly associated with AD risk8-11. However, most 
of these loci are located in non-coding or gene-dense regions, making it difficult to identify causal genes responsible 
for the association. LD between the GWAS top SNPs with other SNPs also prevents the identification of casual risk 
variants for AD. Recent studies have suggested that eQTL-based analyses can relate the GWAS-identified risk 
variants to gene expression from a tissue or cell line, generating hypothesis regarding the putative mechanism 
associated with risk variants and genes106-108,167,168. Additionally, even though recent sequencing studies have shown 
that TREM2 is a bona fide AD risk gene12,13 and identified several potential functional variants12,96,97, functional 
characterization of these novel and potentially functional TREM2 variants in cell systems is essential to the 
understanding of disease mechanisms, which can eventually provide effective targets for therapeutics. 
TREM2 is a type one transmembrane receptor protein expressed on myeloid cells including microglia, 
monocyte-derived dendritic cells, osteoclasts and bone-marrow derived macrophages 85,86. Additionally, protein 
expression of TREM2 in neurons has been reported 87. TREM2 transduces its intracellular signaling through DAP12 
(TYROBP)85,86. Although the natural ligands of TREM2 remain unknown, upon ligand binding, TREM2 associates 
with DAP12 to mediate downstream signaling. In the brain, TREM2 is primarily expressed on microglia and has 
been shown to control two signaling pathways: regulation of phagocytosis and suppression of inflammatory 
reactivity88-90$SUHYLRXVVWXG\XVHGPLFURDUUD\DQGODVHUPLFURGLVVHFWLRQRI$ȕSODTXH-associated areas in an 
animal model of AD and found that TREM2 LVGLIIHUHQWLDOO\H[SUHVVHGLQ$ȕSODTXH-DVVRFLDWHGYHUVXV$ȕSODTXH-
free tissue 91. Several studies have shown that homozygous loss-of-function mutations in TREM2 or DAP12 are 
associated with Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL)92-95. 
Recent studies identified a TREM2 variant p.R47H as a risk factor for LOAD with an OR around 3 12,13, which is a 
similar effect size to the increased AD risk associated with carrying one APOE İDOOHOH67. Several additional rare 
variants were enriched in AD cases; however, these variants failed to reach statistical significance12,13,96.  
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In Chapter 2, we have confirmed that TREM2 is a bona fide AD risk gene and identified two significant 
rare variants (p.R47H and p.R62H) for AD risk. Additionally, several TREM2 variants were enriched or only 
identified in AD cases. However, it remains unclear how these risk variants are involved in AD pathogenesis. Since 
most of the identified variants are located in the TREM2 ectodomain, which is presumed to be involved in ligand 
binding, we hypothesized that these variants affect TREM2 signaling by reducing ligand binding or by reducing cell 
surface expression. Here, we expressed potential functional variants in a T cell hybridoma cell line and performed 
flow cytometry analysis to investigate the effects of TREM2 variants on cell surface expression.  
 In Chapter 3, we observed that rs7937331, an intronic SNP in SLC39A13, was significantly associated with 
&6)$ȕ42 levels. RegulomeDB predicts that several proxies in LD with rs7937331 may be cis-acting eQTLs for 
nearby genes. However, these regulatory function predictions are primarily based on data in blood and cancer cells. 
In this chapter, we performed cis-eQTL analyses for all genes in the LD region surrounding SLC39A13, to identify 
potential eQTL target-gene associations in several brain regions using four large-scale datasets. This information can 
help to identify underlying causal variants of disease-associated loci and to understand the underlying mechanism 
associated with GWAS-identified risk loci. 
4.3 MATERIALS AND METHODS 
4.3.1 Generation of wild-type and mutant constructs and cell-surface experiments 
 Based on our findings in the TREM2 sequencing project, we selected seven missense variants for follow-up 
functional studies. TREM2 p.T66M, a variant shown to cause Nasu-Hakola disease, was included as a positive 
control124. p.R47H was chosen because the association with AD has been replicated across several 
studies12,13,97,125,136. TREM2 P.R52H, p.R62H, p.R136W, p.E151K, p.H157Y were selected because they are only 
present in AD cases in our study or likely to affect protein structure based on SIFT/PolyPhen predictions. Each 
mutation was introduced into the cDNA construct pIRES-hDAP12 full length human TREM2 (hTREM2) WT 
(provided by Dr. Marco Colonna; Figure 1) using site-directed mutagenesis, per the manufacturer’s protocol85. 
These retroviral vectors were transfected into plat-E cells, an efficient and stable cell line for transient packaging of 
retroviruses, using Lipofectamine 2000. Viral supernatants were collected after 48 hours of incubation. Nuclear 
Factor of Activated T-cells (NFAT) 43.1 reporter cells, which express GFP under the control of the NFAT promoter, 
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were transduced with virus containing TREM2 variants. The resulting cells were analyzed for cell surface expression 
of TREM2 by flow cytometry using a TREM2-specific monoclonal antibody developed by Dr. Colonna86. 
4.3.2 Selection of genes and variants 
 In Chapter 3, several proxy SNPs in LD (R20.8) with rs7937331 in SLC39A13 were predicted to have 
regulatory functions based on RegulomeDB database and may be the underlying causal variants. Examination of  
eQTL-gene associations provides an extra layer of information to aid in the identification of functional regulatory 
variants for disease-associated loci. To investigate the cis-eQTL effects on nearby genes, we examined the regional 
plot for CSF Aȕ42  association within the SLC39A13 region (see Figure S4 of Chapter 3) and decided to evaluate 
the association with probes tagging 19 genes: DDB2, ACP2, NR1H3, MADD, MYBPC3, SPI1, SLC39A13, PSMC3, 
RAPSN, CELF1, PTPMT1, KBTBD4, NDUFS3, FAM180B, C1QTNF4, MTCH2, AGBL2, FNBP4, and NUP160. We 
retrieved all genotyped SNPs which were located between chr11:47226493 (10 kb upstream of the 5’ end of DDB2) 
and chr11: 47880057(10 kb downstream of the 3’ end of NUP160). Variants within this region were tested for 
association with mRNA expression levels of aforementioned genes. 
4.3.3 Datasets 
 We downloaded four publicly available expression datasets including GSE15745108, GSE36192106, 
GSE15222107 and GSE5281169 from the NCBI’s Gene Expression Omnibus. We obtained the genotype data via the 
NCBI dbGaP authorized access portal (http://www.ncbi.nlm.nih.gov/gap). 
4.3.3.1 GSE15745+GSE36192 
 The GSE15745 dataset was originally utilized in a study performed by Gibbs et al. to annotate and 
understand the impact of genetic variation on gene expression in human brains108. The mRNA profiling was 
performed using the Illumina humanRef-8 v2.0 expression beadchip. SNP genotyping was performed using the 
Infinium HumanHap550 beadchip (Illumina). Tissue samples of the cerebellum (CRBLM), frontal cortex (FCTX), 
pons (PONS), and temporal cortex (TCTX) from 150 neurologically normal Caucasian individuals were received 
from the University of Maryland Brain Bank, Baltimore. None of the individuals were of Hispanic descent and none 
were previously-diagnosed with neurological or cerebrovascular disease or cognitive impairment during life. The 
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samples had an average age at time of death of 45.8 yrs (range, 15-101) and 31.3% of them were female. The mean 
post-mortem interval (PMI) equals 14.3 hours (range, 3-28). 
 
 The GSE36192 dataset was an extension of the original study conducted by Gibbs et al108 and included 
additional 712 frontal cortex and cerebellum samples from the InCHIANTI study170. However, genotype data was 
only available for 232 of these individuals. In this new dataset, the same expression assay (Illumina HT-12 
beadchips consisting of 48,000 probes) was used for all individuals. The 232 new samples had an average age at 
time of death of 49.5 yrs (range, 0.42-102) and an average PMI of 12.7 hours (range, 1-96). 147 brains (64.5%) were 
from male donors. We combined genotype data for 150 samples from GSE15745 and 232 from GSE36192, which 
consists of data from the Illumina HumanHap550 v3, Human610-Quad v1 or Human660W-Quad v1 Infinium 
BeadChip. After quality control filtering (see Data cleaning), 330 FCTX and 330 CRBLM were used for eQTL 
analyses to investigate the association between 19 mRNA transcripts and 48 single nucleotide polymorphisms 
(SNPs). Since there was no new pons and temporal cortex data from GSE36192, we performed eQTL analyses for 
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the same samples (142 PONS and 144 TCTX) as those used in Gibbs et al108. The numbers of brain samples and 
numbers of SNPs used for analyses in each brain region were summarized in Table 1. 
4.3.3.2 GSE15222 
 We obtained the GSE15222 dataset from a previous study investigating the association between human 
brain transcriptome and genetic variants107. Brains from neuropathologically normal postmortem controls (N = 188) 
and pathologically-confirmed AD cases (N=176) were received from 20 National Alzheimer’s Coordinating Center 
(NACC) brain banks and from the Miami Brain Bank. The 188 control brains consisted of 21% frontal cortex, 73% 
temporal cortex, and 2% parietal cortex. 45% of the control samples were female with an average age of 82.3 yrs 
(range, 65-102) and an average PMI of 9.3 hours (range, 1.17-54). The 176 AD brains contained 19.5% frontal 
cortex, 66.5% temporal cortex, and 5.5% parietal cortex and 8.5% cerebellum. The Affymetrix GeneChip Human 
Mapping 500K Array Set was performed to generate genotype data and the Illumina Human RefSeq-8 Expression 
BeadChip was used to generate the RNA expression data. After quality control (QC), 188 controls and 176 cases 
were used for eQTL analysis. The numbers of brain samples and numbers of SNPs used for analyses in each brain 
region are summarized in Table 1. For detailed descriptions about sample preparation and study design, please 
check Webster et al107. 
4.3.3.3 GSE5281 
 The original study using the GSE5281 dataset investigated the association between RNA expression in 
neuronal nuclear genes and mitochondrial energy metabolism169. The GSE5281 dataset included laser-capture 
microdissected non-tangle bearing neuronal cells from 47 human brains of Caucasian origin that were collected at 
three Alzheimer’s Disease Centers (Washington University, Duke University, and Sun Health Research Institute). 
Samples are composed of clinical and neuropathologically-confirmed AD cases or neurologically confirmed non-
demented controls. Thirty-three samples were AD cases and 54.5% of them were female with an average age 79.9 ± 
6.9 years. Fourteen samples were controls and 28.6% of them were female. The mean age was 79.8 ± 9.1 years. 
Samples from six brain regions were collected (mean PMI = 2.5): the entohinal cortex (EC; Broca’s area [BA] 28 
and 34), superior frontal gyrus (SFG; BA 10 and 11), hippocampus (HIP), primary visual cortex (VC; BA 17), 
middle temporal cingulate cortex (MTG; BA 21 and 37), and posterior cingulate cortex (PCC; BA 23 and 31). RNA  
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Table 1. Summary counts of number of individuals, probes, and SNPs tested per brain region 
  GSE15745+GSE36192 FCTX CRBLM PONS TCTX   
# Samples 330 330 142 144   
# probes tested 22 22 18 18   
# SNPs tested 48 48 52 52   
       
GSE15222 FCTX Parietal TCTX CRBLM   
# Samples 71 20 242 31   
# Probes tested 1 1 1 1   
# SNPs testedd 30 30 30 30   
       
GSE5281 Entorhinal cortex Hippocampus Middle temporal gyrus Posterior cingulate cortex Superior frontal gyrus Visual cortex 
# Samples 23 23 28 22 34 31 
# Probes tested 1 1 1 1 1 1 
FCTX: frontal cortex; CRBLM: cerebellum; PONS: pons; TCTX: temporal cortex. 
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expression profiling was performed using the Affymetrix Human Genome U133 Plus 2.0 Array. The numbers of 
brain samples and numbers of SNPs used for analyses in each brain region were summarized in Table 1. See Liang 
et al. for more details169,171. 
4.3.4 Data cleaning 
 We only performed data cleaning for GSE15745108 and GSE36192106 datasets as QC has been conducted 
for the GSE15222107 and GSE5281169,171 datasets. We identified unanticipated duplicates and cryptic relatedness 
using pair-wise genome-wide estimates of proportion identity by descent (IBD) using the PLINK program122. When 
duplicate samples or a pair of samples with cryptic relatedness was identified, priority was given to samples with 
higher SNP call rates. In order to control for population substructure, a principal component analysis (PCA) was 
conducted using the EIGENSTRAT software121. HapMap samples (CEU: CEPH Europeans from Utah; JPT: 
Japanese in Tokyo; YRI: Yoruba in Ibadan, Nigeria) were included in the analyses in order to remove outliers and 
confirm self-reported ethnicity. Individuals were excluded if they were not located within the CEU cluster (see 
Figure S1). We also checked whether the gender was discordant by analyzing the X-chromosome SNPs using 
PLINK. Individuals were removed if the recorded gender did not match the gender reported by our analyses. As 
previous studies have shown that younger brains may present abnormal RNA expression in genes related to cell 
cycle, DNA damage repair, and cell differentiation172, in the analyses, samples were excluded if the age was under 
15 years. Samples were excluded if they were outliers based on mean expression levels. For GSE15745 and 
GSE36192 datasets, final analyses included 330 FCTX, 330 CRBLM, 142 PONS, and 144 TCTX. Stringent quality 
thresholds were applied to the genotype data. SNPs were dropped if they fulfilled any one of the following criteria: 
i) genotyping success rate<98% per SNP or per individual; ii) HWE (p<1×10í3); iii) MAF<0.02. QCs were carried 
out jointly after combining SNPs common in both datasets (GSE15745 and GSE36192). A total of 52 SNPs were 
analyzed for PONS and TCTX and 48 SNPs were used for FCTX and CRBLM. 
4.3.5 Statistical analysis 
 For the analysis of GSE15745 and GSE36192, a log 10 transformation of the mRNA expression 
measurements was applied in order to normalize the distribution. We then performed a two-step analysis for each of 
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the four brain regions. The first step involves correction for known biological and methodological covariates by 
performing the following multivariate regression model: 
ܻ =  Ⱦ଴ + ȾଵXଵ +  … + Ⱦ୬X୬ + ߝ 
Where Y is the log10 transformed expression value and X1   …… Xn indicate the biological covariates, which 
include age and gender, and methodological covariates, which include PMI, which Brain Bank these samples was 
from and which preparation/hybridization batch the sample was processed in. Within this model, gender, tissue 
bank, and batch were coded as dummy variables. After fitting each trait to the model, the residuals from the model 
were kept and represent the dependent variable in the second regression. This step is essential as variance 
attributable to gender, age, PMI, tissue source and hybridization batch were removed prior to eQTL analyses. Next, 
the second-step analysis was performed by regressing the residuals against allele dosages for each SNP as follows. 
ܻ =  Ⱦ଴ +  ȾଵADD +  ߝ 
Where Y represents the residuals and ADD represents the genotype encoded as allele dosage. The R software 
(version 3.0.2) was used to perform all of the analyses. 
 We then analyzed the GSE5281 dataset for association between mRNA expression levels and AD disease 
status for specific genes of interest. We performed joint analysis for log10 transformed mRNA expression values 
adjusting for age, gender, AD disease status, and which brain region the sample was from. Within the model, 
gender, AD disease status and brain region were treated as dummy variables. We also performed separate analyses 
for each brain region by conducting a two-tailed unpaired t-test.  
 In order to replicate the suggestive SNP-transcript pair association found in GSE15745 and GSE36192 
datasets, we analyzed the GSE15222 dataset using 188 neuropathologically normal postmortem controls in order to 
prevent the confounding effects due to AD disease status. For consistency, we first regressed out the effects due to 
known biological and methodological covariates and then fitted the residuals against allele dosage for each SNP. We 
also compared the expression level between 176 AD cases and 188 controls for the probes of interest. 
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 For GSE15745 and GSE36192, the Bonferroni correction was used to control for type-1 error rate (0.05). 
Since 52 SNPs were tested for association with 18 transcripts within 4 brain regions, the multiple-testing correction 
threshold is approximately equal to 0.05/(52×4×18) = 1.33×10-5. 
4.3.6 Bioinformatic and linkage disequilibrium analyses 
 We used the SeattleSeq Annotation server (http://snp.gs.washington.edu/SeattleSeqAnnotation138/) and the 
SNP and CNV Annotation Database (http://www.scandb.org) to annotate the variants. The LocusZoom tool was 
used to create the regional plots173. The Haploview software174 was used to estimate the LD structure and to generate 
the LD plots for suggestive and significant eQTLs. 
4.4. RESULTS 
4.4.1 TREM2 cell surface expression 
 TREM2 is a cell surface receptor protein expressed on myeloid cells and upon ligand binding, TREM2 
transduces its intracellular signaling through association with DAP1285,86. In this study, we tested the effects of rare 
variants in TREM2 on TREM2 cell surface expression. NFAT 43.1 reporter cells, a cell line expressing GFP under 
the control of the NFAT promoter, were transduced with viral particles containing hDAP12 and either hTREM2 
WT, p.T66M (a known Nasu-Hakola causal mutation served as the positive control), p.R47H, P.R52H, p.R62H, 
p.R136W, p.E151K, or p.R157Y. In hTREM2-WT expressing cells, 74.8 % of TREM2 is detected at the cell surface 
(see Figure 2A). In contrast, the positive control cells expressing a Nasu-Hakola mutation, hTREM2-p.T66M, have 
only 16.8% of expressed TREM2 at the cell surface (see Figure 2H). Cells expressing p.R47H (60.8%, Figure 2B), 
p.R52H (67.5%, Figure 2D), p.R62H (67.9%, Figure 2F), p.E151K (72.3%, Figure 2C), and p.H157Y (52.2%, 
Figure 2E) exhibited slightly lower levels of cell surface TREM2 expression but they were not significantly 
different from hTREM2 WT. Interestingly, we observed a robust effect on TREM2 cell surface expression in cells 
expressing p.R136W (28.8%, Figure 2G), comparable to cells expressing p.T66M. Our data suggest that TREM2 
p.T66M and p.R136W variants have a robust effect on cell surface expression of TREM2. Replication studies have 
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been performed and the results were similar to those in the first run. 
 
4.4.2 Cis-actings eQTLs of C1QTNF4 expression levels 
 To identify genetic variants within the CELF1 fine-mapping region that regulate gene expression in normal 
human brains, we conducted cis-eQTL analysis for four brain regions (FCTX, CRBLM, PONS, and TCTX) using 
two large microarray datasets (GSE15745 and GSE36192)106,108. For PONS and TCTX, we analyzed the GSE15745 
dataset with 150 neurologically normal Caucasian individuals obtained from the University of Maryland Brain 
Bank, Baltimore. For FCTX and CRBLM, we combined the GSE15745 dataset with the GSE36192 dataset, which 
consists of FCTX and CRBLM genotype and phenotype data from 232 neurologically normal Caucasian individuals 
in the InCHIANTI study170 to maximize the power of detecting cis-eQTLs. We extracted genotype data between 
chr11:47226493 (10 kb upstream of the 5’ end of DDB2) and chr11: 47880057(10 kb downstream of the 3’ end of 
NUP160). After QC (see MATERIALS AND METHODS), 52 variants were analyzed in 142 samples and 144 
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samples for association with 18 transcripts in PONS and TCTX respectively while 48 variants were analyzed in 330 
samples for 22 transcripts in FCTX and CRBLM (see Table 1). 
 To minimize brain region specific effects on expression levels, we performed analyses separately for each 
brain region and applied a two-step regression approach to cis-eQTLs. We also checked whether the identified 
variants were located within the probe sequences, which could result in inaccurate mRNA expression due to 
differential hybridization (see Table S1 for C1QTNF4 probe sequences). After multiple test correction (Bonferroni 
correction cutoff=1.33×10-5), C1QTNF4 (C1q and tumor necrosis factor related protein 4), expression levels were 
significantly associated with rs7124681 (located in the intronic region of CELF1; minor allele frequency 
[MAF]=40.46%, p = 8.63×10-8; Table 2 and Figure 3B), rs10838738 (located in the intronic region of MTCH2, 
MAF=35.35%, p=1.67×10-7; Table 2 and Figure 3B), and rs2290850 (located in the intronic region of NUP160, 
MAF=35.89%, p=2.65×10-6; Table 2 and Figure 3B) in cerebellum. After adjusting for the most-significant SNP 
rs7124681, no SNPs within the region remained significant. In order to determine whether these eQTL signals are 
LQGHSHQGHQWRIUVWKHVWURQJHVW613ZLWKLQWKHUHJLRQDVVRFLDWHGZLWK&6)$ȕ42 levels, we performed 
conditional analysis adjusted for rs755553, a proxy for rs7937331 (D’=1, R2=0.99). When conditioning on 
rs755553, no SNPs in the region remained significant (see Figure 3D). Linkage disequilibrium analyses suggest that 
rs7124681, rs10838738, rs2290850, and rs755553 are in tight LD (see Figure 4). Together, these results suggest that 
there is only one independent driver within this region and that the minor allele of the causal variant is associated 
with reduced C1QTNF4 expression levels. Additionally, RegulomeDB predicts that rs10769258, rs4752993, and 
rs755553 are eQTLs for C1QTNF4 in blood and cancer cells (see Table 7 in Chapter 3), which is in line with our 
cis-eQTL analyses for several brain regions. Regional plots for the cis-association with mRNA expression of other 
genes can be found in Figures S2-S22. 
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Table 2. SNP-Transcript pairs with a suggestive or significant association in GSE15745 and GSE36192 
Gene Probe ID SNP Chr:BP MAF (%) ȕFCTX PFCTX ȕCRBLM PCRBLM ȕTCTX PTCTX ȕPONS PPONS 
C1QTNF4 ILMN_2195462 rs7124681 11:47529947 40.5 -0.028 2.26×10-2 -0.047 8.63×10-8 NA NA NA NA 
C1QTNF4 ILMN_2195462 rs10838738 11:47663049 35.4 -0.029 1.98×10-2 -0.047 1.67×10-7 NA NA NA NA 
C1QTNF4 ILMN_2195462 rs2290850 11:47807774 35.9 -0.022 7.43×10-2 -0.042 2.65×10-6 NA NA NA NA 
C1QTNF4 ILMN_2195462 rs755553 11:47432303 32.5 -0.029 2.89×10-2 -0.040 2.24×10-5 NA NA NA NA 
C1QTNF4 ILMN_2195462 rs4752993 11:47410951 32.8 -0.029 2.95×10-2 -0.040 2.80×10-5 NA NA NA NA 
C1QTNF4 ILMN_2195462 rs10769258 11:47391039 32.9 -0.028 3.36×10-2 -0.038 5.42×10-5 NA NA NA NA 
Association between mRNA transcript and SNP pair with significant evidence within at least one brain region using the GSE15745 and GSE36192 datasets. The 
multiple-testing significant threshold is 1.33×10-5. A total of 330 FCTX, 330 CRBLM, 142 PONS and 144 TCTX were used for analyses. 
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4.4.3 Alzheimer’s disease status is significantly associated with C1QTNF4 expression level 
 To determine whether Alzheimer’s disease status affects C1QTNF4 expression levels, we used the 
GSE5281 dataset to compare C1QTNF4 expression levels between 47 AD brains and 14 normal brains in 6 brain 
regions. In the joint analysis, we conducted multivariate linear regression adjusted for disease status, brain region, 
age, and gender. Our results showed that disease status was significantly associated with reduced C1QTNF4 
expression levels (ȕ=-0.73, p=1.76×10-13, adjusted R2=28.91%; Table 3). When we analyzed each brain region 
separately using a two-tailed unpaired t-test, we found that the C1QTNF4 expression levels were significantly lower 
in AD cases compared to controls in all tested brain regions (p=8.82×10-4 in entorhinal cortex, p=6.73×10-2 in 
hippocampus, p=1.08×10-2 in middle temporal gyrus, p=1.17×10-2 in posterior cingulate cortex, p=3.03×10-2 in 
superior frontal gyrus; p=1.15×10-2 in visual cortex; Table 4). Together, these results suggest that reduced 
C1QTNF4 mRNA expression levels are associated with AD disease status. 
Table 3. Association between AD disease status and C1QTNF4 transcripts in the joint analysis in GSE5281 
Probe-Symbol Probe-ID ȕ6( P Adjusted R2 (%) 
C1QTNF4 223708_at -0.73 (0.09) 1.76×10-13 28.91 
Multivariate linear regression was performed to estimate the association with C1QTNF4 mRNA expression levels adjusting 
for brain region, age and gender. Brian region, age, and gender covariates were coded as categorical variables. The effect size, 
standard error, p values, and adjusted R-squared values were reported. SE: Standard error. 
 
 
Table 4. Association between AD disease status and C1QTNF4 expression levels in six brain regions in GSE5281 
 
C1QTNF4_223708_at 
 
AD cases Controls P 
Entorhinal cortex (EC) 24.34 521.49 8.82×10-4 
Hippocampus (HIP) 62.75 141.84 6.73×10-2 
Middle temporal gyrus (MTG) 56.69 326.36 1.08×10-2 
Posterior cingulate cortex (PCC) 33.07 103.24 1.17×10-2 
Superior frontal gyrus (SFG) 64.85 342.69 3.03×10-2 
Visual cortex (VC) 98.08 191.37 1.15×10-2 
A two-tailed unpaired t test was performed to evaluate mRNA expression levels in AD cases versus controls. Average 
expression levels in AD cases and controls, and p values were reported. 
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4.4.4 Replication using the GSE15222 dataset 
 In order to confirm the observations from the GSE15745 and GSE36192 datasets we analyzed C1QTNF4 
expression in the GSE15222 dataset for replication. The GSE15222 dataset contains genotype and expression data 
from both AD cases (N=176) and controls (N=188) and we found 36 SNPs within the defined genomic region. The 
control samples were composed of 40 (21.3%) frontal cortex, 3 (1.6%) parietal cortex, 136 (72.3%) temporal cortex, 
and 9 (4.8%) cerebellar tissues. In the control-only analyses, a similar two-step regression approach was used to 
examine the cis-eQTL effects on C1QTNF4 expression levels for each brain region. In the GSE15222 dataset, we 
did not find the top six SNPs which were associated with C1QTNF4 expression levels in the GSE15745 and 
GSE36192 datasets. The most significant SNP, rs7102372, located in an intronic region of CELF1, showed evidence 
of association with C1QTNF4 expression levels in the TCTX (MAF=15.73%, p=6.44×10-4; Table 5 and Figure 
5A). However, we did not find any significant association of rs7102372 with C1QTNF4 expression levels in FCTX, 
CRBLM, and parietal cortex which may due to the small sample sizes (N=40, 9, and 3 for FCTX, CRBLM, and 
parietal cortex respectively; Figure 5B-5D). Moreover, rs7102372 was not associated with CSF Aȕ42 levels 
(p=0.62) and AD risk (IGAP p=0.83). Overall, these results suggest that rs7102372 may be a false positive 
signal. We next investigated whether there are significant differences in the C1QTNF4 expression levels between 
AD cases and controls for each brain region (71 frontal cortex, 20 parietal cortex, 242 temporal cortex, and 31 
cerebellar tissues). We found that C1QTNF4 expression levels were significantly higher in controls compared to AD 
cases (p=8.82×10-16 in frontal cortex, p=6.07×10-8 in parietal cortex, p=1.67×10-36 in temporal cortex, p=9.69×10-14 
in cerebellar tissues; Table 5), consistent with our findings in the GSE15745+GSE36192 datasets (see Table 4).  
4.5 DISCUSSION 
 TREM2 is an immune phagocytic receptor expressed on brain microglia and is known to trigger 
phagocytosis and regulate the inflammatory response. AD cases that carry TREM2 risk variants have a significantly 
higher rate of brain atrophy than those who do not carry TREM2 risk variants132. A recent study showed that TREM2 
is DVXEVWUDWHRIȖ-secretase upon removal of ectodomain175. These studies suggest that TREM2 may play a role in 
AD. Taken together with our genetic findings that some rare coding variants are more frequently identified in AD 
cases than in controls, these findings suggest some of these rare coding variants may alter TREM2 function. 
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Table 5. Transcript- SNP Pairs with a suggestive or significant association based on the GSE15222 dataset 
  Probe-
Symbol Probe-ID SNP Chr:BP 
MAF 
(%) Function Gene ȕFCTX PFCTX ȕCRBLM PCRBLM ȕTCTX PTCTX ȕParietal PParietal 
C1QTNF4 GI_13994272-S rs7102372 11:47496827 15.73 Intron CELF1 0.16 2.05×10-1 -0.38 2.84×10-2 0.36 6.44×10-4 0.01 9.76×10-1 
Most significant SNP associated with a probe tagging C1QTNF4 transcript in the GSE15222 dataset. A total of 40 FCTX, 9 CRBLM, 3 parietal cortex and 135 TCTX from 
control samples were used for analysis. The six top SNPs identified in GSE15745 and GSE36192 datasets were not found in the GSE15222 dataset and thus were not included in 
the table. 
 
 
Table 6. Association between AD disease status and C1QTNF4 expression levels in four brain regions in GSE15222 
 
C1QTNF4_GI_13994272-S 
 
AD cases Controls P 
Frontal cortex (N = 71) 473.56 535.96 8.82×10-16 
Parietal cortex (N = 20) 472.86 641.83 6.07×10-8 
Temporal cortex (N = 242) 437.52 615.72 1.67×10-36 
Cerebellar tissues (N = 31) 485.4 491.94 9.69×10-14 
A two-tailed unpaired t-test was performed to evaluate mRNA expression levels in AD cases versus controls. Average expression 
levels in AD cases and controls, and p-values were reported.  
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In this chapter, we sought to assess the effects of novel TREM2 risk variants on TREM2 function by 
transducing cells with TREM2 risk variants and measuring cell surface expression of TREM2. Our preliminary data 
demonstrate that the novel risk variant p.R136W results in reduced detection of TREM2 at the cell surface, similar 
to the causative Nasu-Hakola mutation p.T66M. We hypothesize that both the risk variant and the causative 
mutation could impair TREM2 function by preventing its transport to the cell surface. TREM2 trafficking to the cell 
surface is important since if TREM2 does not get to the cell surface, TREM2 cannot bind to its endogenous ligand 
and thus cannot transduce its intracellular signal through DAP12 properly. We cannot yet rule out the possibility that 
p.R136W and p.T66M disrupt transcription or translation of TREM2. Since p.R136W is very close to the 
transmembrane domain of TREM2, it is likely that p.R136W affects folding of TREM2. Follow-up studies are on-
going to distinguish between expression and trafficking defects by measuring TREM2 and DAP12 RNA and protein 
levels inside the cell. Surprisingly, there are no obvious differences in TREM2 cell surface expression for previously 
reported AD risk factors TREM2 p.R47H and p.R62H compared to WT in our first run and following replication 
studies. We hypothesize that p.R47H and p.R62H may affect other mechanisms of TREM2 function such as ligand 
binding. One caveat to the current study is that TREM2 variants may occur in regions of the TREM2 protein that 
would affect the binding affinity of anti-TREM2 antibody used to measure cell surface TREM2. 
Another important goal of this chapter is to identify causal variants and to generate testable hypotheses 
associated with GWAS-identified variants and genes. To date, the majority of these GWAS-identified AD risk 
variants are non-coding variants with very small effect size8,10,11,78; therefore, the functional impact and mechanism 
associated with these variants and genes remained largely unclear. In chapter 3, we analyzed our CSF datasets and 
found that most of these disease-associated variants were not necessarily associated with CSF biomarker levels. 
Several recent studies have suggested that GWAS-identified disease-associated variants may perturb mRNA 
expression levels of neighboring genes as eQTLs160,167. In chapter 3, several SNPs within the CELF1 fine-mapping 
region were predicted to regulate expression levels of neighboring genes based on RegulomeDB database. To 
identify genetic determinants of gene expression within the CELF1 fine-mapping region in human brains, we 
performed comprehensive cis-eQTL analyses using four publicly available microarray datasets with gene expression 
in human brain tissues. After analyzing GSE15745 and GSE36192 datasets, we found that all of the expression-
associated SNPs, including rs7124681, rs10838738, rs2290850, and rs755553, are in tight LD with rs7937331, the 
top SNP in the CELF1 fine-PDSSLQJUHJLRQDVVRFLDWHGZLWK&6)$ȕ42 levels. Conditional analyses suggested that 
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there is only one independent driver within this region and that the minor allele of the underlying causal variant 
mediates both C1QTNF4 expression levels. Moreover, RegulomeDB predictions for these expression-associated 
SNPs, which are based on expression data in blood and cancer tissues, are consistent with our cis-eQTL analyses, 
demonstrating that coincident eQTLs are present between several human tissues.  
Next, we analyzed the GSE5281 dataset and found that AD disease status was significantly associated with 
reduced C1QTNF4 mRNA expression levels (p=1.76×10-13), which indicates that C1QTNF4 is differentially 
expressed between AD brains and control brains. Finally, we analyzed the GSE15222 dataset in order to replicate 
our findings for the C1QTNF4 transcript. We did not identify significant association for any SNP-C1QTNF4 
transcript pair in the control-only analysis; however, C1QTNF4 expression levels were significantly higher in 
controls than in AD cases, which is in line with the results in the GSE5281 dataset. The possible explanation for the 
lack of association in the control-only analysis is the small sample size in each brain region except TCTX in the 
GSE5281 dataset. Additionally, the differences may result from differences in the datasets (laser-capture neurons 
[GSE 5281] versus brain homogenates which contain many cell types that do not control for the heterogeneity in cell 
composition between AD cases and controls [GSE15745, GSE36192 and GSE15222]). In a previous eQTL-analysis 
which consisted of 733 brain samples from the cerebellum and temporal cortex of about 200 AD cases and about 
200 non-AD individuals, a genome-wide significant association of rs10838738 with expression of C1QTNF4 (ȕ=-
0.18, p=1.48×10-9) was reported in cerebellum even though the association was not significant in temporal cortex 
(ȕ=-0.02, p=0.66)176. The direction of effects in the cerebellum is the same as that in GSE15745 and GSE36192 
datasets. When we combined the p value176 for the rs1083878/C1QTNF4 association with that estimated in 
GSE15745 and GSE36192 datasets using the Fisher’s method177, the meta-analysis p-value was 9.1×10-15 in 
cerebellum, which strongly indicates that the observed association is authentic. Although the cerebellum is rarely 
affected in AD brains178, recent studies have indicated a significant overlap in cis-eQTL association between 
different brain regions and different tissue types176,179. These studies also showed that expression patterns are more 
likely to be similar between two brain regions than two different tissue types176,179. Additionally, pathological 
changes have been detected in the AD cerebellum180. However, we cannot rule out the possibilities that eQTLs are 
only specific to certain brain regions and that eQTLs that display similar effects in different brain regions are not 
associated with human diseases. Additional studies need to determine whether disease-associated eQTLs regulate 
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gene expression regardless of brain regions or tissue types. Overall, these findings suggest that eQTL-based analyses 
can reveal potential functional genes and variants and provide a hypothesis as to their functions. 
 The C1QTNF4 gene encodes a protein which triggers NF-kappa-B activity181. A previous study has shown 
that over-expression of C1QTNF4 induces the activation of NF-kappa-B, and IL6/STAT3signaling pathways and 
may be a tumor-promoting regulator of inflammation181. TREM2 expression was recently shown to be regulated by 
an NF-kappa-B-sensitive miRNA182, which suggests that C1QTNF4 may be involved in the same pathway as 
TREM2. Our mRNA expression analyses suggested that C1QTNF4 expression levels are significantly lower in AD 
cases. We also showed that expression-associated SNPs (rs7124681, rs10838738, rs2290850) within this region 
KDYHDFRPSOHWH/'ZLWKWKH&6)$ȕ42 top SNP (rs7937331), which suggests that they tag the same signal. Like 
TREM2, C1QTNF4 PD\EHLQYROYHGLQFOHDUDQFHRI$ȕDJJUHJDWHVRULQQHXURLQIODPPDWLRQ 
 In conclusion, our cell-surface expression experiments found that TREM2 p.T66M and p.R136W reduce 
cell surface expression of TREM2, while p.R47H and p.R62H, two confirmed risk factors for AD, have no robust 
impact on TREM2 cell surface expression. Our cis-eQTL analyses identified significant polymorphisms regulating 
C1QTNF4 expression levels. We also found evidence of differential expression in C1QTNF4 transcript between AD 
cases and controls. These results also illustrated that the underlying causal variants and genes may not be the gene 
originally identified in GWAS studies and that genes involved in the inflammatory response play an important role 
in AD pathogenesis. 
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SUPPLEMENTARY TABLES 
Table S1. Detailed information for probes of interest   
Probe-ID Sequence Start site End site 
C1QTNF4-ILMN_2195462 ACCGAGTTCGTCAACATTGGCGGCGACTTCGACGCGGCGGCCGGCGTGTT 11:47611701 11:47611750 
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Figure S2. Cis association for SPI1-ILMN_1696463 expression levels in (A) FCTX, (B) CRBLM, (C) TCTX, 
and (D) PONS. 
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Figure S3. Cis association for ACP2-ILMN_2104830 expression levels in (A) FCTX, (B) CRBLM, (C) TCTX, 
and (D) PONS. 
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Figure S4. Cis association for AGBL2-ILMN_1688627 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
(A) 
 
(B) 
 
  
154 
 
(C) 
 
(D) 
 
  
155 
 
Figure S5. Cis association for DDB2-ILMN_1660817 expression levels in (A) FCTX, (B) CRBLM, (C) TCTX, 
and (D) PONS. 
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Figure S6. Cis association for FNBP4-ILMN_2108938 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S7. Cis association for KBTBD4-ILMN_1668000 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S8. Cis association for KBTBD4-ILMN_1687092 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S9. Cis association for KBTBD4-ILMN_1687524 expression levels in (A) FCTX and (B) CRBLM. 
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Figure S10. Cis association for MADD-ILMN_1671710 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S11. Cis association for MADD-ILMN_1743583 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S12. Cis association for MADD-ILMN_2328224 expression levels in (A) FCTX and (B) CRBLM. 
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Figure S12. Cis association for MTCH2-ILMN_1785218 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S13. Cis association for MYBPC3-ILMN_1781184 expression levels in (A) FCTX and (B) CRBLM. 
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Figure S14. Cis association for MYBPC3-ILMN_1768761 expression levels in (A) TCTX and (B) PONS. 
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Figure S15. Cis association for NDUFS3-ILMN_1756355 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S16. Cis association for NR1H3-ILMN_1814022 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S17. Cis association for NUP160-ILMN_1652989 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S18. Cis association for PSMC3-ILMN_1809010 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S19. Cis association for RAPSN-ILMN_17024806 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S20. Cis association for RAPSN-ILMN_1803303 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S21. Cis association for RAPSN-ILMN_1803303 expression levels in (A) FCTX, (B) CRBLM, (C) 
TCTX, and (D) PONS. 
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Figure S22. Cis association for SPI1-ILMN_2392043 expression levels in (A) FCTX and (B) CRBLM. 
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Chapter 5 
Conclusion and future directions 
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5.1 State of Alzheimer’s genetics prior to this work 
 Alzheimer’s disease (AD) is a devastating and irreversible brain disease that affects millions of 
Americans25. AD has become a global public health crisis as the estimated worldwide prevalence  is 30 million and 
is predicted to quadruple by 205025. Currently, there is still no effective treatment for AD. Since many studies have 
shown a strong genetic component for AD – an estimated heritability of 80%111, understanding how genetic risk 
factors affect the disease process will help to identify novel targets for therapeutics. 
 In the early 1990s, Alzheimer’s disease genetic research identified dominantly inherited mutations in three 
genes (APP, PSEN1, and PSEN2) causing early onset AD1-4, and one risk gene (APOE)5-7 involved in late-onset AD 
(LOAD) through genetic linkage studies in families. Until about 2005, most studies examined one or more 
polymorphisms in a candidate gene to identify novel risk genes due to technical limitations. Even though over 1,000 
candidate genes were investigated for AD susceptibility, very few reported genetic association could be replicated, 
most likely due to false positive associations resulting from population stratification and small sample size (see 
http://www.alzgene.org). Since 2005, rapid advances in technologies and analytical tools have transformed genetics 
of complex disorders such as AD183. The first advancement was the development of inexpensive and comprehensive 
genotyping platforms a.k.a “genome-wide association study (GWAS) arrays”, which allow simultaneous 
investigation of millions of single-nucleotide polymorphisms (SNPs) in tens of thousands of individuals. To 
facilitate the use of GWAS, the HapMap and 1,000 Genomes Project databases catalogued over 20 million SNPs 
and provided essential resources for SNP queries, genotype phasing, and imputation. Additionally, the use of 
principal component analysis for matching cases and controls has been routinely used in GWAS to control for 
population substructure, reducing false-positive findings. Before 2012, several large-scale GWAS in AD were 
conducted and identified 9 novel loci associated with LOAD: ATP-binding cassette transporter (ABCA7), bridging 
integrator protein 1(BIN1), CD2-associated protein (CD2AP), sialic acid-binding immunoglobulin (Ig) like lectin 
(CD33), clusterin (CLU), complement receptor 1 (CR1), Ephrin receptor A1 (EPHA1), membrane-spanning 4A gene 
cluster (MS4A4A/MS4A4E/MS4A6E), and phosphatidylinositol –binding clathrin assembly protein (PICALM)9-
11,78,184. Remarkably, these GWAS have identified robust and replicable genetic variations across independent 
cohorts ascertained by a variety of methods and individuals diagnosed in innumerable research institutes. However, 
most common variants identified in GWAS are located in non-coding regions and have very small effects on disease 
risk (odds ratio [OR] ~ 0.8-1.2). The known susceptibility loci only explain 50% of the heritability for LOAD, 
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which has an overall heritability of up to 80%111, indicating that additional variants and genes remain unobserved. 
Additionally, most of these GWAS susceptibility loci are located in non-coding or gene-dense regions, making it 
very difficult to identify bona fide genes responsible for the association. Linkage disequilibrium (LD) between the 
GWAS top SNPs with other SNPs also prevents the identification of bona fide risk variants for LOAD. 
 When we started this work, several studies had suggested that low-frequency (minor allele frequency 
[MAF] 1% to 5%) and rare variants (MAF < 1%) could explain part of the missing heritability because GWAS 
genotyping arrays have largely ignored these portions of the allele frequency spectrum185,186. Over the past five 
years, dramatic developments in next-generation sequencing (NGS) have made high-throughput sequencing of 
targeted genomic regions of the human genome in many individuals in a single run both cheap and feasible. 
Moreover, advances in sequencing-based study design and rare-variant association methods enable us to investigate 
the role of low-frequency and rare variants in complex diseases.  
Even though deep-depth whole-genome sequencing (WGS) of a large number of samples remains very 
expensive, several alternatives including targeted re-sequencing, whole-exome sequencing (WES), and low-depth 
WGS have been proposed and widely conducted. Previously, our group performed deep re-sequencing of the 
pathogenic genes (APP, PSEN1, and PSEN2) in LOAD families and uncovered several novel, rare and pathogenic 
variants, demonstrating that the impact of the variants in these AD-causing genes in LOAD families is stronger than 
previously estimated15,16. In 2013, two independent groups utilized low-depth WGS, WES, and targeted Sanger 
sequencing to identify a low-frequency variant p.R47H in triggering receptor expressed on myeloid cells 2 
(TREM2), that increases AD risk by 2 fold12,13. Not long after, our group performed WES in fourteen large LOAD 
families and identified a low-frequency variant p.V232M in phospholipase D3 (PLD3) which segregated with 
disease status in 2 independent families14. The association of p.V232M with AD risk was replicated after performing 
follow-up genotyping in seven case-control studies and demonstrated that the minor allele of p.V232M doubles AD 
risk14. A recent study performed targeted sequencing of CLU, CR1, and PICALM in 96 AD samples, but no 
significant rare variant association was reported187. Another study sequenced TREM2 coding regions in a Belgian 
population and found additional coding variants in TREM296. Although an enrichment of TREM2 variants in both 
AD and FTD patients compared to controls was reported, none of the rare variants were individually significant96. 
To our knowledge, no deep re-sequencing studies in GWAS-identified genes (ABCA7, BIN1, CD2AP, CLU, CD33, 
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CR1, EPHA, MS4A4A/MS4A4E/MS4A6E , and PICALM) and sequencing-identified genes (PLD3 and TREM2) have 
been reported with a larger sample size than this work (N>4,000). 
 Not long after we started this work, the International Genomics of Alzheimer’s Project (IGAP) was 
founded to perform statistically rigorous and comprehensive GWAS meta-analysis in the hope of finding additional 
small effect risk loci for LOAD with participation of the ADGC, CHARGE, and GERAD, and EADI consortia188. 
IGAP conducted meta- and gene-wide analyses of 74,046 individuals and identified 23 loci associated with LOAD, 
of which 13 were novel. These novel signals are close to the following genes: Cas scaffolding protein family 
member 4 (CASS4), CUGBP, Elav-like family member 1 (CELF1), Fermitin family member 2 (FERMT2). Major 
histocompatibility complex class II, DR beta 5-1 (HLA-DRB5/DRB1), Immunoglobulin heavy variable 1-67 
(IGHV1-67), Inositol polyphosphate-5-phosphatase (INPP5D), myocyte enhancer factor 2C (MEF2C), NME/NM23 
family member 8 (NME8), Protein tyrosine kinase 2 beta (PTK2B), solute carrier family 24 (SLC24A4), sortilin-
related receptor L, A repeats containing (SORL1), Tumor protein p53 inducible nuclear protein 1(TP53INP1), and 
zinc finger, and CW type with PWWP domain 1 (ZCWPW1). The IGAP study also identified a suggestive association 
located in the intergenic region between TREM2 and TREML2, but due to the study design (a meta-analysis), it was 
not possible to determine whether this intergenic signal was independent of p.R47H in TREM2. These IGAP-
identified loci contain multiple genes within the associated region and therefore the suggested genes may not contain 
the underlying functional variants. Additionally, the most-significant SNPs within these loci were located in non-
coding regions, and thus there is no clear functional impact of these variants linked to AD pathogenesis. It is also 
possible that multiple functional variants reside within the same locus affecting AD risk independently. 
Endophenotype-based analyses along with conditional analyses can help to identify the potential drivers of the 
associations, infer the underlying mechanisms associated with AD, and determine whether there are multiple 
independent genetic variants affecting AD pathogenesis. 
 In the past few years, our lab has had great success in using CSF biomarkers as endophenotypes to validate 
AD genetic risk factors23, to generate hypotheses regarding the mechanism by which AD risk variants contribute to 
AD development18, and to find novel variants associated with age at onset and disease progression17,19. Several 
candidate gene studies examined the association between GWAS top hits and CSF biomarkers and found evidence 
of association for CSF Aȕ42 levels with variants in SORL1, CLU, and MS4A4A164,189. However, another similar study 
did not find any evidence of association for any GWAS locus24. Our group recently performed the largest CSF 
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GWAS (1,269 individuals) using CSF tau and tau phosphorylated at threonine 181 (ptau181) as endophenoytpes and 
reported four genome-wide significant loci in APOE: at 3q28 between GEMC1 and OSTN, at 9q24.2 within GLIS3, 
and 6p21.1 within the TREM gene cluster22. However, in this paper none of the SNPs within GWAS-identified loci 
showed genome-wide significant evidence (p < 5×10-8) with CSF tau and ptau181 levels, possibly due to a small 
sample size and an extremely stringent genome-wide significance cutoff (Bonferroni correction)22. Despite the work, 
several questions remained to be answered: (1) whether the top SNPs in novel GWAS genes, including CASS4, 
CELF1, FERMT2, HLA-DRB5/DRB1, IGHV1-67, INPP5D, MEF2C, NME8, PTK2B, SLC24A4, SORL1, TP53INP1, 
and ZCWPW1, identified in the IGAP meta-analysis8 are also associated with CSF biomarker levels, (2) whether 
there are multiple independent signals within the same locus affecting AD, (3) whether the intergenic signal located 
between TREM2 and TREML2 drives the association independently of TREM2 p.R47H, and (4) whether TREM2 and 
TREML2 affect AD pathogenesis distinctly and independently. 
 Completion of the ENCODE Project has provided valuable information to identify and characterize 
functional elements in the human genome and facilitate studies of gene expression and the interpretation of non-
coding variants linked to human disease160,190. Two related studies examined gene expression from laser-capture 
microdissected non-tangle-bearing neurons in several brain regions169,171. These studies also provided valuable gene 
expression profiles in anatomically and functionally different brain regions and showed that AD is associated with 
decreased expression of energy metabolism genes in posterior cingulated neurons169,171. More recently, gene-
expression levels were used as endophenotypes and abundant expression quantitative trait loci (eQTLs) were found 
in several human primary tissues106-108,167. These eQTL analyses106-108,167 clearly provide a brain region-specific 
framework for the identification of regulatory variants and genes, which can translate into better understanding of 
the functional mechanism for genetic variants. However, very little work has been done to investigate cis-eQTL 
effects on expression levels for the GWAS-identified genes. A recent study has examined ABCA7, BIN1, CLU, CR1, 
PICALM, and MS4A6A/MS4A6E neighboring regions but did not find eQTL evidence109. Given that a recent 
study142 and our CSF and bioinformatic analyses suggest several SNPs within the CELF1 region are regulatory 
variants of nearby genes, much work is required to perform cis-eQTL analyses for these GWAS-identified regions in 
order to identify potential regulatory variants which can explain the GWAS signals. 
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 Several studies had been done to functionally characterize the TREM2 gene, an immune phagocytic 
receptor expressed on brain microglia known to trigger phagocytosis and regulate the inflammatory response. A 
previous study used microarray and laser microdissHFWLRQRIEHWDDP\ORLG$ȕSODTXH-associated areas in an animal 
model of AD and found that TREM2 LVGLIIHUHQWLDOO\H[SUHVVHGLQ$ȕSODTXH-DVVRFLDWHGYHUVXV$ȕSODTXH-free tissue 
91. A recent study has demonstrated thaW75(0LVHVVHQWLDOIRUWKHPLFURJOLDOUHVSRQVHWR$ȕGHSRVLWLRQZKLOHD
GHFUHDVHLQ75(0H[SUHVVLRQKDVQRHIIHFWRQ$ȕSODTXHEXUGHQ137. Another study characterized several 
TREM2 variants, including, p.C36A, p.Y38C, p.R47H, and p.T66M, and showed that p.T66M but not p.R47H 
impairs TREM2 trafficking to the cell surface191. Our recent work identified 16 rare coding variants in TREM2, 6 of 
which (p.R52H, p.R136W, p.E151K, p.W191X, p.E202D, and p.H215Q) were not discovered in previous 
studies12,13,96. Additionally, nine variants (p.R52H, p.T66M, p.R136W, p.R136Q, p.H157Y, p.W191X, p.E202D, 
p.H215Q and p.T223I) were only found in AD cases. However, no work has been done to functionally characterize 
these novel and potentially functional TREM2 variants in cell systems.  
5.2  Dissertation work 
 Even though recent sequencing efforts have shown that p.V232M in PLD3 and p.R47H in TREM2 increase 
AD risk by 2 fold12-14, additional risk variants within PLD3 and TREM2 remained undiscovered. Therefore we 
hypothesized that if PLD3 and TREM2 are bona fide AD genes, they will carry additional low-frequency and rare 
variants. We performed deep re-sequencing of exonic and flanking intronic sequence in order to identify novel 
functional variants and test for association with AD risk. We sequenced 4,387 European Americans (2,363 AD cases 
and 2,024 controls) and 302 African Americans (130 cases and 172 controls) for PLD3 and 3,730 European 
Americans (2,082 AD cases and 1,648 controls) and 336 African Americans (204 cases and 132 controls) for 
TREM2. We demonstrated that rare variants in PLD3 and TREM2 are more frequently seen in cases than in controls 
of European descent (TREM2: 6.7% in cases and 2.7% in controls; PLD3: 8.0% in cases and 3.1% in controls). 
Single-variant analyses showed that p.M6R (p=0.02; odds ratio [OR]=7.73 [1.09~61]) and p.A442A (p=3.78×10-7; 
OR=2.21 [1.58~2.8]) in PLD3 and p.R62H (p=2.36×10-4; OR=2.36 [1.47~3.80]) in TREM2 are significantly 
associated with AD risk in addition to p.V232M in PLD3 and p.R47H in TREM2. Gene-based tests demonstrated 
that PLD3 (PSKAT-O=1.44×10-11; OR=2.75 [2.05~3.68]) and TREM2 (PSKAT-O=5.37×10-7; OR=2.55 [1.62~3.87]) are 
genome-wide significantly associated with AD. The associations for PLD3 and TREM2 rare variants with AD risk 
are still highly significant after excluding p.V232M (PSKAT-O=1.5×10-8; OR=2.58 [1.87~3.57]) and p.R47H (PSKAT-
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O=7.72×10-5; OR=2.47 [1.62~3.87]) respectively, which indicates that additional PLD3 and TREM2 variants affect 
AD risk. However, we did not find evidence of association for TREM2 variants with AD risk in African Americans 
at either the gene-level or the SNP-level which may be due to our small sample size. Even though TREM2 p.R47H 
has bebn found to be associated with AD risk in Caucasian12,13, Spanish125, and French126 populations, no significant 
association of TREM2 R47H was found  in several Asian populations192-194. Like Asian populations, the reason why 
we did not see any significant association in our dataset may be because TREM2 variants are too rare for any 
meaningful power in the African Americans. In this work, we also confirmed that at least three TREM2 transcripts 
are expressed in human brains, including one encoding a soluble form of TREM2, which suggests that some soluble 
TREM2 results from alternative splicing rather than cleavage of membrane-associated TREM2. 
 Since the most-significant SNPs in GWAS-identified susceptibility loci had very small effect size and only 
explained 50% of the phenotypic heritability for AD (overall heritability of up to 80%), we hypothesized that low-
frequency and rare coding variants within GWAS-identified loci have greater effects on AD risk compared to most-
significantly associated common variants found in GWAS. We performed pooled-DNA sequencing of exonic and 
flanking intronic sequences of GWAS-identified  genes, including ABCA7, BIN1, CD2AP, CD33, CLU, CR1, 
EPHA1, MS4A4A, and PICALM, in 3,730 European Americans (2,082 AD cases and 1,648 controls) and 336 
African Americans (204 cases and 132 controls). Even though this project has not been completed, we have already 
validated 90 coding variants in GWAS-identified genes, 66 of which were not annotated in the Exome Variant 
Server –a database which consists of whole-exome sequencing (WES) data in 2,203 African American and 4,300 
European American unrelated individuals. Bioinformatic analyses predict that 56 of the confirmed variants (62.2%) 
are damaging. Nucleotide conservation analyses suggest that 57 of the validated variants are under evolutionary 
constraint (a GERP score>2), which implies that a large proportion of rare coding variants in GWAS-identified 
genes are potentially functional. Together, these findings suggest that deep re-sequencing is an effective strategy to 
identify additional functional variants in AD-associated genes. 
 Even though IGAP identified 23 loci associated with AD risk through GWAS meta-analysis and gene-wide 
analyses, the mechanisms by which most of these loci affect the molecular pathways leading to AD remain 
unknown. Therefore, we undertook endophenotype-based analyses to determine whether these loci are also 
associated with CSF $ȕ42 and ptau181 levels. We combined CSF biomarker datasets from several studies (N=2,036) 
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and performed single-variant and set-based analyses for each locus. In the APOE locus, rs769449 is genome-wide 
significantly associated with both &6)$ȕ42 and ptau181 levels. Furthermore, as previously reported in a smaller 
dataset, the association between rs769449 and CSF ptau181 levels is only partially explained by differences in CSF 
$ȕ42 levels. We found evidence of association (p<0.05) for the top IGAP SNPs, rs4147929 (ABCA7), rs17125944 
(FERMT2), and rs35349669 (INPP5DZLWK&6)$ȕ42 levels, and for rs6656401 (CR1), rs17125944 (FERMT2), 
rs190982 (MEF2C), rs10792832 (PICALM), rs28834970 (PTK2B), and rs11218343 (SORL1) with CSF ptau181 
levels. Our locus-specific analyses suggested that after multiple test correction, rs7937331, within the CELF1 fine-
mapping region, LVDVVRFLDWHGZLWK&6)$ȕ42 levels and AD risk and tags the same signal as the IGAP top SNP, 
rs10838725. Additionally, rs62003531, located in the intronic region of FERMT2, tags the same association as the 
,*$3WRS613UVDQGLVDVVRFLDWHGZLWK&6)$ȕ42 levels. The association for the CELF1 and FERMT2 
fine-maSSLQJUHJLRQVZLWK&6)$ȕ42 levels was confirmed in set-based analyses. None of the SNPs within the 
IGAP-identified AD risk loci except the APOE locus are significantly associated with CSF ptau181 levels after 
multiple test corrections. This may be due to lack of statistical power. We also tested whether IGAP top SNPs and 
CSF top SNPs have any regulatory potential. We demonstrated that the majority of GWAS top SNPs have no 
significant regulatory potential and are unlikely to be the functional variants for AD risk. However, RegulomeDB 
predicts that several proxy SNPs in LD with rs7937331 in SLC39A13 may be cis-acting expression quantitative trait 
loci (eQTLs) for nearby genes and are located in transcription factor binding sites. Together our results suggest that 
AD risk variants may not necessarily be associated with CSF biomarker levels, and that GWAS-identified 
noncoding variants may affect AD risk through regulatory mechanisms. 
 The IGAP study also identified a suggestive association (p<10-6) located in the intergenic region between 
TREM2 and TREML2, but due to the study design, it was not possible to determine whether this intergenic signal 
was independent of p.R47H in TREM2. As a result, we performed comprehensive analyses using WES data, CSF 
biomarker analyses, and meta-analyses (16,254 cases and 20,052 controls) to demonstrate that the AD risk GWAS 
association is likely driven by a TREML2 missense variant p.S144G (rs3747742) and that this association is 
independent of TREM2 p.R47H risk for AD. Additionally, we demonstrated that the protective role of TREML2 in 
AD is independent of the role of TREM2 gene as a risk factor for AD. Moreover, advances in sequencing-based 
study design and rare-variant association methods enable us to investigate the role of low-frequency and rare 
variants in complex diseases.  
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 Since no work had been done to functionally characterize novel TREM2 variants in vitro, we tested the 
hypothesis that some of these novel TREM2 variants may affect TREM2 trafficking to the cell surface thereby 
interfering with trem2 signaling. To test this hypothesis, we introduced TREM2 variants into TREM2-DAP12 cDNA 
constructs using site-directed mutagenesis and measured cell surface expression using an anti-TREM2 antibody. Our 
flow cytometry analyses suggest that p.T66M and p.R136W variants in TREM2 robustly impact cell surface 
expression. However, we did not find any differences in cell surface expression when comparing p.R47H and 
p.R62H to the wild type (WT). This suggests that p.R47H and p.R62H may affect AD through other mechanisms.  
These results are in line with a recent publication which shows that TREM2 p.T66M variant reduces the cell surface 
expression robustly while TREM2 p.R47H only slightly affect cell surface expression compared to WT191. 
 Finally, we sought to determine whether polymorphisms within the CELF1 fine-mapping region are eQTLs 
for nearby genes. We performed cis-eQTL analysis for mRNA expression levels in several brain regions using four 
publicly available datasets to identify genetic determinants of gene expression in human brains. We found that all of 
the expression-associated SNPs, including rs7124681, rs10838738, rs2290850, and rs755553, are in tight LD with 
UVWKHWRS&6)$ȕ42 SNP in the CELF1 fine-mapping region. Conditional analyses suggest that there is 
only one independent driver within this region and the minor allele of the underlying causal variant mediates 
C1QTNF4 expression levels. Additionally, we found evidence of differential expression in C1QTNF4 and SPI1 
transcripts between AD cases and controls in human brains. Overall, these results illustrated that the underlying 
causal variants and genes may not be the gene originally identified in GWAS studies. Our data suggested the causal 
variants within the CELF1 fine-mapping region mediate differences in C1QTNF4 expression levels and may affect 
AD risk by affecting AȕELRORJ\7KHVHILQGLQJVSURYLGHDGGLWLRQDOHYLGHQFHthat genes involved in the 
inflammatory response play an important role in AD pathogenesis. 
5.3 Future directions 
 While recent deep sequencing studies of AD GWAS genes do not report any positive results96,187, several 
recent papers clearly suggest that a very large sample size (N ~ 4,000) is required for the detection of a significant 
rare-variant association14,97,195. Therefore, the sample size of this work (N > 4000), which is close to the sample size 
of our recently published sequencing papers14,97, provides enough statistical power to identify significant rare-variant 
associations. Additionally, our preliminary sequencing efforts have identified a large number of rare coding variants 
within GWAS-identified variants and over 60% of these variants were predicted to be damaging by more than two 
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bioinformatic algorithms. This implies that a large proportion of rare coding variants in GWAS-identified genes are 
potentially functional. In the next few months, our group will finish all the genotyping, perform single-variant and 
gene-based analyses, conduct bioinformatic predictions, and eventually publish the results. Functional analyses will 
be required to determine the functional impact of rare variants within AD-associated genes in vitro and in vivo. 
 Due to the small sample size (204 cases and 132 controls), we did not find any significant association for 
TREM2 variants in African Americans.  To better determine whether rare TREM2 coding variants are involved in 
AD pathogenesis in African Americans, we are collaborating with researchers at the Mayo Clinic (Mayo), the 
Indiana University School of Medicine (Indiana), the Emory University, and the Alzheimer’s Disease Genetic 
Consortium (see Figure 1 for the study design) to increase our current sample size. We have combined and analyzed 
our genotype data with data from Mayo (183 cases and 351 controls) and Indiana (167 cases and 1,341 controls). 
With the combined data, we identified thirteen coding variants in TREM2 (p.R47H, p.R62H, p.T66M, p.D87N, 
p.T96K, p.T96M, p.A105V, p.P144P, p.E151K, p.H157Y, p.W191X, p.E202D, and p.L211P; Table 1), three 
(p.E151K, p.W191X, and p.L211P; Table 1) of which are non-synonymous variants that achieved suggestive 
association (p<0.15) and risk ORs (1.17~3.32) in a cohort of modest sample size (554 AD cases and 1,824 controls). 
Two (p.W191X and p.L211P) of these 3 non-synonymous variants are in tight LD (D’=1) with the African 
American (AA) GWAS TREM2 hit (rs7748513; OR ± SE 1.16±0.05; p=0.001). This AA GWAS TREM2 hit is an 
intronic variant and is unlikely to be functional based on RegulomeDB (RegulomeDB score=7). Thus functional 
studies of these non-synonymous variants can provide insight into the potential mechanism linking these variants to 
AD etiology.  
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Table 1. Rare variants found in African Americans (WashU+Mayo+Indiana)* 
   
AD Cases Controls  
   
Variant SNP Position 
No. of 
Cases 
No. of 
Carriers 
No. of 
Controls 
No. of 
Carriers p OR (95% CI) SIFT PolyPhen 
p.R47H rs75932628 6:41129252 537 1 1733 3 1 1.12 (0.12-10.82) Tolerated Damaging 
p.R62H rs143332484 6:41129207 552 3 1821 8 0.72 1.29 (0.34-4.88) Tolerated Benign 
p.T66M rs201258663 6:41129195 203 1 132 0 1 NA Damaging Damaging 
p.D87N rs142232675 6:41129133 533 1 1682 2 0.55 1.65 (0.15-18.21) Tolerated Damaging 
p.T96K rs2234253 6:41129105 381 91 479 112 0.82 1.03 (0.77-1.38) Damaging Damaging 
p.T96M NA 6:41129105 160 0 351 1 1 0   
p.A105V rs145080901 6:41129078 353 1 1336 4 1 1.01 (0.11-9.07) Damaging Damaging 
p.P144P NA 6:41127580 156 1 1 0 1 NA Tolerated NA 
p.E151K rs79011726 6:41127561 532 3 1685 3 0.14 3.32 (0.67-16.46) NA Damaging 
p.H157Y rs2234255 6:41127543 203 1 132 0 1 NA Damaging Damaging 
p.W191X rs2234258 6:41126429 515 42 1677 104 0.11 1.37 (0.95-1.97) NA NA 
p.E202D NA 6:41126395 204 0 132 1 0.42 0 Damaging NA 
p.L211P rs2234256 6:41126655 529 130 1679 374 0.15 1.17 (0.95-1.44) Tolerated Benign 
* Samples from the Washington University (WashU), the Mayo clinic (Mayo), and the Indiana University (Indiana) were combined and 
analyzed together. 
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 Several recent papers have shown that loss of a TREM2 DOOHOHDOWHUVPLFURJOLDOUHVSRQVHWR$ȕLQDPRXVH
model137 and that TREM2 mutations can impair cell surface trafficking and phagocytosis191, providing support for 
the hypothesis that AD-associated TREM2 variant are partial loss-of-function alleles. However, similar functional 
studies need to be performed for the novel TREM2 variants identified in recent publications96,97. Our preliminary and 
replication results have shown that T.66M and p.R136W variants in TREM2 robustly impact cell surface expression, 
but we did not find any differences in cell surface expression comparing p.R47H and p.R62H to the wild type (WT). 
This suggests that p.R47H and p.R62H may affect AD through other mechanisms. Stable cell lines should be used to 
determine the long-term cell surface expression of TREM2 variants. TREM2 trafficking to the cell surface is 
important for without it, TREM2 cannot bind to its endogenous ligand and thus cannot transduce its intracellular 
signal properly. Follow-up studies are ongoing to distinguish between expression and trafficking defects by 
measuring TREM2 and DAP12 RNA and protein levels inside the cell. Additionally, since our functional studies 
found that TREM2 p.R136W has very robust effects on cell surface expression, it would be interesting to test 
whether TREM2 p.R136Q21, a different codon change in the same position has a similar functional impact. In other 
words, we can determine whether the variability in TREM2 cell surface expression is directly correlated to a codon 
specific, Tryptophan substitution at 136, or whether conservation of this position alone is important in regulating 
TREM2 cell surface transport. 
 In the past 5 years, dramatic advances in genotyping, sequencing and analytical areas have driven 
substantial progress toward understanding the genetic architecture of AD. GWAS have reported more than 20 
susceptibility loci for AD8,10,11,196. Except APOE, common variants within these loci only influence AD risk 
modestly but they reveal several important disease pathways. Additionally, the use of biomarkers as endophenotypes 
has been detected DGGLWLRQDOJHQHWLFORFLDIIHFWLQJ$'ULVNWDXPHWDEROLVP$ȕPHWDEROLVPDQGQHXURLPDJLQg 
phenotypes19,22-24,163,197. Recently, massively parallel DNA sequencing in small discovery datasets has already led to 
identification of rare large effect variants in several promising genes for AD12-14. Currently, several groups are 
performing large scale WES or WGS analyses in unrelated AD cases and controls and in families with multiply 
affected family members in order to identify novel AD genes. WES or WGS data from more than 20,000 individuals 
are expected to be available before the end of 2014 and subsequently additional AD risk genes are likely to be 
found. The integration of GWAS, WES/WGS, and other large scale datasets such as transcriptomics and 
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epigenomics data from human brain tissues will provide better understanding of disease mechanisms, leading to 
effective targets for therapeutics. 
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